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Immunomodulation As A Potential Therapeutic Approach for Alzheimer’s Disease
William Veljko Nikolic
ABSTRACT

Alzheimer’s disease (AD) is the most prevalent form of progressive dementia and
is characterized by the accumulation of amyloid beta (Aβ) peptide in the brain and in the
cerebral vessels forming cerebral amyloid angiopathy (CAA). As previously reported, an
active immunization strategy of mice with Aβ1-42 peptide results in decreased Th1 and
increased Th2 cytokine responses as well as an effectively clearance of CNS Aβ. This
approach has also yielded favorable results for many patients, unfortunately, a small
percentage of these study participants developed severe aseptic meningoencephalitis
likely secondary to CNS invasion of activated T-cells. We have previously demonstrated
that disruption of CD40-40L pathway reduces Aβ plaque load, promotes Th2 response,
and rescues from cognitive impairments. However, direct blockage of the CD40 pathway
by passive vaccination with anti-CD40L antibody leads to immunosupression. Therefore,
in its current form this therapeutic strategy poses an unacceptable risk to the recipient of
treatment, aged individual. For those reasons, the identification and characterization of
alternative modulators/inhibitors of CD40 signaling may be necessary for the
development of safe and effective AD immunotherapy.
This proposal introduces novel immunomodulatory therapies that are based on
previous vaccination strategies or cell based therapies across medial field. We showed
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that transcutaneous vaccination can both be efficacious and safe, thus clearly
demonstrating that the right combination of the antigens, adjuvants, and the routes of
administration are crucial for the right vaccine. Furthermore, we demonstrated that the
effects of current Aβ vaccine strategies could be enhanced by a simultaneous blockade of
CD40-40L signaling. As an alternative approach, we explored the possibility of cellbased therapies and showed that human umbilical cord blood cells, which are currently
used as a treatment for systemic lupus erythematosus and leukemia, and currently
investigated against stroke, amyotropic lateral sclerosis, age-related macular
degeneration, multiple sclerosis, and Parkinson’s disease, and showed that not just they
improved the AD like pathology in transgenic animals but altered both the brain and
peripheral inflammation levels. Lastly, we discussed the involvement of microglia, one of
the key players in both AD pathogenesis and Aβ clearance and suggesed that microglia in
actuality has a continuum of physiological activation states that contribute to
proinflammation, antiinflammation, and phagocytosis.
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CHAPTER ONE
INTRODUCTION

1.1 The impact of Alzheimer’s disease
First described in 1906 by Alois Alzheimer, the Alzheimer’s disease (AD) is the
leading cause of dementia among elderly. Dementia is a collective name for progressive
degenerative brain syndromes, which affect memory, behavior, emotions, and thinking.
Currently, about 10 percent of Americans over the age of 65 and half of those over age of
85 have been diagnosed with AD, which equates to over 5.2 million Americans that
suffer from this disease. According to 2008 Alzheimer’s Association Facts and Figures
report, AD is the seventh-leading cause of death in U.S. and where every 71 seconds
someone develops AD. The report also estimates that the direct and indirect costs of
Alzheimer's and other dementias to Medicare, Medicaid and businesses amount to more
than $148 billion each year, which makes it a third most expensive disease to threat in the
U.S.
Generally speaking, Alzheimer’s disease can be divided into three basic stages.
The early stage is characterized by mild cognitive decline, i.e. word- or name-finding
problems, decline in ability to organize, and performance issues in social or work
settings. The middle stage is characterized by severe cognitive decline (confusion,
disorientation, and delusions), disruption in normal sleep/walking cycle, and increasing
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episodes of urinary or fecal incontinence. The late and final stage of AD is characterized
by the loss of capacity of recognizable speech, individuals lose the ability to work, lose
the ability to walk without assistance, then the ability to sit without support, the ability to
smile, the ability to hold their head up, and individuals need help with eating and toileting
and there is general incontinence of urine.

1.2 Pathology of Alzheimer’s disease
Brain regions being affected early are entorhinal cortex, hippocampus, and basal
forebrain. These are small specialized structures that play a crucial role in memory. Over
time, the disease destroys large areas of the brain that control vital body functions and as
a result AD patients typically die from pneumonia or lack of nutrition. Pathologically
speaking, major AD characteristics are senile plaques (caused by amyloid beta peptide
deposition), neurofibrilary tangles (caused by tau protein deposition), and neuronal loss
(characterized by dystrophic neurites). Amyloid or “senile” plaque is primarily composed
of 39-43 amino acid peptide amyloid beta (Aβ). Aβ is derived by a proteolytic cleavage
of amyloid precursor protein (APP). There are Aβ is normally water soluble, however it
does have a tendency to aggregate, ex. especially longer forms of the peptide (Aβ1-40 and
Aβ1-42) as regular β-plated sheet conformations and come out as insoluble amyloid
plaques. These plaques are normally detergent resistant. Aβ can also be deposited as
diffused deposits, often believed to be the intermediate step before the more compact
amyloid plaques form. In recent years, Aβ deposition has been identified in the vascular
wall. This is know as a cerebral amyloid angiopathy (CAA), a pathology that was
identified in as much as 83 percent of AD patients (Ellis et al., 1996). Neurofibrilary
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tangles are intraneuronal inclusions of abnormal fibers that consist of paired helical
filaments. The filaments consist of microtubule-associated hyperphosphorylated tau
proteins. Lastly, neuronal loss is thought to originate from amyloid plaques,
inflammatory reactions due to cytokine releases, oxidative injury that disrupt neuronal
metabolic and ionic homestasis, and impaired neuronal trafficking due to
hyperphosphorylated tau filaments.

1.3 Microglia and central nervous system
Microglia are somewhat enigmatic central nervous system (CNS) cells that have
been traditionally regarded as CNS macrophages (MΦs). They represent about 10% of
the adult CNS cell population (Pessac et al., 2001). In mice, microglial progenitors can
be detected in neural folds at the early stages of embryogenesis. Murine microglia are
thought to originate from the yolk sac at a time in embryogenesis when
monocyte/macrophage progenitors (of hematopoeitic origin) are also found (Pessac et al.,
2001) (Alliot et al., 1999). Based on this observation, it is now generally accepted that
adult mouse microglia originate from monocyte/macrophage precursor cells migrating
from the yolk sac into the developing CNS, most likely independently of CCR2 (Mildner
et al., 2007). Once CNS residents, these newly migratory cells actively proliferate during
development, thereby giving rise to the resident CNS microglial cell pool. More recently
however, it has been shown that bone marrow-derived cells can enter the CNS and
become cells that phenotypically resemble microglia in the adult mouse (Eglitis and
Mezey, 1997) (Brazelton et al., 2000) (Mezey et al., 2000). Interestingly, under
conditions of CNS damage such as stroke, cholinergic fiber degeneration, or motor
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neuron injury, Priller and colleagues found that green fluorescent protein-labeled bone
marrow cells could enter the CNS and take up a microglial phenotype (Priller et al.,
2001). On other hand it was shown that bone-marrow derived cells do not contribute at
all to the CD11b+/Iba-1+ population when the CNS was protected from irradiation,
suggesting that proliferation of endogenous microglia is the most plausible explanation
for the increase in Iba-1+ cell number (Mildner et al., 2007). This latter view could be
further supported with citings that local microglia proliferate following lesioned CNS
with intact blood-brain barrier (Priller et al., 2006) (Remington et al., 2007).
Microglia normally exist in a quiescent (resting) state in the healthy CNS, and are
morphologically characterized by small soma and ramified processes. However, upon
“activation” in response to invading viruses or bacteria or CNS injury, microglia undergo
morphological changes including shortening of cellular processes and enlargement of
their soma (sometimes referred to as an “amoeboid” phenotype). Activated microglia
also up-regulate a myriad of cell surface activation antigens and produce innate cytokines
and chemokines (discussed in detail below). As the microglial lineage originates from
peripheral myeloid precursor cells, it is helpful to consider the activation states of such
peripheral innate immune cells to better understand the nature of microglial activation.

1.4 Classical roles of peripheral innate immune cells
It is now widely accepted that both innate and adaptive arms of the immune
system play important roles in maintaining immune homeostasis. However, little
attention was paid to the evolutionarily much older innate immune system until the late
Charlie Janeway proposed the involvement of innate mechanisms in vertebrate immunity.
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Specifically, Janeway pioneered the idea that lymphocyte activation could be critically
regulated by the evolutionarily ancient system of antigen clearance by phagocytic cells of
myeloid origin. Together with Ruslan Mezhitov, they originated the concept that these
phagocytic innate immune cells recognize pathogen-associated molecular patterns
(PAMPs) through pattern recognition receptors, the most notable examples being a set of
phylogenetically conserved, germ-line encoded Toll-like receptors (TLRs, currently 1112 members, (Qureshi and Medzhitov, 2003) (Yamamoto et al., 2004) (Zhang et al.,
2002) (Tabeta et al., 2004), resulting in expression of cell-surface activation molecules
[for example, major histocompatibility complex (MHC) class I and II, B7.1, B7.2, and
CD40] and secretion of innate cytokines (e.g., tumor necrosis factor-α (TNF-α),
interleukin (IL)-1, IL-6, IL-12, and IL-18 (Janeway and Medzhitov, 2002) (Medzhitov
and Janeway, 2000a). Once activated, the innate arm of the immune response calls
adaptive immune cells into action, and both branches act in concert to promote
neutralization and clearance of invading pathogens. Thus, innate immune cells are able
to discriminate “non-infectious self” from “infectious non-self” and thereby form the first
line of defense against invading bacteria and viruses (for review see (Medzhitov and
Janeway, 2000b) (Medzhitov and Janeway, 2002) (Medzhitov and Janeway, 2002)
(Iwasaki and Medzhitov, 2004).

1.4.1 The macrophage: prototypical phagocyte
Macrophages (MΦs) are quintessential phagocytes whose primary role is to
engulf pathogens such as invading bacteria and to remove debris and detritus, i.e.,
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remnants of apoptotic cells. Tissue MΦs develop when blood monocytes enter into the
various organs and tissues and differentiate into specialized, site-specific MΦs depending
on their anatomical location, such as alveolar MΦs (lung), histiocytes (connective tissue),
kupffer cells (liver), mesangial cells (kidney), osteoclasts (bone), or microglia (brain)
(Goldsby et al., 2002). Resting MΦs are both weak phagocytes and weak lymphocyte
activators (Adler et al., 1994). Upon activation however, for example in response to TLR
stimulation by PAMPs, their phagocytic potential greatly enhances (Blander and
Medzhitov, 2004) and they up-regulate cell-surface co-stimulatory molecules and
produce pro-inflammatory innate cytokines as mentioned above. Typically, engulfment
of the pathogen by phagocytosis triggers a “respiratory burst” involving production of
reactive oxygen species such as superoxide and peroxinitrite that kill the pathogen (Adler
et al., 1994) (Forman and Torres, 2001). In addition, activated MΦ up-regulate cellsurface Fc receptors that aid in phagocytosis of pathogens opsonized by antibodies
produced by plasma cells (Tsukada et al., 1994) (Blom et al., 2003). On the other hand,
in response to debris from apoptotic cells, the MΦ mounts a phagocytic response
essentially in the absence of pro-inflammatory cytokines (Gregory and Devitt, 2004).
The most likely reason for this anti-inflammatory phagocytic response is that proinflammatory cytokines such as TNF-α promote bystander injury which may further
damage tissues in which the apoptotic cells reside. Thus, MΦs are highly capable of
“innate activation” characterized by a strong phagocytic response sometimes
accompanied by pro-inflammatory cytokine production (for a review see (Fujiwara and
Kobayashi, 2005).
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1.4.2 The dendritic cell: professional antigen presenting cell
Whereas MΦs have limited ability to process and present antigen to T cells,
dendritic cells (DCs) are considered professional antigen presenting cells (APCs). DCs
can be found under the epithelia and in most organs where they capture and process nonself antigens, migrate to lymphoid organs, and present antigen in the context of MHC to
CD4+ and CD8+ T lymphocytes. With their many finger-like cellular processes, DCs are
morphologically optimized to simultaneously display antigen to many T cells. Like
MΦs, DCs respond to invading pathogens by recognizing PAMPs through TLRs, and
subsequently phagocytose and process antigen. DCs then up-regulate cell-surface costimulatory molecules and secrete innate cytokines and chemokines (typically at levels an
order of magnitude higher than those secreted by MΦs) to promote recruitment and
activation of CD4+ and/or CD8+ T lymphocytes. There are three generally accepted
classifications of DCs in mice: plasmacytoid (p) DCs (CD11clo, CD11blo, B220+, CD8-),
lymphoid (l) DCs (CD11c+, CD11b-, CD8+), and myeloid (m) DCs (CD11c+, CD11b+,
B220-, CD8-, there are several subtypes,) (Banchereau et al., 2000). In humans, there are
clearly two distinct subsets of DCs: pDCs (CD11c-, CD11b-, CD14-, CD45RA+) and
monocyte DCs (CD11c+, CD11b+, CD14+, CD45RA-) (for a review see (Shortman and
Liu, 2002). DC classes differ from each other predominately in tissue distribution,
production of specific cytokines, TLR expression, and ability to promote innate versus
adaptive immune responses (for a review see (Iwasaki and Medzhitov, 2004). For
example, freshly isolated human pDCs express TLR7 and 9, whereas mDCs express
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TLR1, 2, 3, 5, 6, and 8 (Hornung et al., 2002) (Jarrossay et al., 2001) (Kadowaki et al.,
2001). Stimulation of human pDCs or monocytic DCs with synthetic TLR7 ligands
induces the secretion of interferon (IFN)-α (important for anti-viral innate immunity) or
IL-12 [a key inducer of the adaptive T helper (Th) type I response], respectively (Ito et
al., 2002). Similarly, stimulation of TLR9 via DNA containing unmethylated CpG motifs
results in IFN-α secretion by pDCs and IL-12 production by murine mDCs (Hemmi et
al., 2003). Despite these relative differences between DC classes, the major role of DCs
on the whole remains; they act as potent APCs capable of strongly activating T
lymphocytes. Their APC capacity is much stronger than that of MΦs, as DCs are able to
directly activate naïve T cells whereas MΦs are not (Iwasaki and Medzhitov, 2004).
Thus, by virtue of their ability to promote T cell activation responses, DCs are highly
capable of “adaptive activation”. Activation markers of phagocytosis and APC responses
in various innate immune cells are presented in the Table 1.

1.5 Microglial activation after toll-like receptor stimulation: a mixed response
Recent evidence indicates that microglia, like their peripheral innate immune cell
counterparts, express a wide array of TLRs, including mRNA for TLRs 1-9 in mice
(Olson and Miller, 2004) and in humans (Bsibsi et al., 2002). Furthermore, many of
these TLRs have been shown to be functional, allowing microglial recognition of a
variety of PAMPs. For example, Kielian and coworkers found that heat-killed
Staphylococcus aureus and its cell wall product peptidoglycan (PGN) are able to
stimulate innate activation of microglia characterized by pro-inflammatory cytokine and
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chemokine production (Kielian et al., 2002). Those authors found that the effect of PGN
was critically dependent on TLR2, as TLR2-deficient mice demonstrated reduced
cytokine and chemokine production after PGN challenge (Kielian et al., 2005).
Furthermore, murine microglia respond to the TLR9 agonist, unmethylated CpG-DNA,
by secreting numerous pro-inflammatory innate cytokines (probably responsible for
neurotoxicity in oganotypic brain slice cultures treated with CpG-DNA (Iliev et al.,
2004), by up-regulating co-stimulatory cell surface molecules, and by promoting adaptive
activation by secreting IL-12 to affect T cell activation (Dalpke et al., 2002). In two
recent studies, murine microglial pro-inflammatory responses to bacterial
lipopolysaccharide (LPS), a known TLR4 ligand, resulted in dramatic injury to cultured
oligodendrocytes (Lehnardt et al., 2002) and neurons (Lehnardt et al., 2003), further
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demonstrating microglial bystander injury after TLR stimulation (probably mediated by
over-production of innate pro-inflammatory cytokines). It has recently been shown that
microglia respond to poly I:C [a synthetic double-stranded (ds) RNA analog thought to
be recognized by TLR3, (Alexopoulou et al., 2001)] by producing pro-inflammatory
cytokines and chemokines (Jack et al., 2005), and microglial pro-inflammatory responses
to dsRNA seem to be dependent on TLR3, as TLR3-deficient microglia have blunted
innate cytokine responses in vitro and markedly reduced cell surface activation markers
in brain after poly I:C stimulation (Town et al., submitted). Finally, infection with West
Nile virus, a retrovirus that produces dsRNA during its life cycle, results in profound
microglial activation as assessed by pro-inflammatory cytokine production in vitro and
cell surface activation markers in vivo, effects that are dramatically reduced in TLR3deficient animals (Wang et al., 2004).
In peripheral innate immune cells, TLR responses to PAMPs seem to be
dependent on at least four different TLR intracellular adapter molecules: MyD88
(involved in TLR1, 2, 4, 6, 7, 8, and 9 signaling), TRIF/TICAM-1 (mediates TLR3 and 4
signaling), TIRAP/Mal (involved in TLR1, 2, 4, and 6 responses) and
TIRP/TRAM/TICAM-2 (mediates TLR4 signaling). These adapter molecules bind to the
intracellular leucine-rich repeat region of the TLR and promote recruitment of additional
factors such as IRAKs and TRAF6 that allow for activation of transcription factors
including IRF-3 and NF-κB, which are responsible for activation of numerous innate
cytokines and cell-surface activation antigen genes (for review see (Vogel et al., 2003)
(Hemmi and Akira, 2005). It is still unclear how different TLR responses in innate
immune cells (i.e., promotion of innate versus adaptive responses) can be achieved when
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many TLRs share intracellular signaling molecules. While little work has been done on
intracellular signaling following TLR stimulation in microglia, it is likely that microglia
utilize the same signaling cascades described for MΦs and DCs.
1.6 Adaptive response of activated microglia in demyelinating disease via CD40CD40 ligand interaction

1.6.1 Brain inflammation in demyelinating disease
Experimental autoimmune encephalomyelitis (EAE) is a mouse model of the
human disease multiple sclerosis (MS), an autoimmune disease characterized by
inflammatory CNS demyelinating lesions accompanied by motor disturbances. EAE can
be induced in different strains of mice by subcutaneous or intraperioteneal inoculation
with adjuvant plus epitopes found in myelin such proteolipid protein, myelin basic
protein, or myelin oligodendrocyte glycoprotein. The disease is critically dependent on
activation of pro-inflammatory CD4+ T helper type I (Th1) cells by APCs, and these
auto-aggressive Th1 cells can be adoptively transferred to non-diseased recipient mice
that subsequently develop disease. EAE is characterized by paralysis, typically
beginning in the tail and hind limbs and progressing to the fore limbs. In the SJL mouse
strain, animals develop a relapsing-remitting form of the disease while C57BL/6 mice
manifest paralysis that progressively worsens until death. Upon histopathological
analysis, brains from EAE mice generally show infiltration of Th1 cells (and other
lymphocytes including MΦs and DCs) and activation of microglia, typically in white
matter regions where demyelinating lesions are found (for review see (Olsson, 1995)
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(Swanborg, 1995) (Cornet et al., 1998).

1.6.2 CD40-CD40 ligand interaction in experimental autoimmune encephalomyelitis
Immune/inflammatory cells receiving a primary stimulus (i.e., MHC-T cell
receptor interaction between APCs and T lymphocytes, respectively) typically require costimulatory signals via other pairs of molecules in order to become activated [for
instance, the B7-CD28 and/or CD40-CD40 ligand (L) dyads in APC/T-cell activation;
(van Kooten and Banchereau, 2000)]. CD40L is a key immunoregulatory molecule that
plays a co-stimulatory role in the activation of immune cells from both the innate and
adaptive arms of the immune system, and is typically expressed by activated CD4+ and
some CD8+ T cell subsets (Grewal and Flavell, 1998). CD40 receptor, a member of TNF
and nerve growth factor super-family, is expressed on many professional and nonprofessional APCs, including dendritic cells, B cells, monocytes/macrophages and
microglial cells (O'Keefe et al., 2002) (Carson et al., 1998) (Havenith et al., 1998) (Tan et
al., 1999b) (Tan et al., 1999a). Nearly 10 years ago, activated Th cells that expressed
CD40 ligand (CD40L) were found in brains of MS patients, and these cells were found in
close apposition to CD40-bearing cells in active demyelinating lesions (Gerritse et al.,
1996). The authors determined that the CD40-expressing cells were either macrophages
or microglia based on staining for acid phosphatase or CD11b.
To evaluate whether the CD40-CD40L interaction was pathogenic in EAE,
Gerritse and co-workers administered a CD40L neutralizing antibody to SJL mice that
were given proteolipid protein with adjuvant to induce EAE. Strikingly, EAE was
prevented in a prophylactic treatment regimen of anti-CD40L, and, when EAE was
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induced in another cohort of animals, CD40L antibody treatment significantly reduced
disease severity in an active treatment paradigm (Gerritse et al., 1996). It was later
shown that genetic deficiency in CD40L (Grewal et al., 1996) or antibody-mediated
blockade of CD40L (Howard et al., 1999) resulted in attenuation of Th1 differentiation
and effector function, including marked inhibition of the Th1 cytokine IFN-γ and reduced
numbers of encephalitogenic effector T cells. In an effort to further understand the nature
of the CD40-CD40L interaction responsible for promotion of EAE, Becher and
colleagues used a bone marrow reconstitution system to determine which CD40expressing cells were responsible for promoting EAE (Becher et al., 2001). In that
report, the authors showed that CD40 expression by parenchymal microglia was
responsible for recruitment/retention of encephalitogenic T cells in EAE. Strikingly,
treatment of microglia with a combination of granulocyte macrophage-colony stimulating
factor and CD40L has been shown to promote differentiation of these cells into cells that
(1) express the pan-DC marker CD11c, (2) morphologically resemble DCs, and (3)
secrete the Th1-promoting cytokine IL-12 p70 (Fischer and Reichmann, 2001). Such
CD11c+ CD11b+ “DC-like” microglia were found in EAE brain lesions in inflammatory
foci containing T cells, and exhibited potent stimulation of allogeneic T cell proliferation
versus CD11c- CD11b+ microglia (Fischer and Reichmann, 2001). Although their origin
was not determined, it was recently shown that “CNS DCs” (possibly “DC-like”
microglia) are responsible for activation of naïve T cells in response to endogenous
myelin epitopes (termed “epitope spreading”), and this process was initiated in the CNS
as opposed to the peripheral lymphoid organs (McMahon et al., 2005). Thus, in the
context of EAE, CD40-CD40L interaction on microglia seems to promote adaptive
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function of these cells, resulting in a “DC-like” activated microglia phenotype that
promotes encephalitogenic Th1 cell differentiation and effector function.

1.7 Activation of microglia after CD40 ligation in Alzheimer disease: a shift from
innate to adaptive response

1.7.1 Alzheimer disease and microglial responses to β-amyloid
It has been suggested that activated microglia play a key role in AD pathogenesis
as they secrete pro-inflammatory innate cytokines such as TNF-α and IL-1β, which have
been shown to promote neuronal injury at high levels (Meda et al., 1995) (Barger and
Harmon, 1997) (McGeer and McGeer, 1998). Furthermore, there is a large body of
evidence that non-steroidal anti-inflammatory drug (NSAID) use is associated with
reduced risk for AD in humans (Shapshak et al., 2004) (in t' Veld et al., 2001) (Zandi et
al., 2002), for a review see (Szekely et al., 2004), and NSAID treatment of AD mice
results in reduced β-amyloid plaque burden concomitant with ameliorated microglial
activation (Matsushima et al., 1994) (Matsushima et al., 1994) (Lim et al., 2001). Work
done in Maxfield’s laboratory showed that challenge of microglia with labeled Aβ
peptides promotes phagocytosis but poor degradation of soluble or fibrillar Aβ via
scavenger receptors (Paresce et al., 1996) (Paresce et al., 1997) (Chung et al., 1999).
Using knockout mice, his laboratory showed that the class A scavenger receptor (type I
and II) is the predominant scavenger receptor responsible for Aβ uptake by microglia,
with other scavenger receptors playing a more minor role (including the class B
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scavenger receptor CD36) (Chung et al., 1999).
1.7.2 Microglial responses to β-amyloid in the context of CD40 ligation
We previously showed that, while murine microglial challenge with soluble Aβ
peptides alone does not elicit TNF-α secretion, co-stimulation provided in the form of
CD40 ligation (either via CD40L or an agonistic CD40 antibody) results in TNF-α
production being synergistically affected (Tan et al., 1999a). Further, microglia cultured
from AD mice deficient in CD40L demonstrate reduced TNF-α secretion versus CD40Lsufficient AD mouse microglia. This form of microglial activation in CD40L-sufficient
AD mice is pathogenic, as CD40L-deficient AD mice demonstrate reduced activated
(CD11b+) microglia, an effect that is associated with mitigated abnormal hyperphosphorylation of tau protein (a key indicator of neuronal stress) (Tan et al., 1999a).
Furthermore, genetic ablation of CD40L or administration of a CD40L-neutralizing
antibody markedly reduces β-amyloid plaques in mouse models of AD, effects that are
associated with mitigated astrocytosis and microgliosis (Tan et al., 2002a), for review see
(Town et al., 2001) (Tan et al., 2002b). More recently, overproduction of microgliaassociated CD40 and of astrocyte-derived CD40L was found in and around β-amyloid
plaques in AD patient brains (Togo et al., 2000) (Calingasan et al., 2002), raising the
possibility that the CD40-CD40L interaction may contribute to AD pathogenesis by
promoting brain inflammation.
In order to better understand the form of microglial activation affected by Aβ plus
CD40L stimulation, we examined innate and adaptive activation of murine microglia
challenged with Aβ in the presence or absence of CD40L co-stimulation (Townsend et
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al., 2005). When microglia were challenged with fluorescent-tagged synthetic human
Aβ alone, they mounted a time-dependent phagocytic response (from 15 min to 60 min)
which could be enhanced by Fc receptor stimulation using an anti-human Aβ antibody.
This phagocytic response to Aβ alone was not associated with production of the proinflammatory innate cytokines TNF-α, IL-6, or IL-1β, a result similar to that seen when
microglia are challenged with apoptotic cells and mount an anti-inflammatory, prophagocytic innate response (Minghetti et al., 2005). Importantly, CD40L treatment
opposed this phagocytic response, as determined by measuring both cell-associated
Aβ and free extracellular Aβ. As mentioned above, Maxfield’s laboratory demonstrated
that microglia slowly degrade phagocytosed Aβ peptides (Paresce et al., 1996) (Paresce
et al., 1997) (Chung et al., 1999). We examined the ability of microglia to degrade Aβ
peptides by first pulsing them with Aβ and then chasing these cells after 1 hour of culture
in the presence or absence of CD40L stimulation. Using this experimental approach, we
found that CD40L also retarded microglial clearance of the peptide. We further assessed
putative modulation of microglial Aβ phagocytosis by cytokines known to promote
effector T cell function, and found that the pro-inflammatory Th1-type cytokines IFN-γ
and TNF-α inhibited Aβ phagocytosis whereas the anti-inflammatory Th2-type cytokines
IL-4 and IL-10 boosted this response.

1.8 Immunotherapy and Alzheimer’s disease
Alzheimer’s disease is described by many pathological characteristics and
yet the predominant theory of the disease process in the amyloid hypothesis. This
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hypothesis suggests that Aβ deposition can directly through diffuse or compact plaques,
or indirectly through inflammatory cascade, result in progressive synaptic and neuritic
injury. This injury causes alterations in intracellular kinases functions that further
contribute to tau protein hyperphosphorylation and the formation of neurofibrilary
tangles. The combination of these events and their propagation is believed to contribute
to neuronal dysfunction and loss which will contribute to dementia observed in
Alzheimer’s disease (Hardy and Selkoe, 2002). Thus, methods developed to clear or
prevent formation of Aβ in the brains of AD patients represent a possible treatment
modality. One promising approach involves utilization of “active” Aβ immunization
strategies, which produce dramatic reductions in Aβ pathology in animal studies (Schenk
et al., 1999). However, a phase IIa clinical trial was abandoned after about 6% of Aβimmunized AD patients developed aseptic meningoencephalitis (Nicoll et al., 2003;
Orgogozo et al., 2003) that appeared to involve brain inflammatory reactions mediated by
T-cells and microglia (Monsonego et al., 2001; Schenk and Yednock, 2002; Greenberg et
al., 2003; Monsonego et al., 2003a). Interestingly, a 12 month post-vaccination period
analysis revealed an inverse correlation between titers of amyloid plaque-reactive
antibodies and rate of cognitive decline (Hock et al., 2003), suggesting clinical efficacy.
Despite the discontinuation of the clinical trials, Aβ vaccination studies have continued in
effort to identify an immunization approach that is both safe and effective. Current
approaches have focused on minimizing T-cell mediated inflammatory responses in
efforts to prevent CNS invasion of auto-aggressive T-cells, while promoting Aβ
antibody-mediated clearance mechanisms (Chackerian et al., 2006; Maier et al., 2006;
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Okura et al., 2006; Nikolic et al., 2007). A possible avenue to both enhance Aβ clearance
and down-regulate CNS inflammatory responses (including invasion of reactive T-cells)
involves modulation of the CD40 receptor (CD40)-CD40 ligand (CD40L) system. In the
periphery, a variety of innate immune cells known as antigen-presenting cells (APCs)
express CD40, including dendritic cells, B-cells, and monocytes/macrophages. In the
CNS, CD40 is expressed by resident cells including microglia, neurons, and astrocytes, as
well as by peripherally-derived APCs (Tan et al., 2002a; Town et al., 2005). Recently, the
CD40-CD40L interaction was determined to play a central role in promoting and
maintaining dendritic cell APC phenotype during infections (Straw et al., 2003). In the
context of CNS immunity, the CD40-CD40L interaction is required for microglial
maturation into functional APCs (Ponomarev et al., 2006). We have recently shown that
CD40L treatment of primary cultures of microglia inhibits phagocytosis of Aβ antibody
opsonized, as well as non-opsonized Aβ species (Townsend et al., 2005). A blockade of
the CD40-CD40L system down-regulates T-cell/microglia-mediated injury in the context
of experimental autoimmune encephalitis (EAE) (Howard et al., 1999; Howard et al.,
2002). Altogether, these studies suggest that blockade of the CD40-CD40L interaction
could enhance Aβ vaccination-mediated Aβ clearance mechanisms, while minimizing
pro-inflammatory T-cell-mediated damage in the CNS. However, a complete blockade of
CD40-40L interaction would lead to distortion of immune functioning and hence an
autoimmunity would emerge. Therefore, the need for an immunomodulator that can
partially block the CD40-40L interaction and yet still allow normal immune functioning
would be needed. Human umbilical cord blood cells (HUCBC) have been shown to
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oppose the pro-inflammatory T helper cell type 1 (Th1) response, as demonstrated in an
animal model of stroke where HUCBC infusion promoted a strong anti-inflammatory Thelper 2 (Th2) response (Vendrame et al., 2004). Importantly, this effect was associated
with reduced infarct volume and rescue of behavioral deficit (Vendrame et al., 2004).
HUCBC infusion has also shown therapeutic benefit in other neuroinflammatory
conditions including multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative
macular degeneration, and Parkinson’s disease (El-Badri et al., 2006; Garbuzova-Davis et
al., 2006; Henning et al., 2006). In AD preclinical models, administration of these cells
to the PSAPP mouse model of AD was associated with extension of lifespan, although
high doses were administered in this paradigm (Ghorpade et al., 2001). So perhaps a
proper immunomodulator together with active Aβ vaccine working in tangent could be a
right step towards future Alzheimer’s disease treatment.
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CHAPTER TWO
PERIPHERALLY ADMINISTERED HUMAN UMBILICAL CORD BLOOD
CELLS REDUCE PARENCHYMAL AND VASCULAR β-AMYLOID DEPOSITS
AND SUPPRESS CD40-CD40L INTERACTION

2.1 Abstract
Modulation of immune/inflammatory responses by diverse strategies including
amyloid-β (Aβ) immunization, non-steroidal anti-inflammatory drugs, and manipulation
of microglial activation states has been shown to reduce Alzheimer’s disease (AD)-like
pathology and cognitive deficits in AD transgenic mouse models. Human cord blood
cells (HUCBC) have unique immunomodulatory potential, and we wished to test whether
these cells might alter AD-like pathology after infusion into the PSAPP mouse model of
AD. Here, we report a marked reduction of Aβ levels/β-amyloid plaques and associated
astrocytosis following multiple low dose infusions of HUCBC. HUCBC infusions also
reduced cerebral vascular Aβ deposits in the Tg2576 AD mouse model. Interestingly,
these effects were associated with suppression of the CD40-CD40L interaction as
evidenced by decreased circulating and brain soluble CD40L (sCD40L) and elevated
systemic IgM levels, attenuated CD40L-induced inflammatory responses, and reduced
surface expression of CD40 on microglia. Importantly, deficiency of CD40 abolishes the
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effect of HUCBC on elevated plasma Aβ levels. Moreover, microglia isolated from
HUCBC-infused PSAPP mice demonstrated increased phagocytosis of Aβ. Further, sera
from HUCBC-infused PSAPP mice significantly increased microglial phagocytosis of
Aβ1-42 peptide while inhibiting IFN-γ-induced microglial CD40 expression. Increased
microglial phagocytic activity in this scenario was inhibited by addition of recombinant
CD40L protein. These data suggest that HUCBC infusion confers mitigation of AD-like
pathology by disrupting CD40L activity.

2.2 Introduction
Alzheimer’s disease (AD) is the most common progressive dementia, and is
pathologically characterized by deposition of amyloid-β-peptide (Aβ) in the brain
parenchyma. Aβ plaques are potent activators of both microglia and astrocytes, central
nervous system (CNS)-resident immunocompetent cells that respond to cerebral
amyloidosis by chronic, pro-inflammatory activation (Benzing et al., 1999). While it was
once thought that activation of microglia and astrocytes in the AD brain was an
epiphenomenon and not a pathoetiological contributor to AD, more recent studies have
suggested that the Aβ-mediated inflammatory cascade is an etiological perpetrator in AD.
For example, therapeutic strategies aimed at manipulating this inflammatory cascade,
including Aβ immunization (Schenk et al., 1999; Bard et al., 2000; Nicoll et al., 2003),
non-steroidal anti-inflammatory drugs (NSAID) (Matsushima et al., 1994; in t' Veld et
al., 2001; Szekely et al., 2004), and modulation of microglial activation (Tan et al.,
1999a; Town et al., 2001; Tan et al., 2002b; Todd Roach et al., 2004; Laporte et al.,
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2006), are able to reduce AD-like pathology and improve behavioral impairment in
Alzheimer’s transgenic mouse models and, in some cases, reduce AD pathology in
humans.
We previously showed that the CD40-CD40 ligand (CD40L) interaction plays a
critical role in Aβ-induced pro-inflammatory microglial activation (Tan et al., 1999a).
Moreover, we have demonstrated that disruption of this signaling pathway reduces
cerebral Aβ deposits in the Tg2576 mouse model of AD and improves cognitive deficits
in PSAPP AD mice (Town et al., 2001; Tan et al., 2002a; Tan et al., 2002b; Todd Roach
et al., 2004). The implication of CD40-CD40L interaction in AD-associated brain
inflammatory process is supported from studies demonstrating increased expression of
CD40 and CD40L in and around β-amyloid plaques in AD brain (Togo et al., 2000;
Calingasan et al., 2002). Recently, Desideri and colleagues (Desideri et al., 2006)
reported circulating soluble CD40L (sCD40L) levels are significantly increased in AD
patients vs. healthy elderly controls, further supporting a role for this receptor/ligand dyad
in the pathogenesis of AD.
Human umbilical cord blood cells (HUCBC) have been shown to oppose the proinflammatory T helper cell type 1 (Th1) response, as demonstrated in an animal model of
stroke where HUCBC infusion promoted a strong anti-inflammatory T-helper 2 (Th2)
response (Vendrame et al., 2004). Importantly, this effect was associated with reduced
infarct volume and rescue of behavioral deficit (Vendrame et al., 2004). HUCBC
infusion has also shown therapeutic benefit in other neuroinflammatory conditions
including multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative macular
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degeneration, and Parkinson’s disease (El-Badri et al., 2006; Garbuzova-Davis et al.,
2006; Henning et al., 2006). In AD preclinical models, administration of these cells to
the PSAPP mouse model of AD was associated with extension of lifespan, although high
doses were administered in this paradigm (Ghorpade et al., 2001).
Based on these lines of evidence, we investigated whether multiple low-dose
administration of HUCBC to AD transgenic mouse models could reduce AD-like
pathology through suppression of deleterious inflammatory responses involving the
CD40 pathway. To address this possibility, we infused both double transgenic PSAPP
mice and Tg2576 AD mouse models with HUCBC and then examined cerebral
parenchymal and vascular Aβ levels/deposits, astrocytosis, microgliosis, and CD40
pathway-associated molecules.

2.3 Materials and methods

2.3.1 Animals and administration of human umbilical cord cells
HUCBC (95-98% mononuclear cells) were provided by Saneron CCEL
Therapeutics, Inc. (Tampa, FL). Transgenic PSAPP (APPswe, PSEN1dE9) and Tg2576
mice were obtained from the Jackson Laboratory (Jankowsky et al., 2001; Garcia-Alloza
et al., 2006) and Taconic Inc. (Hsiao et al., 1996), respectively, and were intravenously
(i.v.) treated with HUCBC (100,000 cells/mouse) or PBS bi-weekly for the first two
months and monthly for the remaining four months (n = 10/group, 5♂/5♀). Mice were
treated starting at 7 months of age (after appreciable Aβ deposits), and blood was
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collected by sub-mandibular bleeding at 0, 2, 4 and 6 months to monitor plasma
cytokines, sCD40L and Aβ levels throughout the study. We analyzed brains of these
mice for Aβ deposits and gliosis at 13 months of age (when these mice manifest wellestablished AD-like pathology, including Aβ deposits and gliosis). For PSAPP mice
deficient in CD40, we treated these mice and controls at 8 weeks of age (preliminary
studies showed that we can clearly detect plasma Aβ levels at this age) with HUCBC.
Blood samples were collected by sub-mandibular bleeding at the 2nd month after the
treatment. Animals were housed and maintained in the College of Medicine Animal
Facility at the University of South Florida (USF), and all experiments were performed in
compliance with protocols approved by USF Institutional Animal Care and Use
Committee.

2.3.2Immunohistochemistry analysis
Mice were anesthetized with isofluorane and transcardially perfused with ice-cold
physiological saline containing heparin (10 U/mL). Brains were rapidly isolated and
quartered using a mouse brain slicer (Muromachi Kikai, Tokyo, Japan). The first and
second anterior quarters were homogenized for Western blot analysis, and the third and
fourth posterior quarters were used for microtome or cryostat sectioning (Tan et al.,
2002a). Brains were then fixed in 4% paraformaldehyde in PBS at 4°C overnight and
routinely processed in paraffin in a core facility at the Department of Pathology (USF
College of Medicine). Five coronal sections from each brain (5 µm thickness) were cut
with a 150 µm interval [for cingulate cortex (CC) bregma -0.10 mm to -0.82 mm; for
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entorhinal cortex (EC) and hippocampus (H), bregma -2.92 mm to -3.64 mm]. Sections
were routinely deparaffinized and hydrated in a graded series of ethanol before
preblocking for 30 min at ambient temperature with serum-free protein block (Dako
Cytomation, Carpinteria, CA). Aβ immunohistochemical staining was performed using
anti-human amyloid-β antibody (4G8) in conjunction with the VectaStain Elite ABC kit
(Vector Laboratories, Burlingame, CA) coupled with diaminobenzidine substrate. Congo
red staining was done according to standard practice using 10% (w/v) filtered Congo red
dye cleared with alkaline alcohol. These sections were rinsed three times for 5 min each
in 70% ethanol, hydrated for 5 min in PBS, and mounted in Vectashield fluorescence
mounting media (Vector Laboratories). β-amyloid plaques positive for 4G8 or Congo red
were visualized under bright field using an Olympus BX-51 microscope. Aβ burden was
determined by quantitative image analysis. Briefly, images of five 5-µm sections (150
µm apart) through each anatomic region of interest (hippocampus and neocortex) were
captured and a threshold optical density was obtained that discriminated staining form
background. Manual editing of each field was used to eliminate artifacts. Data are
reported as percentage of immunolabeled area captured (positive pixels divided by total
pixels captured). Quantitative image analysis was performed by a single examiner (TM)
blinded to sample identities.

2.3.3 Immunofluorescence analysis
Double immunofluorescence for Aβ and CD40 was performed using rat antimouse CD40 (1:1000; Pharmingen) and rabbit anti-pan Aβ (1:100; Biosource
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International, Inc) with overnight incubation followed by incubation at ambient
temperature with goat anti-rat IgG FITC (1:50; PharMingen) and donkey anti-rabbit
Alexa Fluor555 (1:500; Invitrogen) for 45 min. Double immunofluorescence for Aβ and
activated astrocytes was performed using a biotinylated human amyloid-β monoclonal
antibody (4G8; 1:100, Signet Laboratories, Dedham, MA) and GFAP polyclonal
antibody (1:500, DAKO). Normal rabbit, normal mouse serum (isotype control), or
phosphate buffered saline (PBS, 0.1 M, pH 7.4) were used instead of primary antibody or
ABC reagent as a negative control. Quantitative image analysis was done based on a
previous method (Tan et al., 2002a) with minor modifications. Images were acquired as
digitized tagged-image format files to retain maximum resolution using an Olympus
BX60 microscope with an attached digital camera system (DP-70, Olympus, Tokyo,
Japan), and digital images were routed into a Windows PC for quantitative analyses using
SimplePCI software (Compix, Inc. Imaging Systems, Cranberry Township, PA). The
cingulate cortex region was captured from the image of the cortex adjacent to the sagittal
fissure, and the entorhinal cortex region was captured from the image of the cortex
ventral to the rhinal fissure. In images from cingulate and entorhinal regions, the cortical
edge was not included in order to capture the full anatomic region of interest. The
hippocampal region was captured from between a portion of the CA1 subfield of the
pyramidal cell layer and the lacunosum molecular layer. The anatomical locations and
boundaries of the regions analyzed were based on those previously defined (Obregon et
al., 2006). Images of five 5 µm sections through each anatomic region of interest were
captured, and a threshold optical density was obtained that discriminated staining from
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background. Each anatomic region of interest was manually edited to eliminate artifacts.
For “burden” analyses, data are represented as percentage of immunolabeled area
captured (positive pixels) relative to the full area captured (total pixels).

2.3.4 Flow cytometric and Western blot analyses of CD40 expression
For flow cytometric analysis of microglial CD40 expression, primary cultured
microglial cells were plated in 6-well tissue culture plates at 5 x 105 cells/well and
incubated with IFN-γ (100 ng/mL) in the presence or absence of serum derived from
HUCBC- or PBS-infused individual PSAPP mice. Twelve hours after incubation,
microglial cells were washed with flow buffer [PBS containing 0.1% (w/v) sodium azide
and 2% (v/v) FCS] and re-suspended in 250 µl of ice-cold flow buffer for fluorescence
activated cell sorting (FACS) analysis, according to methods described previously (Tan et
al., 1999d). Briefly, cells were pre-incubated with anti-mouse CD16/CD32 monoclonal
antibody (clone 2.4G2, PharMingen) for 10 min at 4°C to block non-specific binding to
Fc receptors. Cells were then centrifuged at 5,000 x g, washed 3 times with flow buffer,
and then incubated in flow buffer with hamster anti-mouse CD40-FITC or isotype control
antibody-FITC (1:100 dilution; PharMingen). After 30 min incubation at room
temperature, cells were washed twice with flow buffer, re-suspended in 250 µL of flow
buffer and analyzed by a FACScanTM instrument (Becton Dickinson). A minimum of
10,000 cells were accepted for FACS analysis. Cells were gated based on morphological
characteristics using CellQuestTM software (Beckton Dickinson) such that apoptotic and
necrotic cells were not accepted for FACS analysis. Percentages of positive (CD40-
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expressing) cells were calculated as follows: for each treatment, the mean fluorescence
value for the isotype-matched control antibody was subtracted from the mean
fluorescence value for the CD40-specific antibody.
For Western immunoblotting analysis of brain CD40 expression, mouse brain
homogenates were prepared from HUCBC- and PBS-infused PSAPP mice as previously
described (Tan et al., 2002a). An aliquot corresponding to 100 µg of total protein of each
sample was separated by SDS-PAGE and transferred electrophoretically to
immunoblotting PVDF membranes. Nonspecific antibody binding was blocked with 5%
nonfat dry milk for 1 hr at room temperature in Tris-buffered saline (TBS; 20 mM Tris
and 500 mM NaCl, pH 7.5). Subsequently, membranes were first hybridized with rabbit
anti-CD40 antibody (1:1,500 dilution; StressGen) for 2 hrs and then washed 3 times in
TBS and immunoblotting was by an anti-rabbit HRP-conjugated IgG secondary antibody
as a tracer. The luminol reagent was used to develop the blots. To demonstrate equal
loading, the same membranes were then stripped with β-mercaptoethanol stripping
solution (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM β-mercaptoethanol) and reprobed with mouse monoclonal antibody to actin. Densitometric analysis was done as
previously described (Tan et al., 2002a) using a FluorS Multiimager with Quantity One™
software (BioRad).

2.3.5 β and cytokine ELISAs
Mouse brains were isolated under sterile conditions on ice and placed in ice cold
lysis buffer as previously described (Tan et al., 2002a). Brains were then sonicated on ice
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for approximately 3 minutes, allowed to stand for 15 minutes at 4°C, and centrifuged at
15,000 rpm for 15 minutes. This fraction represented the detergent-soluble fraction.
Detergent-insoluble Aβ1-40, 42 species were further subjected to acid extraction of brain
homogenates in 5 M guanidine buffer (Johnson-Wood et al., 1997), followed by a 1:5
dilution in lysis buffer. Aβ1-40, 42 were detected in brain homogenates prepared with lysis
buffer or in plasma samples at a 1:10 or 1:5 dilution, respectively, in dilution buffer (PBS
+ 1% BSA + PMSF). Aβ1-40, 42 was quantified in these samples using our own Aβ1-40, 42
ELISA kits (Rezai-Zadeh et al., 2005) and further evaluated with commercially available
Aβ1-40, 42 ELISA kits (IBL-America) in accordance with the manufacturer’s instructions,
except that standards included 0.5 M guanidine buffer in some cases to facilitate Aβ
aggregation. Aβ1-40, 42 were represented as pg/mL of plasma and pg/mg of total protein
(mean ± SD).
Cell suspensions of splenocytes from individual mice were prepared as previously
described (Town et al., 2002) and passed in 0.5 mL aliquots into 24-well plates at 3
×106/mL. These cells were treated for 48 hrs with concanavalin A (Con A, 5 µg/mL).
Supernatants were then collected and assayed by IL-10, TNF-α, and IL-12(p70) cytokine
ELISA kits in strict accordance with the manufacturer's instruction (R&D Systems). The
Bio-Rad protein assay (Bio-Rad) was performed to measure total cellular protein from
each of the cell groups under consideration just prior to quantification of cytokine release
by ELISA, and cytokine secretion is expressed as pg/mg total cellular protein (mean ±
SD). To verify whether stimulation of splenocytes produced any between-groups
differences on cell death that might account for altered cytokine profiles, LDH release
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assay was carried out as described (Town et al., 2002), and LDH was not detected in any
of the wells studied. ELISAs for IgM and IgG antibodies were carried out as previously
described (Nikolic et al., 2007). Optical densities were determined by a microplate
reader at 450 nm. The ratio of IgM to IgG was calculated using optical density values and
then the average ratio for each group was determined (mean ± SD). Brain tissue-derived
(from the detergent-soluble brain homogenate fraction) and serum-derived (plasma)
samples were analyzed for sCD40L (Bener MedSystems Burlingame, CA), IL-4, IL-10,
IL-2, IFN-γ, TNF-α, IL-1β, IL-12 (p70), and TGF-β cytokines by Bioplex assays (BioRad Laboratories, Hercules, CA) according to the manufacturer’s protocol.

2.3.6 Microglial phagocytosis assay
Primary cultures of murine microglia were established as previously described
(Tan et al., 1999a; Townsend et al., 2005). For fluorometic analysis of FITC-Aβ1-42,
primary murine microglia were seeded at 1 x 105 cells/well (n = 6 for each condition) in
24-well tissue-culture plates containing 0.5 mL of complete RPMI 1640 medium. These
cells were treated for 60 min with “aged” Aβ1-42 conjugated with FITC (Biosource
International) (Townsend et al., 2005). In the presence of FITC-Aβ1-42, microglia were
then co-treated with serum (1/200, 1/400, 1/800 dilution) derived from HUCBC- or PBSinfused individual PSAPP mice in the presence or absence of CD40L protein (2 µg/mL).
Microglia were rinsed 3 times in Aβ-free complete medium, and media were exchanged
with fresh Aβ-free complete medium for 10 min both to allow for removal of nonincorporated Aβ and to promote concentration of the Aβ into phagosomes. Extracellular
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and cell associated FITC-Aβ were quantified using an MSF reader (SpectraMax®,
Molecular Devices) with an emission wavelength of 538 nm and an excitation
wavelength of 485 nm. A standard curve from 0 nM to 500 nM of FITC-Aβ was run for
each plate. Total cellular proteins were quantified using the Bio-Rad protein assay. The
mean fluorescence values for each sample were determined by fluorometic analysis.
Relative fold change values were calculated as the mean fluorescence value for each
experimental sample over control. In this manner, both extracellular and cell associated
FITC-Aβ were quantified. To determine the extent to which cell death might have
influenced phagocytic activity in the various treatment groups, we performed LDH
release assay, and no significant cell death was detected over the 3 h time-frame in any of
the treatment groups (p > 0.05).
Primary culture peripheral macrophages were collected from 3-month old wild
type mice by infusing their peritoneal cavity with ice-cold PBS following a four day i.p.
immunization with 1mL of 3% (w/v) brewer’s thyoglycollate resuspended in PBS. Cells
were pooled following the isolation in order to decrease the variables. Further, they were
plated in a culture medium (RPMI-1640; 10% fetal bovine serum and antibiotics) to give
1.5 × 106 cells/well in 6 well plates. Cells were incubated overnight at 37 °C under 5%
CO2 in a humidified incubator, and non-adherent cells were removed by washing twice
with PBS at 37 °C. Following the removal of non-adherent cells, the remaining cells
were tested for Aβ phagocytosis as described above with the addition of 1:200, 1:400,
and 1:800 dilution of sera derived from HUCBC-treated mice, sera derived from PBStreated mice, as well as supernatants from cultured HUCBC cells.
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2.3.7 Statistical Analysis
Data are presented as mean ± SD. All statistics were calculated using one-way
analysis of variance (ANOVA) for multiple comparisons. A p value of < 0.05 was
considered significant. The statistical package for the social sciences release 10.0.5
(SPSS Inc., Chicago, Illinois) was used for all data analysis.

2.4 Results

2.4.1 Cerebral parenchymal and vascular β-amyloid plaques are reduced in AD
transgenic mice peripherally infused with HUCBC
Previous work in a mouse model of stroke has shown that HUCBC infusion
results in significant reduction in infarct volume as well as rescue of behavioral deficits
associated with decreased pro-inflammatory cytokine production (Vendrame et al., 2004).
We sought to determine whether HUCBC (95-98% mononuclear cells) infusion could
impact Aβ-associated pathology in PSAPP double transgenic mice. These animals were
intravenuously (i.v.) injected with HUCBC (100,000 cells/mouse) beginning at 7 months
of age (when β-amyloid deposits have already accumulated). At 13 months of age, mice
were sacrificed and evaluated for changes in AD-like pathology. We chose to administer
multiple low doses of HUCBC because, in our pilot studies, we observed that this
strategy was superior compared to a single high dose of HUCBC on reducing cerebral
amyloidosis in Tg2576 mice (data not shown). HUCBC infusion in PSAPP mice resulted
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in marked reduction of cerebral β-amyloid pathology as assayed by Aβ antibody (4G8)
immunohistochemistry (Figure 1A) and Congo red histochemistry (Figure 1C).
Quantitative image analysis revealed statistically significant differences for each brain
region examined (P < 0.001) between PSAPP mice infused with HUCBC
(PSAPP/HUCBC) and PSAPP mice peripherally infused with PBS (PSAPP/PBS) for
both Aβ antibody (Figure 1B) and Congo red staining (Figure 1D). Furthermore, ELISA
analysis of brain extracts showed that levels of both detergent-soluble and -insoluble Aβ140, -42

peptides were reduced in PSAPP mice infused with HUCBC (by 62% and 70%,

respectively; Figure 1E). A t-test for independent samples revealed significant betweengroups differences for each group examined (P < 0.001).
Given that peripheral administration of HUCBC reduces cerebral parenchymal
Aβ deposits and brain Aβ levels in PSAPP mice, we wished to investigate the impact of
HUCBC infusion on cerebral amyloid angiopathy (CAA), which is characterized by Aβ
deposits in the cerebral vasculature and is known to occur in 83% of AD patients (Ellis et
al., 1996). For this analysis, we used the Tg2576 mouse model of AD, which is known to
manifest copious Aβ deposits in cerebral vessels at 15 to 20 months of age (Kaul et al.,
2000; Christie et al., 2001; Li et al., 2003; Friedlich et al., 2004; Robbins et al., 2006).
We peripherally infused these mice with HUCBC or controls (PBS vehicle treatment or
no treatment) (n = 10, 5♂/5♀ per group) at 12 months of age using the identical
procedure above. Six months thereafter, these mice were sacrificed for analyses of
cerebral parenchymal or vascular β-amyloid deposits by Congo red histochemistry. As
shown in Figure 1F, Tg2576 mice receiving HUCBC treatment demonstrated reduction
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of both cerebral parenchymal and vascular Congo red deposits compared with controls.
Quantitative image analysis revealed statistically significant differences between
Tg2576/HUCBC and Tg2576/PBS or non-treated control groups when examining total
(78%), vascular (86%), or parenchymal (74%) Congo red staining (P < 0.001; Figure
1G). No significant difference was revealed between Tg2576/PBS and non-treated
Tg2576 control mice (P > 0.05). In addition, we also analyzed cerebral Aβ levels/βamyloid deposits by Aβ ELISA and Aβ antibody immunohistochemistry, and we
obtained statistically significant results similar to those observed in HUCBC-infused
PSAPP mice (P < 0.001; data not shown).
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Figure 1. Cerebral Aβ/β-amyloid pathology is reduced in PSAPP and Tg2576 mice
peripherally infused with HUCBC. Mouse paraffin-embedded coronal brain sections
from the cingulate cortex (CC), hippocampus (H), and entorhinal cortex (EC) were
stained with monoclonal human Aβ antibody, (A) 4G8 or (C) Congo red. Percentages
(plaque area/total area) of (B) Aβ antibody-immunoreactive deposits or of (D) Congo
red-stained deposits were calculated by quantitative image analysis (mean ± SD; n = 10,
5♀/5♂ per group). (E) Aβ ELISA analysis was carried out for both levels of detergentsoluble Aβ1-40, 42 (top panel) or 5 M guanidine-extracted Aβ1-40, 42 (bottom panel). Data
are represented as mean ± SD of Aβ1-40, 42 (pg/mg protein). Mouse paraffin-embedded
coronal brain sections from hippocampal regions of Tg2576 mice were stained with (F)
Congo red. Positions of the hippocampal subfields CA1, CA3, and dentate gyrus (DG)
are indicated in the upper left panel. Arrows indicate Aβ deposit-affected vessels. (G)
Percentages (% labeled area) of Congo red-stained plaques/vessels were quantified by
image analysis (mean ± SD; n = 10, 5♀/5♂), and percentage reduction is indicated.
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2.4.2 Reduced CD40-positive microglia and GFAP-positive astrocytes in PSAPP mice
peripherally infused with HUCBC
It has previously been suggested that brain inflammation resulting from activated
microglia and astrocytes contributes to β-amyloid plaque formation (Frackowiak et al.,
1992; Potter et al., 2001), and we have previously shown that ligation of microglial CD40
enables activation in response to Aβ peptides (Tan et al., 1999a; Tan et al., 1999b; Tan et
al., 1999c). To investigate whether HUCBC could inhibit brain inflammation, we
examined co-localization of β-amyloid deposits with CD40-positive microglia [an in vivo
microgliosis marker (Togo et al., 2000)] or reactive [glial fibrillary acidic protein
(GFAP)-positive] astrocytes by immunohistochemistry and Western blot analyses in
PSAPP mice. As shown in Figure 2A, CD40-positive microglial cells were reduced in
the PSAPP/HUCBC-infused group. Quantitative image analysis revealed statistically
significant reductions when comparing PSAPP/HUCBC-infused and PSAPP/PBSinfused groups for both Aβ and CD40 staining in hippocampal dentate gyrus and CA1
regions (**P < 0.001) (Figure 2B). Western blot analysis of CD40 expression showed a
statistically significant decrease in brain homogenates from HUCBC-infused PSAPP
mice (P < 0.001) (Figure 2C). Furthermore, immunohistochemistry/histochemistry and
immunofluorescence analyses showed reductions in β-amyloid-associated astrocytosis in
PSAPP/HUCBC mice vs. PSAPP/PBS-treated mice (Figure 2D), and morphometry
revealed reductions for neocortex and hippocampus by 84% and 86%, respectively in
PSAPP/HUCBC mice (P < 0.001) (Figure 2E).
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Figure 2. β-amyloid associated microgliosis and astrocytosis are reduced in HUCBC
infused-PSAPP mice. (A) Immunofluorescence was performed on mouse brain coronal
paraffin sections prepared from PSAPP mice infused with HUCBC or PBS. Red signal
indicates Aβ positive (top panels); green indicates CD40 positive (middle panels), and
merged images (bottom panels) reveal co-localization of CD40 and Aβ. DAPI (blue) was
used as a nuclear counterstain. (B) Immunofluorescence intensity for Aβ and CD40 was
determined. (C) Western blot analysis shows reduced CD40 expression in brain
homogenates from PSAPP/HUCBC vs. PSAPP/PBS mice as indicated (actin was used as
an internal reference control). Densitometry analysis shows the ratio of CD40 to actin as
indicated below the figure. (D) Immunohistochemistry analysis shows GFAP and Aβ
double staining (top panel), and immunofluorescence (bottom panel) reveals colocalization of GFAP (red signal) and Aβ (green signal). (E) Morphometric analysis
results (mean GFAP/β-amyloid double positive plaques per mouse ± SD) are shown for
the neocortex and the hippocampus of PSAPP/HUCBC vs. PSAPP/PBS mice. Percent
reduction of plaques double positive for GFAP and Aβ in PSAPP/HUCBC mice is
indicated.
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2.4.3 Increased plasma Aβ levels correlate with decreased CD40-CD40L interaction in
HUCBC-infused PSAPP mice
We have previously shown that administration of neutralizing CD40L antibody to
PSAPP mice results in increased levels of plasma Aβ concomitant with reduced cerebral
Aβ/β-amyloid pathology, suggesting that depletion of CD40L promotes brain-to-blood
clearance of Aβ (Tan et al., 2002a). It is well-known that the CD40-CD40L interaction
promotes pro-inflammatory Th1 and opposes anti-inflammatory Th2 immune responses
(Grewal and Flavell, 1998; Mackey et al., 1998). In addition, HUCBC treatment has
been shown to be an immunoregulator in an animal model of stroke (Vendrame et al.,
2004; Newman et al., 2006). We investigated whether reduction of cerebral Aβ levels/βamyloid deposits in HUCBC-infused PSAPP mice might 1) result from increased brainto-blood clearance of Aβ, and 2) be associated with suppression of the pro-inflammatory
CD40-CD40L interaction. We probed individual blood samples from PSAPP mice
infused with HUCBC or PBS for Aβ1-40, 42 and soluble CD40L (sCD40L). ELISA
revealed increased plasma Aβ1-40, 42 levels in PSAPP/HUCBC mice which inversely
correlated with decreased levels of plasma sCD40L in these animals (Figures 3A-C).
One-way ANOVA followed by post hoc comparison revealed significant differences
between PSAPP/HUCBC-infused and PSAPP/PBS-infused mice for plasma Aβ1−40, 42
levels and plasma sCD40L levels at each time point indicated (Figures 3A-C) (**P
<0.001). It is well established that CD40-CD40L interaction on B cells is required for
IgM to IgG antibody class switching. Therefore, we went on to evaluate the functional
consequence of HUCBC-mediated suppression of the CD40-CD40L interaction on IgM
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and IgG titers in mouse blood samples obtained at the time of sacrifice. ELISA data
revealed a significantly increased ratio of IgM to IgG in PSAPP/HUCBC mice when
compared to control (Figure 3D, *P < 0.05), suggesting that the CD40 signaling pathway
is functionally suppressed in HUCBC-infused PSAPP mice. It has been recently reported
that CD40 deficiency in APP transgenic mice confers a decrease in Aβ/β-amyloid loads
(Laporte et al., 2006). Although to a lesser extent than PSAPP/CD40+/+ mice, we also
found PSAPP/CD40-/- mice do clearly manifest β-amyloid deposits (data not shown),
allowing us to test whether administration of HUCBC to PSAPP/CD40-/- mice resulted in
further amelioration of amyloidosis in these animals. Thus, we treated PSAPP/CD40-/- at
8 weeks of age with HUCBC or PBS (control) and assayed circulating Aβ levels, which
correlate with cerebral amyloid levels in transgenic AD mice (DeMattos et al., 2002a).
Results indicate no further benefit of HUCBC in PSAPP/CD40-/- mice on enhanced Aβ
plasma levels (Figures 3E and F; P > 0.05), a presumed indicator of Aβ brain-to-blood
efflux. These data suggest that HUCBC mediate beneficial effects on reduction of
amyloidosis via reducing CD40 pathway bioactivity, and are consistent with our previous
studies showing that genetic or pharmacologic ablation of CD40-CD40L interaction
mitigates AD-like pathology in transgenic mice (Tan et al., 1999a; Tan et al., 2002a).
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Figure 3
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Figure 3. HUCBC infusion results in CD40-dependent increased plasma Aβ levels in
PSAPP mice. ELISA analysis results are shown from blood (plasma) for (A) Aβ1-40, (B)
Aβ1-42, (C) sCD40L, and (D) IgM/IgG. Data are presented as mean ± SD (n = 10) for
Aβ1-40, Aβ1-42 or sCD40L (pg/mL plasma). Arrows below the panels show the time for
each peripheral infusion with HUCBC or PBS. (D) data are presented a ratio of IgM to
IgG in blood (plasma) from mice at the 6th month following the treatment. Aβ ELISA
analysis for (E) Aβ1-40 and (F) Aβ1-42 in blood (plasma) derived from PSAPP/CD40+/+ or
PSAPP/CD40-/- mice at the 2nd month following the third HUCBC infusion. Data in (E
and F), are presented as mean ± SD (n = 4, 2 ♂/2♀) of Aβ1-40 or Aβ1-42 (pg/mL plasma).
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We hypothesized that, if HUCBC mediated reduced amyloidosis by reducing
CD40 pathway activity, this should be associated with a shift from pro- to antiinflammatory cytokines in HUCBC-infused PSAPP mice. Consistent with this
hypothesis, we found that plasma levels of the anti-inflammatory cytokines IL-4 and IL10 were increased in HUCBC-infused PSAPP mice (Figure 4A, **P < 0.001).
Furthermore, primary splenocytes from HUCBC-infused PSAPP mice showed reduced
pro-inflammatory TNF-α and IL-12 (p70) and increased anti-inflammatory IL-10
secretion. We also analyzed brain cytokine levels by ELISA, and results showed
statistically significant increases in anti-inflammatory TGF-β1 and IL-10 levels in
PSAPP/HUCBC-infused mouse brain homogenates (Figures 4B and C; **P < 0.001).
Consistent with our data showing reduction in circulating sCD40L after HUCBC
treatment, we also measured sCD40L in brain homogenates and found a significant
decrease in PSAPP/HUCBC mice compared to control (Figure 4D, **P < 0.001).
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Figure 4. HUCBC infusion promotes anti-inflammatory/Th2 responses and decreases
sCD40L in the CNS. ELISA results are shown for (A) plasma-derived, (B) splenocyte
culture-derived, (C) brain tissue derived cytokines, and (D) brain tissue derived sCD40L.
Data are presented as mean ± SD (n = 10) values of cytokines (pg/mL plasma or medium)
(D and E), or fold increase of cytokines over control (untreated) mice (C and D).
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2.4.4 HUCBC inhibit microglial CD40 expression and enhance in vitro phagocytosis of
Aβ peptides
We and others have previously shown that microglial CD40 expression is
important for CNS inflammatory responses (Tan et al., 1999a; Tan et al., 1999b; Tan et
al., 1999c; Togo et al., 2000; Calingasan et al., 2002; Tan et al., 2002a; Tan et al., 2002b),
and IFN-γ is a strong inducer of microglial CD40 expression (Carson et al., 1998; Tan et
al., 2000; Sokol et al., 2006). In order to investigate whether a soluble factor secreted
following HUCBC infusion could modulate microglial expression of CD40, we treated
primary microglial cells with serum from HUCBC- or PBS-infused individual PSAPP
mice in the presence of IFN-γ (100 ng/mL) for 8 hrs. We then examined CD40
expression by FACS analysis. As shown in Figure 5A, sera derived from HUCBCinfused PSAPP mice significantly inhibited IFN-γ-induced microglial CD40 expression
compared to controls (P < 0.001). However, this effect was not directly mediated by
HUCBC or human adult mononuclear cells (HAMNC), but was rather due to a soluble
circulating factor produced by HUCBC-infused PSAPP mice (Figure 5A).
We and others have shown that stimulation of microglial CD40 results in
impaired Aβ phagocytic activity (Townsend et al., 2005) and promotion of microgial
neurotoxic inflammatory responses (Ponomarev et al., 2006). Thus, we wished to
examine whether HUCBC could enhance microglial phagocytosis of Aβ peptide. We
prepared primary cultures of adult microglia from HUCBC- and PBS-infused PSAPP
mice according to previously described methods (Lue and Walker, 2002), and then
subjected these cells to Aβ phagocytosis assay using native or Aβ antibody-opsonized
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fluorescent-tagged Aβ1-42 (FITC-Aβ1-42) according to our previously described methods
(Townsend et al., 2005). As shown in Figure 5B, when measuring FITC-tagged Aβ1-42 in
cell supernatants or lysates, one-way ANOVA followed by post-hoc comparison showed
a significant increase in Aβ uptake by microglia derived from HUCBC- vs. PBS-infused
PSAPP mice (**P < 0.001). Interestingly, the presence of Aβ IgG [2.5
µg/mL;(Townsend et al., 2005)] significantly enhanced Aβ uptake by PSAPP/HUCBCvs. PSAPP/PBS-derived microglial cells (##P < 0.001). Given that sera from HUCBCinfused PSAPP mice suppressed IFN-γ-induced microglial CD40 expression, we wished
to test if the sera could increase microglial Aβ phagocytosis. We incubated primary
cultures of neonatal microglia with serum from individual PSAPP/HUCBC- vs.
PSAPP/PBS mice at 1:200, 1:400, and 1:800 dilutions in the presence of FITC-Aβ1-42.
We found that sera at the 1:200 dilution markedly enhanced microglial phagocytosis of
Aβ1-42 peptide, which was opposed by the presence of recombinant mouse CD40L
protein at 2 µg/mL (Figure 5C).
In addition, we wished to test if sera-derived HUCBC-treated mice could increase
peripheral macrophage phagocytic activity. We incubated both sera derived from
HUCBC and PBS-treated animals at 1:200, 1:400, and 1:800 dilutions with primary
macrophage cells from wild-type mice in six-well tissue-culture plates in the presence of
300 nM FITC-Aβ1-42 as described above. We found that sera at the 1:200 dilution
significantly enhanced macrophage phagocytosis of Aβ1-42 peptide (Figure 5D) (**P <
0.01 with n = 4 for each mouse group presented). However these effects were not
observed in cultured HUCBC media (data not shown).
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Figure 5. HUCBC modulate microglial CD40 expression and promote Aβ
microglial/macrophage phagocytic activity. (A) FACS analysis for CD40 expression in
primary wild-type neonatal microglial cells treated with cultured medium from HUCBC
or human adult mononuclear cells (HAMNC), or serum from individual PSAPP/HUCBC
or PSAPP/PBS mice following IFN-γ challenge. Data are presented as percentage of
CD40 expressing cells (mean ± SD; n = 5). (B,C,D) Microglial/macrophage
phagocytosis assay results for extracellular and cell-associated FITC-Aβ1-42, which was
detected using a fluorometer. Data are represented as the relative fold of mean (± SD)
fluorescence over control for each sample (n = 4 for each condition presented). Primary
microglial cells from (B) adult PSAPP/HUCBC or PSAPP/PBS mice, (C) wild-type
neonatal microglia, and (D) primary peripheral macrophage.
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2.5 Discussion
Based on genetic, biochemical, and post-mortem evidence, Aβ peptides are key
etiological contributors to AD pathogenesis (Hardy and Selkoe, 2002). In addition to
parenchymal Aβ deposits, deposition of Aβ in the cerebral vasculature (known as CAA)
is a pathological feature of AD, and occurs with 83% frequency in AD patients (Ellis et
al., 1996; Hardy and Selkoe, 2002; Jellinger, 2002; Green et al., 2005). Aβ has been
shown to mediate pro-inflammatory and neurodegenerative changes, and oligomeric
forms of the peptide are neurotoxic (Malinin et al., 2005). It is well-documented that
brain inflammatory mechanisms mediated by reactive glia are activated in response to Aβ
plaques (Benzing et al., 1999; Eikelenboom and van Gool, 2004; Rozemuller et al., 2005;
Townsend et al., 2005). Expression profiles of two such pro-inflammatory molecules,
CD40 and CD40L, are markedly increased in and around Aβ plaques in AD patients and
in mouse models of the disease (Togo et al., 2000; Calingasan et al., 2002), and genetic
or pharmacologic blockade of CD40-CD40L interaction reduces AD-like pathology in
transgenic AD mice (Tan et al., 2002a), suggesting an etiologic role of this
receptor/ligand dyad in the disease (Town et al., 2001; Tan et al., 2002b). In a recent
clinical report, it was found that circulating sCD40L levels are significantly increased in
AD patients (Desideri et al., 2006), suggesting that peripheral as well as brain
dysregulation of the CD40 pathway occurs in AD. We have previously shown that CD40
ligation promotes pro-inflammatory activation of microglia and reduces microglial
phagocytosis of Aβ peptide in vitro (Tan et al., 1999a; Townsend et al., 2005), supporting
a mechanistic explanation for reduced AD-like pathology after blocking the CD40-
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CD40L interaction (Tan et al., 2002b).
HUCBC have been shown to down-regulate pro-inflammatory Th1 response in an
animal model of stroke (Vendrame et al., 2004), and have also shown therapeutic benefit
in other neuroinflammatory/neurodegenerative conditions (El-Badri et al., 2006;
Garbuzova-Davis et al., 2006; Henning et al., 2006). Based on this evidence, we sought
to examine their putative therapeutic value in mitigating AD-like pathology in transgenic
mice. After HUCBC infusion, treated mice exhibited diminished cerebral Aβ/β-amyloid
pathology and down-regulation of pro-inflammatory responses in the brain and in the
periphery. Based on the conspicuous role of CD40-CD40L interaction in mediating brain
pro-inflammatory response and exacerbating AD-like pathology, we investigated whether
HUCBC-mediated reduction of AD-like pathology might be associated with alteration in
this receptor/ligand dyad. Our results show decreased expression of microglial CD40 and
reduction in both CNS and peripheral sCD40L concomitant with HUCBC-induced
diminished AD-like pathology, raising the possibility that disruption of CD40-CD40L
interaction may be responsible for mitigation of AD-like pathology in this scenario. To
directly address this hypothesis, we treated PSAPP mice deficient for CD40 with
HUCBC and assayed circulating Aβ levels as a marker of brain-to-blood Aβ efflux, and
results showed no further benefit of HUCBC in these mice.
Here, we demonstrate that infusion of the HUCBC mononuclear fraction into
PSAPP and Tg2576 mice results in reduced levels of both soluble and insoluble brain
Aβ1-40, 42 concomitant with increased plasma Aβ1-40, 42 levels. Past studies have suggested
brain-to-blood clearance mechanisms that selectively remove Aβ from the brain,
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potentially reducing Aβ levels in normal as well as AD patient brains (Shibata et al.,
2000; DeMattos et al., 2002a; DeMattos et al., 2002b; Shiiki et al., 2004; Crossgrove et
al., 2005). Experiments in rat models demonstrating clearance of Aβ1-40 peptide from the
brain via the blood-brain-barrier (BBB) support this notion (Shibata et al., 2000; Shiiki et
al., 2004; Terasaki and Ohtsuki, 2005). Vascular endothelial cells, which are important
BBB constituents, express CD40 (Suo et al., 1998; Tan et al., 1999d; Town et al., 2001;
Sokol et al., 2006), and we now show that sCD40L is reduced in blood plasma from
HUCBC-treated PSAPP mice, raising the possibility that interruption of CD40-CD40L
interaction at the level of cerebrovascular endothelial cells may promote brain-to-blood
clearance of Aβ. Further, reduced circulating sCD40L levels in HUCBC-treated PSAPP
mice raises the possibility that inflammatory cytokines produced by CD40-CD40L
interaction on endothelial cells are reduced, and this idea is consistent with our finding of
a shift towards anti-inflammatory cytokines in the CNS after HUCBC infusion.
Interestingly, we also demonstrate that CAA [which is present in 83% of AD patients
(Ellis et al., 1996)] is reduced by 68% after HUCBC treatment in Tg2576 AD mice. This
result shows that reduction in parenchymal Aβ does not come at the cost of increased
vascular Aβ deposits, unlike a model in which transforming growth factor-β1
overexpression reduces parenchymal plaques but increases vascular Aβ deposits (WyssCoray et al., 1997; Wyss-Coray et al., 2001).
In vitro HUCBC studies have shown that these cells secrete soluble factors that
have beneficial effects (Vendrame et al., 2005; Newman et al., 2006). For example,
supernatants from cultured HUCBC promote survival of NT2 neural cells and peripheral
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blood mononuclear cells cultured under conditions designed to induce cell stress and
limit protein synthesis (El-Badri et al., 2006). Additionally, HUCBC have been shown to
produce a number of neurotrophic factors and cytokines that modulate inflammatory
responses, including nerve growth factor, colony stimulating factor-1, thrombopoietin,
and IL-11 (Suen et al., 1994; McGowan et al., 1999; Vendrame et al., 2004). Previous
reports have shown that HUCBC entry into the brain is not required to promote
neuroprotection (Borlongan et al., 2004), and that recovery following brain injury is
mediated through peripheral responses (Townsend et al., 2005). We did not detect
infiltration of HUCBCs into brain parenchyma, either at 4 hrs after HUCBC
administration or at the time of mouse sacrifice (data not shown), making it unlikely that
these cells were directly involved in ameliorating cerebral amyloidosis. Therefore, we
hypothesized that a soluble factor produced after HUCBC infusion in the periphery was
responsible for reduced AD-like pathology and inflammatory response. To test this, we
1) measured cytokines in blood plasma, spleen, and brains from HUCBC- or PBS-treated
PSAPP mice, 2) evaluated the impact of sera from these treated mice on IFN-γ-induced
microglial CD40 expression, and 3) assayed Aβ phagocytosis in vitro in neonatal
microglia treated with sera from HUCBC/PSAPP or PBS/PSAPP mice and in adult
microglial cultures derived from these mice. Results generally show a shift from proinflammatory Th1-type cytokines towards anti-inflammatory Th2 cytokines in tissues
from HUCBC-treated PSAPP mice. Further, sera from HUCBC-treated mice are able to
reduce microglial CD40 expression and enhance Aβ phagocytosis by these cells. Finally,
adult microglia from HUCBC-treated PSAPP mice have increased capacity to
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phagocytose Aβ.
When taken together, the above results suggest that, in addition to promoting
brain-to-blood Aβ efflux, HUCBC infusion promotes production of a peripheral antiinflammatory soluble factor that is likely able to cross the BBB and affect microglial Aβ
clearance. Previous reports have show that soluble factors, including heat-shock proteins
and pro-inflammatory cytokines, are capable of modulating Aβ phagocytosis by
microglia (Kakimura et al., 2002; Koenigsknecht-Talboo and Landreth, 2005), and our
previous work has shown that microglial CD40-CD40L interaction retards Aβ
phagocytosis/clearance (Townsend et al., 2005). Non-saturable BBB transport
mechanisms have been described for a number of cytokines including TNF-α (which is
transported via TNF receptors) and IL-1, and other soluble factors such as leukemia
inhibitory factor, chemoattractant-1, and epithelial growth factor (Quan and Banks,
2007). Thus, it remains possible that soluble factors produced by the host in response to
HUCBC treatment gain access to the brain via the BBB and encounter microglia.
Ultimately, we propose that infused HUCBCs exert their effect on reducing cerebral
amyloidosis by causing the host to secrete a soluble factor that acts by reducing sCD40LCD40 interaction on microglia, which then promotes microglial clearance of Aβ. This
mechanism is supported by our observations of 1) reduced brain levels of sCD40L in
HUCBC-infused PSAPP mice, 2) reduced CD40 expression on microglia cultured in the
presence of HUCBC-infused PSAPP mouse sera, 3) increased Aβ phagocytosis/removal
by microglia cultured in the presence of HUCBC-infused PSAPP mouse sera or cultured
from adult PSAPP/HUCBC mice, and 4) our previous observations that microglial CD40
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ligation shifts these cells away from a Aβ phagocytic phenotype and towards a proinflammatory response (32). Future studies designed to identify this soluble factor are
warranted, and may yield additional pharmacotherapeutic target(s). Additionally, our
observation of no further therapeutic benefit of HUCBCs when administered to
PSAPP/CD40-/- mice establishes a CD40 pathway-dependent mechanism for HUCBC
therapeutic benefit on reduction of cerebral amyloidosis. These results dovetail with our
previous studies showing that CD40-CD40L interaction mitigates AD-like pathology in
transgenic mice (Tan et al., 1999a; Tan et al., 2002a).
It was recently shown that peripheral macrophages are able to infiltrate the brain
and limit cerebral amyloidosis in AD mice after irradiation, suggesting that
hematogenously-derived macrophages are efficient at phagocytosing and clearing Aβ
deposits (Simard et al., 2006). However, earlier studies have shown that brain-resident
microglia are also able to phagocytose/clear Aβ (Paresce et al., 1996; Paresce et al., 1997;
Chung et al., 1999). We did not detect the presence of brain infiltrating macrophages in
the current experimental paradigm. Specifically, we stained for CD40 (a marker for both
macrophages and microglia), and noted the presence of process-bearing cells that
morphologically resembled microglia in and around Aβ plaques (see Figure 2A). Also,
we did not observe vascular “cuffing” that would suggest the presence of infiltrating
macrophages that are frequently observed in other CNS inflammatory conditions such as
experimental autoimmune encephalomyelitis (Imrich and Harzer, 2001). Furthermore,
our results provide evidence that both primary culture microglia and macrophages posses
the ability for enhanced Aβ phagocytosis following in vitro stimulation with sera derived

65

from HUCBC-treated animals. This too is consistent with peripheral immunomodulation
of CD40-CD40L interaction by HUCBC treatment. Additionally, given the difficulties
inherent to discriminating macrophages from microglia, and the ability of peripheral
macrophages to engraft into the CNS and take up a microglial phenotype after brain
injury (Priller et al., 2001), it remains possible that peripheral macrophages may
contribute to reduced cerebral amyloidosis after HUCBC treatment.
In this report, we have shown that HUCBC infusion ameliorates AD-like
pathology, including reductions in 1) cerebral Aβ levels/β-amyloid pathology, 2) CAA,
and 3) brain inflammation including CD40-positive activated microglia and GFAPpositive activated astrocytes. These effects of HUCBCs were associated with increased
brain-to-blood efflux of Aβ and a shift from pro-inflammatory Th1 to anti-inflammatory
Th2 cytokines both in the brain and in the periphery, similar to what we observed after
Aβ immunization (Town et al., 2002; Town et al., 2005a; Town et al., 2005b). Further,
HUCBC infusion of PSAPP mice reduces both CNS and circulating sCD40L levels, and
sera from these mice is able to promote microglial Aβ phagocytosis. When taken
together, our results provide the basis for a novel immunomodulatory strategy for AD
using HUCBC.
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3.1 Abstract
Amyloid-β (Aβ) immunization efficiently reduces amyloid plaque load and
memory impairment in transgenic mouse models of Alzheimer’s disease (AD) (Schenk et
al., 1999; Morgan et al., 2000). Active Aβ immunization has also yielded favorable
results in a subset of AD patients (Hock et al., 2003). However, a small percentage of
patients developed severe aseptic meningoencephalitis associated with brain
inflammation and infiltration of T-cells (Nicoll et al., 2003; Orgogozo et al., 2003). We
and others have shown that blocking the CD40-CD40 ligand (L) interaction mitigates
Aβ-induced inflammatory responses and enhances Aβ clearance (Tan et al., 2002b;
Townsend et al., 2005). Here, we utilized genetic and pharmacologic approaches to test
whether CD40-CD40L blockade could enhance the efficacy of Aβ1-42 immunization,
while limiting potentially damaging inflammatory responses. We show that genetic or
pharmacologic interruption of CD40-CD40L interaction enhanced Aβ1-42 immunization
efficacy to reduce cerebral amyloidosis in the PSAPP and Tg2576 mouse models of AD.
Potentially deleterious pro-inflammatory immune responses, cerebral amyloid angiopathy
(CAA) and cerebral microhemorrhage were reduced or absent in these combined
approaches. Pharmacologic blockade of CD40L decreased T-cell neurotoxicity to Aβproducing neurons. Further reduction of cerebral amyloidosis in Aβ-immunized PSAPP
mice completely deficient for CD40 occurred in the absence of Aβ immunoglobulin G
(IgG) antibodies or efflux of Aβ from brain to blood, but was rather correlated with antiinflammatory cytokine profiles and reduced plasma soluble CD40L. These results
suggest CD40-CD40L blockade promotes anti-inflammatory cellular immune responses,
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likely resulting in promotion of microglial phagocytic activity and Aβ clearance while
precluding generation of neurotoxic Aβ-reactive T-cells. Thus, combined approaches of
Aβ immunotherapy and CD40-CD40L blockade may provide for safer and more
effective Aβ vaccine.

3.2 Introduction
Amyloid-β (Aβ), a proteolytic product of amyloid precursor protein (APP), is a
key molecule in the pathogenesis and progression of Alzheimer’s disease (AD) (Blennow
et al., 2006). Overproduction of soluble and aggregated Aβ species drives cerebral
amyloidosis including β-amyloid plaque formation, a hallmark pathological feature of
AD. Thus, methods developed to clear or prevent formation of Aβ in the brains of AD
patients represent a possible treatment modality. One promising approach involves
utilization of “active” Aβ immunization strategies, which produce dramatic reductions in
Aβ pathology in animal studies (Schenk et al., 1999). However, a phase IIa clinical trial
was abandoned after about 6% of Aβ-immunized AD patients developed aseptic
meningoencephalitis (Nicoll et al., 2003; Orgogozo et al., 2003) that appeared to involve
brain inflammatory reactions mediated by T-cells and microglia (Monsonego et al., 2001;
Schenk and Yednock, 2002; Greenberg et al., 2003; Monsonego et al., 2003).
Interestingly, a 12 month post-vaccination period analysis revealed an inverse correlation
between titers of amyloid plaque-reactive antibodies and rate of cognitive decline (Hock
et al., 2003), suggesting clinical efficacy. Despite the discontinuation of the clinical
trials, Aβ vaccination studies have continued in effort to identify an immunization
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approach that is both safe and effective. Current approaches have focused on minimizing
T-cell mediated inflammatory responses in efforts to prevent CNS invasion of autoaggressive T-cells, while promoting Aβ antibody-mediated clearance mechanisms
(Chackerian et al., 2006; Maier et al., 2006; Okura et al., 2006; Nikolic et al., 2007).
A possible avenue to both enhance Aβ clearance and down-regulate CNS inflammatory
responses (including invasion of reactive T-cells) involves modulation of the CD40
receptor (CD40)-CD40 ligand (CD40L) system. CD40 is a ~ 45-50 kDa cell surface
molecule, which is a member of the tumor necrosis factor-α (TNF-α)/nerve growth factor
(NGF) receptor super-family. In the periphery, a variety of innate immune cells known
as antigen-presenting cells (APCs) express CD40, including dendritic cells, B-cells, and
monocytes/macrophages. In the CNS, CD40 is expressed by resident cells including
microglia, neurons, and astrocytes, as well as by peripherally-derived APCs (Tan et al.,
2002a; Town et al., 2005). CD40L (also known as CD154), is expressed as a membraneanchored molecule by activated T-cells and astrocytes, and can also be secreted as a
smaller soluble protein (van Kooten and Banchereau, 2000). The CD40-CD40L
interaction acts as an accessory co-stimulatory pathway involved in key immune cell
processes including: activation, maturation/differentiation, growth/proliferation, and
regulation of apoptosis (Town et al., 2001a).
We have previously shown that CD40 ligation is a molecular trigger for proinflammatory microglial activation in response to Aβ peptides (Tan et al., 1999).
Further, genetic or pharmacologic blockade of the CD40-CD40L interaction reduces βamyloid pathology in the brains of transgenic mouse models of AD (Tan et al., 1999; Tan
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et al., 2002a). Increased CD40 and CD40L immunoreactivity has been found in and
around β-amyloid plaques in AD brain (Togo et al., 2000; Calingasan et al., 2002),
further suggesting that CD40-CD40L interaction may contribute to Aβ and β-amyloid
plaque pathology.
Recently, the CD40-CD40L interaction was determined to play a central role in
promoting and maintaining dendritic cell APC phenotype during infections (Straw et al.,
2003). In the context of CNS immunity, the CD40-CD40L interaction is required for
microglial maturation into functional APCs (Ponomarev et al., 2006). We have recently
shown that CD40L treatment of primary cultures of microglia inhibits phagocytosis of
Aβ antibody opsonized, as well as non-opsonized Aβ species (Townsend et al., 2005).
Associated with reduced Aβ phagocytic capacity, CD40L treatment up-regulated cell
surface markers indicative of an APC phenotype including CD45, CD86, MHC II, and
promoted the release of pro-inflammatory molecules including interleukin (IL)-1β and
TNF-α (Townsend et al., 2005). Thus, CD40-CD40L interaction may act as a molecular
switch necessary to drive pro-inflammatory microglial APC phenotype maturation at the
cost of reducing phagocytosis (Townsend et al., 2005; Ponomarev et al., 2006).
Additionally, blockade of the CD40-CD40L system down-regulates T-cell/microgliamediated injury in the context of experimental autoimmune encephalitis (EAE) (Howard
et al., 1999; Howard et al., 2002). Altogether, these studies suggest that blockade of the
CD40-CD40L interaction could enhance Aβ vaccination-mediated Aβ clearance
mechanisms, while minimizing pro-inflammatory T-cell-mediated damage in the CNS.
To investigate this hypothesis, we studied transgenic “PSAPP” mice overexpressing
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mutant human presenilin-1 (DeltaE9), and “Swedish” mutant human APP (APPSwe),
which develop AD-like pathology (Jankowsky et al., 2001). We took a genetic approach
to CD40 blockade by crossing these mice with CD40-/- mice to yield: CD40 wild-type
(PSAPP), CD40 heterozygous deficient (PSAPP/CD40+/-), and CD40 homozygous
deficient (PSAPP/CD40-/-) animals. We then vaccinated these mice over a course of 4
months utilizing aggregated Aβ1-42 peptide or vehicle. We also took a pharmacologic
approach by administering CD40L neutralizing antibody to Aβ1-42-vaccinated PSAPP
mice. Results from both strategies showed enhanced reduction of cerebral amyloidosis as
evidenced by reductions in Aβ load, β-amyloid plaque burden, and cerebral amyloid
angiopathy (CAA). Moreover, we report reduced cerebral microhemorrhage and
inflammatory immune responses as measured by cytokine analysis and T-cell induced
neurotoxicity to Aβ producing neurons. These results were associated with inhibition of
microglial APC phenotype. Interestingly, homozygous CD40 deficient Aβ1-42immunized PSAPP mice displayed reduced cerebral amyloidosis in the absence of
immunoglobulin G (IgG) antibodies or efflux of Aβ from brain to blood. These effects
were correlated with reduced plasma CD40 ligand (CD40L) and increased antiinflammatory cytokine levels. Altogether these data suggest that disruption of the CD40CD40L interaction enhances Aβ1-42-immunization mediated Aβ clearance mechanisms by
promoting anti-inflammatory cellular immunity to support microglial clearance of Aβ.

3.3 Materials and methods
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3.3.1 Reagents
Anti-human Aβ monoclonal antibody (4G8) was purchased from Signet
Laboratories. Aβ1-42 peptide was obtained from Biosource International (Camarillo, CA).
Aβ1-42 peptide was added to 0.9% saline (4 mg/mL), vortexed, and incubated for 24 h at
37º C. This solution was aliquoted, frozen and stored at −80º C. Immediately prior to
use, Aβ1-42 aliquots were thawed and then mixed with adjuvant or PBS at 1:1 (v/v).
Complete and incomplete Freund's adjuvant were purchased from Sigma. DuoSetTM
enzyme-linked ELISA kits (including TNF-α, transforming growth factor-β1 (TGF-β1),
IL-1β, and IL-10) were obtained from R&D Systems (Minneapolis, MN). Purified rat
anti-mouse MHC class II antibody was obtained from PharMingen (San Diego, CA).
Congo red and concanavalin A (Con A) were obtained from Sigma. Aβ1-40 and Aβ1-42
ELISA kits were purchased from IBL-America (Minneapolis, MN). Murine IgG and
HRP-conjugated goat anti-mouse IgG were obtained from Pierce Biotechnology, Inc.
(Rockford, IL). Goat anti-mouse IgM peroxidase conjugate antibody (A8786) was
obtained from Sigma.

3.3.2 Mice
Wild-type C57BL/6, PSAPP mice (APPSwe, PSEN1dE9) and CD40 deficient
(CD40-/-) mice were all obtained from Jackson Laboratories (Bar Harbor, ME). We
crossed CD40-/- mice with PSAPP mice and characterized offspring by polymerase chain
reaction-based genotyping for the mutant APP construct and mutant presenilin1 (PS1)
gene (to examine PSAPP status) and neomycin selection vector (to type for CD40
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deficiency), followed by Western blot for brain APP and splenic CD40 protein,
respectively. Animals were housed and maintained under specific pathogen-free
conditions in the College of Medicine Animal Facility at the University of South Florida,
and all experiments were in compliance with protocols approved by the University of
South Florida Institutional Animal Care and Use Committee. The animals that we
studied were PSAPP/CD40+/+, PSAPP/CD40+/-, PSAPP/CD40-/-, CD40-/-, and their
littermates. All of the mice included did not develop infections or neoplasms during the
duration of this study.

3.3.3 Immunization strategies
For our genetic approach to CD40-CD40L blockade, we crossed PSAPP and
CD40-/- mice and, at 8 months of age, divided them into groups consisting of Aβ1-42 or
vehicle (PBS)-vaccinated CD40-/- and wild-type mice (n = 8 for each group, 4♂/4♀), or
PSAPP/CD40+/+ (PSAPP/CD40+/+/Aβ1-42, PSAPP/CD40+/+/PBS), PSAPP/CD40+/(PSAPP/CD40+/-/Aβ1-42, PSAPP/CD40+/-/PBS), or PSAPP/CD40-/- (PSAPP/CD40-/-/Aβ142,

PSAPP/CD40-/-/PBS) mice (n = 16 for each group, 8♂/8♀). Immunization of these

mice was performed at regular time intervals in a similar fashion to the methods
described by Schenk et al. (Schenk et al., 1999). Briefly, 8 month-old mice were injected
with Aβ1-42 (100 µg/mouse) or PBS emulsified in monophosphoryl lipid A (detoxified
endotoxin) from S. minnesota (MPL) and synthetic trehalose dicorynomycolate (TDM)
biweekly until 9 months of age, and monthly injection with Aβ1-42 or PBS alone was
performed thereafter.
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For our pharmacologic approach to CD40-CD40L blockade, we studied 8 monthold PSAPP mice divided into five groups (n = 16 for each group, 8♂/8♀) as follows:
PBS-treated Aβ1-42 immunized PSAPP mice (PSAPP/Aβ1-42/PBS), CD40L antibodytreated Aβ1-42 immunized PSAPP mice (PSAPP/Aβ1-42/CD40L antibody), Isotype control
IgG-treated Aβ1-42 immunized PSAPP mice (PSAPP/Aβ1-42/IgG antibody), or CD40L
antibody-treated non- Aβ1-42 immunized PSAPP mice (PSAPP/CD40L antibody). We
immunized these mice with Aβ1-42 as described above and treated them with CD40L
antibody (200 µg/mouse) based on our previous report (Tan et al., 2002a). For all mice,
blood samples were collected from the sub-mandibular vein just before immunization and
then on a monthly basis thereafter 1-2 days prior to the succeeding monthly injection
(except the final collection, which was taken one month after the final injection)
throughout the course of immunization, and mice were sacrificed at 12 months of age.

3.3.4 Measurement of plasma IgG and IgM Aβ antibodies by ELISA
Aβ antibodies in individual mouse plasma and brain homogenates were measured
in duplicate according to previously described methods (Maier et al., 2005). Briefly,
human Aβ1-42 peptide was coated at 1 µg/mL in 50 mM carbonate buffer, pH 9.6 (coating
buffer) on 96-well immunoassay plates overnight at 4º C. The plates were washed with
0.05% Tween 20 in PBS (washing buffer) five times and blocked with blocking buffer
(PBS with 1% BSA, 5% horse serum) for 2 hrs at room temperature. Murine IgG or IgM
was serially diluted in coating buffer (1,000-0 µg/mL) to generate a standard curve.
Mouse plasma and brain homogenate samples were diluted in blocking buffer at
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concentrations ranging from 1:400 to 1:102,400, added to the plates, and incubated for 2
hrs at room temperature. After 3 washes with washing buffer, a detection antibody
(HRP-conjugated goat anti-mouse IgG, or HRP-conjugated goat anti-mouse IgM was
diluted at 1:4,000), added to the plates and incubated for 1 hr at 37º C. Following 4
washes, tetramethylbenzidine substrate was added to the plates and incubated for 15 min
at room temperature. Fifty µL of stop solution (2 N H2SO4) was added to each well of
the plates. The optical density of each well was immediately determined by a microplate
reader at 450 nm. Aβ antibody data are reported as µg per mL of plasma (mean ± SD).

3.3.5 Measurement of Aβ species from plasma and brain homogenates by ELISA
Mouse brains were isolated under sterile conditions on ice and placed in ice-cold
lysis buffer (containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1mM EDTA, 1 mM EGTA,
1% v/v Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM
Na3VO4, 1 µg/mL leupeptin, 1 mM PMSF) as previously described (Rezai-Zadeh et al.,
2005). Brains were then sonicated on ice for approximately 3 min, allowed to stand for
15 min at 4°C, and centrifuged at 15,000 rpm for 15 min. Aβ1-40 and Aβ1-42 species were
detected by a 2-step extraction protocol, similar to previously published methods
(Johnson-Wood et al., 1997; Rezai-Zadeh et al., 2005). Detergent-soluble Aβ1-40 and
Aβ1-42 were directly detected in plasma and brain homogenates prepared with lysis buffer
described above by a 1:4 or 1:10 dilution, respectively. Total Aβ1-40 and Aβ1-42 species
were detected by acid extraction of brain homogenates in 5 M guanidine buffer, followed
by a 1:10 dilution in lysis buffer. Aβ1-40 and Aβ1-42 were quantified in individual
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samples in duplicate using Aβ1-40 and Aβ1-42 ELISA kits in accordance with the
manufacturer’s instructions (IBL-America), except that standards included 0.5 M
guanidine buffer in some cases. Aβ1-40 and Aβ1-42 are represented as pg per mL of plasma
or pg per mg of total protein (mean ± SD).

3.3.6 Brain and plasma cytokine analysis
Enzyme-linked immunoabsorbance assay (ELISA) for detection of IL-1β, IL-10,
TGF-β1, or TNF-α was carried out for measurement of cytokines in mouse blood plasma,
or brain. Tissues were obtained at the time of sacrifice, and were diluted in PBS and
assayed using the kits described above in strict accordance with the manufacturer's
instruction (R&D Systems). The Bio-Rad protein assay (Bio-Rad Laboratories, Hercules,
CA) was performed to measure total cellular protein from each sample prior to
quantification of cytokine release by ELISA, and cytokine secretion is expressed in
pg/mg total protein.

3.3.7 Histology
Mice were anesthetized with isofluorane and transcardially perfused with ice-cold
physiological saline containing heparin (10 U/ml). Brains were rapidly isolated and
quartered using a mouse brain slicer (Muromachi Kikai, Tokyo, Japan). The first and
second anterior quarters were homogenized for Western blot analysis, and the third and
fourth posterior quarters were used for microtome or cryostat sectioning as previously
described (Tan et al., 2002a). Brains were then fixed in 4% paraformaldehyde in 0.9%
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saline at 4°C overnight and routinely processed in paraffin in a core facility at the
Department of Pathology (University of South Florida College of Medicine). Five
coronal sections from each brain (5 µm thickness) were cut with a 150 µm interval.
Paraffin sections were routinely deparaffinized and hydrated in a graded series of ethanol.
All sections were pre-blockading for 30 min at ambient temperature with serum-free
protein block (Dako Cytomation, Carpinteria, CA).
Aβ immunohistochemical staining was performed using anti-human amyloid-β
antibody (clone 4G8; 1:100; Signet Laboratories) in conjunction with the VectaStain Elite
ABC kit (Vector Laboratories, Burlingame, CA) coupled with the diaminobenzidine
substrate. For microglia/macrophage immunostaining (MHC II, Iba, and CD45), sections
were prepared as described above. Following pre-blocking, sections were treated
overnight with anti-mouse MHC II (1:500) Iba (1:100) or CD45 (1:500) antibodies
diluted in PBS (obtained from Santa Cruz (O'Keefe et al., 2002)), incubated with HRPconjugated anti-mouse IgG, and developed. For congo red histochemistry, sections were
routinely deparaffinized and rinsed in 70% (v/v) ethanol before staining with freshfiltered 1% (w/v) congo red diluted in 70% ethanol for 5 min. These sections were rinsed
three times for 5 min each in 70% ethanol, hydrated for 5 min in 0.9% saline, and
mounted. β-amyloid plaques and reactive microglia were visualized using an Olympus
BX-51 microscope (Olympus, Tokyo, Japan).
Quantitative image analysis was performed for 4G8 immunohistochemistry and
congo red histochemistry. Images were obtained using an Olympus BX-51 microscope
and digitized using an attached MagnaFire™ imaging system (Olympus, Tokyo, Japan).
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Briefly, images of five 5-µm sections (150 µm apart) through each anatomic region of
interest (hippocampus or cortical areas) were captured and a threshold optical density was
obtained that discriminated staining form background. Manual editing of each field was
used to eliminate artifacts. Data are reported as percentage of immunolabeled area
captured (positive pixels) divided by the full area captured (total pixels). Quantitative
image analysis was performed by a single examiner (TM) blinded to sample identities.

3.3.8 Splenocyte cultures
Cell suspensions of splenocytes from individual mice were prepared as previously
described (Town et al., 2001b; Town et al., 2002) and passed in 0.5 mL aliquots into 24well plates at 3 × 106 cells/mL. These cells were cultured for 48 h in the presence or
absence of Con A (5 µg/mL), or Aβ1-42 (20 µg/mL). Supernatants were then collected
and assayed by IFN-γ, IL-2, and IL-4 cytokine ELISA kits in strict accordance with the
manufacturer's instruction (R&D Systems). The Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA) was performed to measure total cellular protein from each
well prior to quantification of cytokine release by ELISA, and cytokine secretion is
expressed in pg/mg total cellular protein (mean ± SD). To verify whether stimulation of
splenocytes produced any between-groups differences on cell death that might account
for altered cytokine profiles, LDH release assay was carried out as described (Townsend
et al., 2005) and LDH was not detected in any of the wells studied.

3.3.9 Aβ-specific lymphocyte neurotoxicity assay

87

Primary cultured neuronal cells were used as target cells in 51Cr release assay for
Aβ-specific lymphocyte neurotoxicity (Tan et al., 1999). We co-cultured primary
neuronal cells from PSAPP mice or their littermates with CD3+ T-cells (including CD4+
and CD8+ T-cells) isolated from primary cultures of splenocytes derived from Aβ1-42/IgGor Aβ1-42/CD40L antibody-treated PSAPP mice as described above. As in our previous
studies (Tan et al., 1999; Town et al., 2002), primary neuronal cells were labeled with
51

Cr as target cells and co-cultured with T-cells as effectors. Four hour-51Cr release assay

was then carried out. Total release represents the radioactivity released after lysis of
target cells with 5% Triton X-100.

3.3.10 Statistical analysis
All data were normally distributed; therefore, in instances of single mean
comparisons, Levene’s test for equality of variances followed by t-test for independent
samples was used to assess significance. In instances of multiple mean comparisons,
analysis of variance (ANOVA) was used, followed by post-hoc comparison using
Bonferroni’s method. Alpha levels were set at 0.05 for all analyses. The statistical
package for the social sciences release 10.0.5 (SPSS Inc., Chicago, Illinois) was used for
all data analysis.

3.4 Results

3.4.1 CD40 deficiency modulates Aβ antibody production after Aβ vaccination
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It is well-established that B-cells require CD40 engagement by T-cell-derived
CD40L to produce IgG antibodies in response to vaccination (Kawabe et al., 1994;
Bishop and Hostager, 2003). To determine the effects of Aβ1-42 vaccination on Aβ
antibody production in the absence of CD40 expression, strain- and gender-matched
CD40 deficient (CD40-/-) and wild type mice (n = 8 per group, 4♂/4♀) were immunized.
We employed a four-month vaccination strategy according to modified previous methods
(Schenk et al., 1999) utilizing synthetic aggregated Aβ1-42 peptide or PBS with
MPL/TDM as adjuvant. Mouse plasma samples were collected monthly over this fourmonth vaccination period and subjected to ELISA for measurement of Aβ antibodies.
Results indicated potent Aβ IgG production in wild-type mice, whereas CD40-/- mice
produced no detectable Aβ IgG (Figure 6A, top panel). While CD40-/- mice did not
produce detectable Aβ IgG, they did produce Aβ IgM that was not significantly different
from wild-type mice [98.56 ± SD 7.45 vs. 86.98 ± SD 12.09 (µg/mL at 1 month after the
first immunization).
To investigate the impact of CD40 deficiency on Aβ1-42 vaccination-induced
humoral immune responses in a mouse model of AD, we vaccinated 8 month-old PSAPP
mice with three CD40 genotypes (PSAPP/CD40+/+, PSAPP/CD40+/-, and PSAPP/CD40/-

) with either Aβ1-42 or vehicle (PBS). Blood samples from all mice were individually

collected once monthly over the four month vaccination period. As expected, Aβ1-42
vaccinated PSAPP/CD40-/- mice demonstrated no detectable Aβ IgG, whereas
PSAPP/CD40+/- and PSAPP/CD40+/+ mice produced similar increases in Aβ antibodies
throughout the four-month Aβ1-42 vaccination program (Figure 6A, bottom panel).
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3.4.2 Increased plasma Aβ1-40 and Aβ1-42 in heterozygous CD40 deficient PSAPP mice
after Aβ vaccination
Activation of Aβ efflux from the CNS to the systemic circulatory system is a
well-recognized clearance mechanism underlying Aβ vaccination in AD mouse models
(Sigurdsson et al., 2002; Lemere et al., 2003). To determine the effect of partial or
complete CD40 deficiency on activation of Aβ efflux after Aβ1-42 vaccination, we
separately measured plasma Aβ1-40 and Aβ1-42 species by ELISA monthly over the fourmonth vaccination period. Importantly, PSAPP/CD40+/-/Aβ1-42 mice exhibited
dramatically increased plasma Aβ1-40 and Aβ1-42 compared to PSAPP/CD40-/-/Aβ1-42
animals at the time points analyzed (Figure 6B, P < 0.001), pointing to a shift in Aβ load
from the CNS to the systemic circulation in this group. PSAPP/CD40-/-/Aβ1-42 mice
displayed very low levels of plasma Aβ species, similar to unvaccinated mouse groups.
The lack of elevated Aβ plasma levels in PSAPP/CD40-/-/Aβ1-42 mice can most likely be
explained by the absence of Aβ IgG in this mouse group, as homozygous CD40
deficiency conferred absence of Aβ IgG production to either Aβ species (Figure 6A,
bottom panel). Interestingly, PSAPP/CD40+/-/Aβ1-42 mice displayed similarly elevated
plasma levels of Aβ1-40 and Aβ1-42 when compared with the PSAPP/CD40+/+/Aβ1-42 mouse
group (P > 0.05). These data further suggest that Aβ IgG production may be required for
Aβ efflux from the CNS to the periphery in this vaccination paradigm.
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Figure 6. Evaluation of the effects of CD40 deficiency on Aβ antibody generation and
Aβ efflux in Aβ1-42-immunized mice. Peripheral blood samples were collected monthly
throughout the four-month Aβ immunization course. (A) The graph shows antibody
levels for wild-type vs. CD40-/- mice (top panel) and PSAPP mice deficient for CD40 vs.
appropriate controls as indicated (bottom panel) following Aβ1-42 vaccination.
PSAPP/CD40+/+/Aβ1-42 and PSAPP/CD40+/-/Aβ1-42 mice produced similar elevations in
Aβ IgG antibodies, in contrast to PSAPP/CD40-/-/Aβ1-42, PSAPP/CD40+/+/PBS,
PSAPP/CD40+/-/PBS, and PSAPP/CD40-/-/PBS mice that produced undetectable levels of
Aβ IgG antibodies. Data are presented as mean ± SD of plasma Aβ antibodies (µg/mL).
(B) Plasma Aβ1-40 and Aβ1-42 peptides were measured separately by ELISA. Data are
represented as mean ± SD of Aβ1-40 (top panel) or Aβ1-42 (bottom panel).
PSAPP/CD40+/+/Aβ1-42 and PSAPP/CD40+/-/Aβ1-42 mice produced similar elevations in
plasma Aβ1-40 and Aβ1-42, in contrast to PSAPP/CD40-/-/Aβ1-42, PSAPP/CD40+/+/PBS,
PSAPP/CD40+/-/PBS, and PSAPP/CD40-/-/PBS mice that produced minimal levels of
plasma Aβ1-40 and Aβ1-42.
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3.4.3 Reduced cerebral Aβ1-40 and Aβ1-42 in heterozygous CD40 deficient PSAPP mice
vaccinated with Aβ1-42
As shown in Figure 7, results revealed that Aβ1-42 vaccination of mice completely
(PSAPP/CD40-/-) and partially (PSAPP/CD40+/-) deficient for CD40 yielded decreased
amounts of soluble (top panels) and insoluble (bottom panels) Aβ1-40 and Aβ1-42 in brain
homogenates as measured by ELISA. Most importantly, a significantly greater reduction
in both soluble and insoluble Aβ1-40 and Aβ1-42 levels was evident in the PSAPP/CD40+//Aβ1-42 group compared to either PSAPP/CD40+/+/Aβ1-42 or PSAPP/CD40-/-/Aβ1-42
groups (*P < 0.05; **P < 0.001). We further observed that β-amyloid histopathology
was also markedly reduced in the PSAPP/CD40+/-/Aβ1-42 group as determined by Aβ
antibody immunohistochemical analysis (Figure 8A), and congo red staining (Figure 8B)
of mouse coronal brain sections from Aβ vaccinated mice. Quantitative analysis of
results revealed significantly reduced Aβ antibody- and congo red-positive β-amyloid
plaque burden in each brain region examined from PSAPP/CD40+/-/Aβ1-42 mice as
compared to either PSAPP/CD40+/+/Aβ1-42 or PSAPP/CD40-/-/Aβ1-42 groups (Figure 8C,
**P < 0.001). Together, these data indicate that CD40 heterozygosity confers the
greatest reduction in Aβ load in PSAPP mice when compared to all other groups
following Aβ1-42 vaccination, and suggest that partial disruption of CD40 signaling could
maximize Aβ1-42 vaccination efficacy.
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Figure 7
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Figure 7. Cerebral Aβ levels are significantly reduced in Aβ1-42-immunized PSAPP
mice heterozygous for CD40. Detergent-soluble Aβ1-40 and Aβ1-42 (A) and insoluble (5M
guanidine-soluble) Aβ1-40 and Aβ1-42 peptides (B) were measured separately in brain
homogenates by ELISA. Data are presented as mean ± SD of Aβ1-40 or Aβ1-42 (pg/mg
protein).
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Figure 8
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Figure 8. β-amyloid pathology is reduced in Aβ1-42-immunized PSAPP mice
heterozygous for CD40. Mouse coronal brain sections were embedded in paraffin and
stained with monoclonal human Aβ antibody (A), or were stained with congo red (B),
and the hippocampus is shown. (C) Percentages [plaque area/total area; mean ± SD with
n = 16 mice (8♂/8♀)] of Aβ antibody-immunoreactive Aβ plaques (top panel) and congo
red-positive Aβ deposits (bottom panel) were calculated by quantitative image analysis
for each brain region (CC/H: cingulate cortex and hippocampus; EC: entorhinal cortex)
as indicated.
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Interestingly, Aβ plaque reduction in PSAPP/CD40-/-/Aβ1-42 mice was
significantly reduced when compared to PSAPP/CD40+/+/Aβ1-42, or PSAPP/CD40-/-/PBS
groups (Figure 8C, *P < 0.05). These data are additionally supported by ELISA analyses
of both soluble and insoluble Aβ1-40 and Aβ1-42 in brain homogenates (Figure 7), and
suggest other mechanisms besides Aβ IgG production, such as cellular immune
responses, might be involved in the observed reductions of cerebral Aβ/β-amyloid in
PSAPP mice after Aβ1-42 vaccination.

3.4.4 Aβ1-42 vaccination results in markedly increased anti-inflammatory cytokines and
reduced plasma soluble CD40L in PSAPP/CD40-/- mice
Due to the observed lack of Aβ IgG antibodies in PSAPP/CD40-/- mice following
Aβ1-42 vaccination, we wished to investigate whether cellular immune responses could be
involved in the reductions of cerebral Aβ and β-amyloid deposits in these animals. To
test this hypothesis, we performed ELISA to examine anti-inflammatory cytokine profiles
in brain homogenates from PSAPP/CD40+/+, PSAPP/CD40+/-, and PSAPP/CD40-/- mice
vaccinated with either Aβ1-42 or vehicle (PBS). As shown in Figure 9A, analysis of data
revealed significantly (**P <0.001) elevated expression of brain IL-10 from either
PSAPP/CD40-/-/Aβ1-42 or PSAPP/CD40-/+/Aβ1-42 mice compared to PSAPP/CD40+/+/Aβ142

mice, but not for IL-1β ( P >0.05). Moreover, we found a significant decrease in

plasma soluble CD40L (sCD40L) when comparing PSAPP/CD40-/-/Aβ1-42 to either
PSAPP/CD40+/+/Aβ1-42 or PSAPP/CD40-/-/PBS mice (**P <0.001, Figure 9B). Reduced
sCD40L in PSAPP/CD40-/-/Aβ1-42 compared to PSAPP/CD40+/+/Aβ1-42 mice occurred in
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the absence of significantly different levels of Aβ IgM antibodies (data not shown).
These data indicate that reductions in cerebral Aβ after Aβ1-42 vaccination of
PSAPP/CD40-/-/PBS mice is associated with a rise in the anti-inflammatory cytokines IL4, IL-10 and TGF-β1, and a decrease in plasma sCD40L levels.
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Figure 9
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Figure 9. PSAPP/CD40-/- mice have increased anti-inflammatory IL-10 cytokine and
decreased plasma soluble CD40L (sCD40L) after Aβ1-42 vaccination. (A) ELISA
analysis of cytokine levels in brain homogenates from the indicated mouse groups. Data
are presented as mean ± SD of each cytokine (pg/mg total protein). (B) ELISA for
plasma sCD40L levels in the indicated mouse groups. Data are presented as mean ± SD
of plasma sCD40L protein (pg/mL).
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3.4.5 Neutralizing CD40L antibody increases circulating Aβ1-40 and Aβ1-42 levels and
reduces cerebral amyloidosis in Aβ1-42 vaccinated PSAPP and Tg2576 mice
To determine whether pharmacologic inhibition of CD40-CD40L interaction
might produce a similar effect as genetic disruption on enhancing Aβ1-42 vaccination
efficacy, we administered neutralizing CD40L antibody to PSAPP mice in combination
with active Aβ1-42 vaccination described in “Materials and Methods.” Blood samples
were individually collected from all mice at a monthly time interval. Similar to the
effects observed in Aβ1-42 vaccinated PSAPP/CD40+/- mice, Aβ1-42 vaccinated PSAPP
mice treated with CD40L antibody displayed elevations in plasma levels of Aβ1-40 and
Aβ1-42 and Aβ IgG antibodies that did not significantly differ from Aβ1-42 vaccinated
PSAPP mice injected with an isotype-matched IgG control antibody (Figure 10A, top to
bottom, respectively). The PSAPP/Aβ1-42/CD40L antibody and PSAPP/Aβ1-42/IgG
groups produced greater plasma levels of Aβ1-40 and Aβ1-42 species and Aβ antibodies
than either PSAPP mice receiving PBS or treatment with CD40L antibody alone,
confirming that 1) immunization of this cohort of animals was successful and 2)
neutralizing CD40L did not hamper Aβ antibody production (Figure 10A). Additionally,
no significant differences were revealed for either plasma Aβ1-40 and Aβ1-42 levels or Aβ
antibodies when comparing PSAPP/Aβ1-42/IgG to PSAPP/Aβ1-42 groups (P > 0.05; data
not shown).
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Figure 10. Peripheral and cerebral Aβ levels are reduced in Aβ1-42-immunized PSAPP
mice treated with CD40L neutralizing antibody. (A) ELISA analysis for plasma levels of
Aβ1-40 and Aβ1-42 and Aβ antibodies. Plasma Aβ1-40 (top panel) and Aβ1-42 (middle panel)
were measured separately by ELISA. PSAPP/Aβ1-42/CD40L antibody and PSAPP/Aβ142/IgG

mice produced similar elevations in plasma Aβ1-40 and Aβ1-42, in contrast to

PSAPP/CD40L antibody and PSAPP/PBS mice which produced minimal levels of
plasma Aβ1-40 and Aβ1-42. Data are represented as mean ± SD of Aβ1-40 or Aβ1-42 (pg/mL)
in plasma. Aβ antibody levels (bottom panel) were measured by ELISA. PSAPP/Aβ142/CD40L

antibody and PSAPP/Aβ1-42/IgG mice produced similar elevations in plasma

Aβ IgG antibodies in contrast to PSAPP/CD40L antibody and PSAPP/PBS mice which
had undetectable levels of plasma Aβ IgG antibodies. Data are presented as mean ± SD
of Aβ antibodies (µg/mL) in plasma. No significant difference in Aβ antibody levels
between PSAPP/Aβ1-42/CD40L antibody and PSAPP/Aβ1-42/IgG mice (P > 0.05) was
observed. (B) Soluble Aβ1-40 and Aβ1-42 peptides (top panel) and insoluble Aβ1-40 and
Aβ1-42 (bottom panel) in brain homogenates were measured separately by ELISA. Data
are presented as mean ± SD of Aβ1-40 or Aβ1-42 peptides normalized to total protein
(pg/mg).
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We next examined the effect of neutralizing CD40L antibody on cerebral Aβ
levels in PSAPP mice vaccinated with Aβ1-42. ELISA analysis revealed that PSAPP/Aβ142/CD40L

antibody mice display significantly reduced amounts of cerebral soluble and

insoluble Aβ1-40 and Aβ1-42 peptides as compared with PSAPP/Aβ1-42/IgG,
PSAPP/CD40L antibody, or PSAPP/PBS groups (**P < 0.001; Figure 10B).
Furthermore, PSAPP/Aβ1-42/CD40L antibody mice showed a marked reduction in
cerebral Aβ deposits compared to PSAPP/Aβ1-42/IgG mice or other control groups (**P <
0.001; Figs. 11A –C). These data show additional reduction in cerebral Aβ and βamyloid in the context of Aβ1-42 vaccination provided by pharmacologic blockade of
CD40-CD40L interaction.
Together, these data demonstrate that disruption of the CD40-CD40L interaction
by 1) a genetic approach or 2) pharmacologic depletion of available CD40L by
neutralizing antibody enhances reduction of cerebral amyloidosis after Aβ1-42
vaccination. Recent studies have shown CAA and cerebral microhemorrhage often occur
in AD mice following intraperitoneal injection (i.p) active or passive Aβ vaccination
(Wilcock et al., 2004; Wilcock et al., 2007). Thus, we next investigated if disruption of
CD40L activity could reduce CAA following Aβ vaccination in the Tg2576 mouse model
of AD. Since Tg2576 mice are known to produce CAA pathology at 15 to 20 months of
age (Christie et al., 2001; Li et al., 2003; Friedlich et al., 2004; Kim et al., 2007), we
initiated i.p. injection of these mice with CD40L antibody at 12 months of age (n = 16,
8♂/8♀) in conjunction with active Aβ1-42 immunization using an identical procedure as
described above. Four months later, we sacrificed these mice and examined CAA. As
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shown in Figs. 11D – E, disruption of CD40L activity by the depleting antibody not only
promotes additional reduction in total congo red after Aβ1-42 vaccination, but also further
reduces vascular congo red signal. This was confirmed by statistical analysis, which
revealed significant differences between Tg2576/Aβ1-42/IgG and Tg2576/Aβ1-42/CD40L
antibody groups (**P < 0.001) for both total and vascular congo red. In addition, we also
analyzed cerebral Aβ levels/β-amyloid deposits in these two groups by Aβ ELISA and
immunochemistry. Similar to the effects observed in Aβ1-42/CD40L antibody-vaccinated
PSAPP mice, Tg2576 mice receiving both Aβ1-42 immunization and depleting CD40L
antibody displayed a marked decrease in cerebral soluble and insoluble Aβ1-40 and Aβ1-42
levels and β-amyloid load compared to Aβ1-42-alone-immunized mice (P < 0.001; data
not shown).
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111

112

113

114

115

Figure 11. Cerebral β-amyloid deposits and cerebral amyloid angiopathy are reduced in
Aβ1-42-immunized PSAPP or Tg2576 mice treated with CD40L neutralizing antibody.
Mouse paraffin-embedded coronal brain sections from were stained with rabbit Pan-βamyloid antibody (A) or with congo red (B), and the hippocampus is shown. (C)
Percentages (plaque area/total area; mean ± SD) of Aβ antibody-immunoreactive deposits
(top panel) or of congo red-stained sections (bottom panel) were calculated by
quantitative image analysis. (D) Tg2576 received Aβ1-42 vaccination plus neutralizing
CD40L antibody or isotype-matched control IgG both Aβ1-42, and brain sections were
stained with congo red (hippocampus is shown). Positions of the hippocampal subfields
CA1, CA3, and DG (dentate gyrus) are indicated in the upper left panel. Arrows indicate
Aβ deposit-affected vessels. (E) Percentages (% of area) of congo red-stained plaques
were quantified by image analysis [mean ± SD with (n = 16, 8♂/8♀)].
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3.4.6 CD40 pathway blockade decreases MHC II and CD45-positive microglia and
increases anti-inflammatory cytokines in Aβ1-42 immunized PSAPP mice
To evaluate the effects of CD40/CD40L blockade on pro-inflammatory APC-like
microglial activation in the Aβ1-42 vaccination paradigm, we first stained brain sections
from PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody mice with Iba1 antibody
(Figure 12A). We quantified Iba1 positive microglia/macrophages with/without the
spindle-shaped morphology, as it has been previously reported that microglial cells
become spindle-shaped when exposed to stimuli including LPS and Con A that promote
the pro-inflammatory APC phenotype (Washington et al., 1996; Bernhardi and Nicholls,
1999). Interestingly, disruption of CD40L activity significantly reduced spindle-shaped
microglia/macrophages by morphologic analysis (**P < 0.001), but did not alter nonspindle-shaped cells (Figure 12B). To further evaluate whether CD40L neutralization
mitigated APC-like microglia, we fluorescently labeled brain sections with MHC II and
CD45 antibodies. As shown in Figure 12C, Iba1 positive microglial cells were largely
positive for CD45 and MHC II in Aβ1-42/IgG immunized PSAPP mice, but not in Aβ1-42
and CD40L antibody co-immunized PSAPP mice. These data indicate that depletion of
functional CD40L results in decreased pro-inflammatory APC-like microglial activation
in PSAPP/Aβ1-42/CD40L antibody mice. It should be noted that Iba1 immunostaining
does not distinguish resident microglia from peripherally-derived monocytes that may
migrate to the CNS and take up a microglial phenotype.
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Figure 12. CD40L blockade inhibits APC-like microglial activation in Aβ1-42 vaccinated
PSAPP mice and promotes anti-inflammatory cellular immunity. (A) Representative
hippocampal sections from PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody
mouse brains were stained with Iba1 antibody to illustrate both microglial load and
morphology. (B) Quantitative image analysis of microglial load (Iba1 positive) and
percentage of spindle-shaped Iba1 positive microglia is shown. (C) Representative
hippocampal sections from PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody
mouse brains were stained with Iba1 together with MHC II or CD45 antibodies to
illustrate microglial load and activation status (DAPI was used as a nuclear counterstain).
(D) Th1 and Th2 cytokine analysis by ELISA was conducted on mouse brain
homogenates from PSAPP, PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody
mice. Data are represented as mean ± SD of each cytokine in brain homogenates (pg/mg
total protein) from PSAPP, PSAPP/Aβ1-42/CD40L antibody or PSAPP/Aβ1-42/IgG mice.
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To further determine the consequences of this phenomenon in terms of
inflammatory responses, we analyzed brain homogenates from PSAPP/Aβ1-42/CD40L
antibody, PSAPP/Aβ1-42/IgG, and other control groups by ELISA for expression of proinflammatory and anti-inflammatory cytokines. Analysis of results revealed a
significantly (**P <0.001) greater expression of anti-inflammatory TGF-β1 and IL-10
cytokines from PSAPP/Aβ1-42/CD40L antibody mice compared to the PSAPP/Aβ1-42/IgG
mice (Figure 12D). Moreover, PSAPP/Aβ1-42/CD40L antibody mice also produced
significantly (P <0.001) greater expression of TGF-β1 and IL-10 when compared to other
controls including PSAPP/IgG and PSAPP/Aβ1-42/PBS mice (data not shown). No
significant between-groups differences were revealed when considering TNF-α or IL-1β.
These data indicate that CD40L blockade correlates with a rise in the anti-inflammatory
cytokines TGF-β1 and IL-10, without affecting the pro-inflammatory cytokines TNF-α
and IL-1β.

3.4.7 Aβ1-42-immunized PSAPP mice treated with CD40L neutralizing antibody exhibit
increases in anti-inflammatory cytokines and decreases in neurotoxic inflammatory
responses in vitro
To investigate Aβ-specific T-cell immune responses after Aβ1-42 immunization
plus neutralizing CD40L antibody treatment, we established primary cultures of
splenocytes from: PSAPP/Aβ1-42/IgG, PSAPP/Aβ1-42/CD40L antibody, PSAPP/CD40L
antibody, and PSAPP/PBS mice. We then quantified key cytokines produced by
activated T-cells (IFN-γ, IL-2, and IL-4) in supernatants by ELISA. Both non-specific
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(Con A) and specific recall stimulation of primary cultured splenocytes with Aβ1-42
resulted in increases in the pro-inflammatory T-cell cytokines, IFN-γ and IL-2, in both
PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody groups compared to the
PSAPP/CD40L antibody group (Figure 13A). However, these pro-inflammatory T-cell
cytokines were reduced in the PSAPP/Aβ1-42/CD40L antibody group versus PSAPP/Aβ142/IgG

mice. Moreover, PSAPP/Aβ1-42/CD40L antibody mice demonstrated increased

anti-inflammatory T helper type 2 cytokine IL-4 when compared to PSAPP/Aβ1-42/IgG
mice. These data indicate that disruption of CD40L activity in Aβ1-42 vaccinated mice
reduces pro-inflammatory Aβ-specific T-cell immune responses in favor of an antiinflammatory response. One-way ANOVA followed by post hoc comparison revealed
significant differences when comparing PSAPP/Aβ1-42/CD40L antibody to
PSAPP/CD40L antibody or PSAPP/Aβ1-42/IgG mouse groups for levels of each of the
three cytokines (**P < 0.001) after in vitro Aβ1-42 challenge. Of note, there were
significant differences within mouse groups between IL-4 and either IFN-γ or IL-2 after
Aβ1-42 recall challenge (##P < 0.001). Following challenge, no significant difference in
cytokine release was observed from splenocytes between PSAPP/PBS and PSAPP/Aβ142/IgG

control mouse groups (P > 0.05; data not shown).
To determine whether CD40L neutralization could mitigate potentially damaging

effects of Aβ-specific T-cells, we co-cultured primary neuronal cells from PSAPP mice
or their littermates with CD3+ T-cells (including CD4+ and CD8+ T-cells) isolated from
the primary cultured splenocytes derived from PSAPP/Aβ1-42/IgG or PSAPP/Aβ142/CD40L

antibody mice as described above. Per our previous reports (Tan et al., 2000;
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Tan et al., 2002a; Town et al., 2002), we labeled primary neuronal cells with 51Cr as
target cells and co-cultured them with T-cells as effectors, and carried out four-hour 51Cr
release assay. ANOVA showed main effects of effector:target ratio for Aβ1-42 vaccinated
PSAPP mouse-derived T-cells (effectors) and PSAPP mouse-derived neuronal cells
(target cells) (**P <0.001; n = 8 mice for PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L
antibody groups; n = 5 mice for both control groups) (Figure 13B), but not when
unvaccinated PSAPP mouse-derived T-cells were used (control 1) or when control
littermate (non-transgenic mouse)-derived neuronal cells (control 2) were used (P >
0.05). ANOVA followed by post-hoc comparison revealed a significant difference across
ratios between PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody T-cells (**P <
0.001), indicating an overall decrease in percentage of cell lysis as a result of disrupting
CD40L activity.
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Figure 13
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Figure 13. Aβ-specific neurotoxic inflammatory responses are reduced in Aβ1-42immunized PSAPP mice deficient for CD40. (A) Splenocytes were individually isolated
and cultured from mice as indicated after Aβ1-42 immunization and either CD40L
antibody treatment or PBS injection (control). These cells were stimulated with Con A (5
µg/mL) or Aβ1-42 (20 µg/mL) for 48 hrs. Cultured supernatants were collected from these
cells for IFN-γ, IL-2, and IL-4 cytokine analyses by ELISA. Data are represented as
mean ± SD (n = 10) of each cytokine in supernatants (pg/mg total intracellular protein).
(B) Aβ specific T cell-mediated neuronal cell injury was determined by 51Cr release
assay. Data are reported as mean 51Cr release values ± SD, and n = 8 for each condition
presented. PSAPP/Aβ1-42/IgG mouse group, effectors: Aβ1-42/IgG-immunized PSAPP
mouse-derived T cells; target cells: PSAPP-mouse-derived primary neuronal cells.
PSAPP/Aβ1-42/CD40L antibody mouse group, effectors: Aβ1-42/CD40L antibodyimmunized PSAPP mouse-derived T cells; target cells: PSAPP-mouse-derived primary
neuronal cells. Control 1, effectors: unvaccinated PSAPP mouse-derived T cells; target
cells: PSAPP mouse-derived neuronal cells. Control 2, effectors: Aβ1-42-immunized
PSAPP mouse-derived T cells; target cells: non-transgenic mouse-derived primary
neuronal cells.
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3.5 Discussion
We have previously shown the CD40-CD40L interaction enhances proinflammatory microglial activation triggered by cerebral Aβ deposits (Tan et al., 1999).
This form of microglial activation is deleterious, as both genetic ablation of CD40L and
CD40L neutralizing antibody reduce brain levels of several neurotoxic inflammatory
cytokines and mitigate cerebral amyloidosis in AD mouse models (Tan et al., 2002a). To
establish a possible mechanism to explain these results, we previously quantified
microglial phagocytic activity in CD40 deficient versus CD40 sufficient AD mice. We
observed inhibition of microglial Aβ phagocytosis upon CD40 ligation. This coincided
with increased microglial co-localization of MHC class II with non-opsonized
Aβ peptide. Moreover, this APC phenotype was accompanied by upregulation of proinflammatory Th1 cytokines such as TNF-α, IL-1β, IL-2, and IFN-γ (Townsend et al.,
2005). These data suggest that CD40 pathway blockade induces “switching” of the
microglial phenotype from a pro-inflammatory APC state to an anti-inflammatory, prophagocytic state (Townsend et al., 2005). Interestingly, brain Aβ clearance in the Aβ
immunotherapy paradigm has previously been suggested to rely on microglial
phagocytosis (Bard et al., 2000), and microglial Fc receptor (i.e., microglial phagocytosis
of Aβ antibody-opsonized deposits) is not required for brain Aβ clearance (Das et al.,
2003). Thus, we suggest that the combination of blocking the microglial CD40 pathway
and Aβ immunotherapy further enhances microglial Abeta clearance.
Previous clinical investigation has revealed that active immunization with Aβ in
humans confers the unacceptable risk of aseptic meningoencephalitis associated with T-
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cell infiltration, gliosis, and associated rise in CNS pro-inflammatory mediators (Schenk
et al., 1999; Schenk and Yednock, 2002; Nicoll et al., 2003). Based on these data and our
work on the CD40-CD40L association with brain Aβ levels, we investigated whether
CD40 blockade could reduce cerebral Aβ deposits without the undesirable inflammatory
events in the CNS.
First, we tested whether active Aβ1-42 vaccination of CD40 deficient mice could
produce significant levels of Aβ antibodies. Consistent with the requirement of CD40
signaling for IgM to IgG class switching (Kawabe et al., 1994), homozygous CD40
deficient mice vaccinated with Aβ1-42 did not produce detectable Aβ IgG antibodies, but
had slightly increased levels of Aβ IgM antibodies vs. wild-type controls. However,
active Aβ1-42 vaccination of PSAPP/CD40+/- mice produced elevated plasma anti-Aβ IgG
antibodies comparable to CD40 sufficient PSAPP mice which are consistent with a gene
dose-effect (Figure 6A). Interestingly, further reduction in cerebral amyloidosis in Aβvaccinated PSAPP/CD40-/- occurred essentially in the absence of Aβ IgG antibodies. It is
well known that the CD40 pathway is essential for antibody isotype switching from IgM
to IgG, and this result suggests that the additional therapeutic benefit from blocking the
CD40 pathway is independent of IgG in our system. However, given 1) the requirement
of CD40 signaling for a diverse set of immunological responses and 2) that we did not
use IgG deficient mice, this conclusion should be taken with caveats.
Next, we quantified plasma levels of Aβ1-40 and Aβ1-42 species across the various
groups of Aβ-immunized PSAPP mice in an attempt to determine the relationship
between IgG, IgM, and efflux of Aβ from the brain to the periphery. Similar elevations
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of plasma Aβ1-40, 42 species between CD40 heterozygous deficient or CD40 sufficient
PSAPP mice were observed (Figure 6B). Thus, we suggest that Aβ IgG-mediated brain
to blood efflux was operating similarly in CD40 heterozygous and CD40 sufficient
PSAPP mice. By contrast, Aβ1-42 vaccinated PSAPP/CD40-/- mice did not exhibit
elevations in plasma Aβ1-40, 42 species (Figure 6B). This lack of elevated plasma Aβ1-40,
42

correlated positively with the lack of Aβ IgG antibody production in the homozygous

CD40 deficient PSAPP mice. This is consistent with a lack of brain-to-blood efflux of
Aβ via the peripheral sink hypothesis (DeMattos et al., 2001), and suggests that a distinct
mechanism is operating in these PSAPP/CD40-/- mice. While CD40 deficient mice do
produce normal levels of Aβ IgM antibodies, no detectable elevation in peripheral Aβ
was observed. This, too, is in accord with the notion that Aβ IgG is required for brain to
blood efflux of Aβ (DeMattos et al., 2001). As pharmacotherapeutic “proof of
principle”, we administered CD40L neutralizing antibody to Aβ1-42 vaccinated PSAPP
mice, and confirmed greater reductions in cerebral amyloidosis compared to Aβ1-42
vaccinated PSAPP mice given control IgG. This experimental approach was performed
to offset the possibility that genetic ablation, in and of itself, does not confer
developmental changes that would result in modulation of Aβ loads.
We next went on to test T-cell specific immune responses against Aβ and found
that recall stimulation of primary cultured splenocytes with Aβ1-42 peptide resulted in
reduced IFN-γ and IL-2 production in the PSAPP/Aβ1-42/CD40L antibody mouse group
compared to PSAPP/Aβ1-42/IgG mice (Figure 13A). Further, PSAPP/CD40+/-/Aβ1-42 mice
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exhibited an increase in the anti-inflammatory Th2 cytokine, IL-10, and produced less
circulating soluble CD40L (sCD40L) compared to PSAPP/CD40+/+/Aβ1-42 mice (Figure
9). Taken together, these findings suggest partial CD40 pathway inhibition reduces proinflammatory but increases anti-inflammatory T-cell immune responses to Aβ challenge.
This is particularly attractive as these results raise the possibility that 50%
pharmacological inhibition of CD40 might be of benefit in the attenuation of the proinflammatory meningoencephalitis associated with active Aβ vaccination in humans,
while still allowing for production of Aβ IgG antibodies.
In addition to developing parenchymal Aβ deposits and associated elevated
inflammatory cytokines seen in the PSAPP model, the Tg2576 mouse model of AD also
develops cerebrovascular Aβ deposits not unlike cerebral amyloid angiopathy (CAA),
which is observed in the majority of AD patients (Nicoll et al., 2003; Wilcock et al.,
2004; Wilcock et al., 2007). To determine if reducing available CD40L might also
mitigate CAA, we administered neutralizing CD40L antibody to Aβ vaccinated Tg2576
mice. Indeed blockade of the CD40L with neutralizing antibody in combination with Aβ
vaccination produced the highest therapeutic effect (reduction of parenchymal Aβ) and
the most minimal CAA-like pathology as measured by parenchymal and congo red
staining respectively (Figs. 11D – E). These results suggest CD40L antibody
neutralization not only improves the cerebral amyloid reducing effect of Aβ vaccination,
but also confers a reduction in undesirable CAA-like pathology in Tg2657 mice.
Previously, we showed that CD40 ligation shifts microglial response to Aβ from an antiinflammatory phagocytic phenotype to a pro-inflammatory APC response (Town et al.,
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2002; Townsend et al., 2005). In accord, here we observed downregulation of microglial
APC morphology in situ (Figs. 12A – B), and reduction in CD45 and MHC II-positive
microglia from Aβ1-42 vaccinated PSAPP mice treated with CD40L neutralizing antibody
(Figure 12C). Indeed, reduction in MHC II expression, a measure of microglial APC
phenotype, correlated with elevated brain levels of anti-inflammatory Th2 cytokines
TGF-β1 and IL-10 (Figure 12D). Although NK cell-mediated activation of microglia can
bypass MHC and T cell receptors to produce a vaccine immune response, infiltration of
NK cells into the CNS has not been reported in the Aβ vaccination paradigm, making this
less likely.
Another possibility is that so-called “anti-ergotypic” responses, defined as an
immune response to the vaccine-activated host immune cells, could play a role in
enhanced efficacy of Aβ immunotherapy in conjunction with CD40 blockade. Shortterm anti-ergotypic lines isolated from vaccinated Multiple Sclerosis (MS) patients
demonstrate a mixed phenotype (both CD4+ and CD8+ cells). These cells secrete IFN-γ
and TNF-α, but not TGF-β1 (Correale et al., 1997; Hellings et al., 2004). Although we
can not fully rule out this mechanism in our studies of CD40 blockade enhancement of
reduced cerebral amyloidosis after Aβ vaccination, it is interesting to note that our results
in the CNS and in splenocytes show the converse: a reduction in IFN-γ and TNF-α, but
an increase in TGF-β (Figure 12D and Figure 13A), suggesting the involvement of a
different mechanism.
Given our previous observation CD40 ligation induces “switching” of the
microglial phenotype from a pro-phagocytic state endorsing Aβ phagocytosis to a pro-
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inflammatory APC state (Townsend et al., 2005), we propose that combined CD40
blockade and Aβ vaccination promotes microglial phagocytosis/clearance of Aβ from the
CNS. Additionally, T-cells derived from neutralizing CD40L antibody-treated Aβ1-42
vaccinated PSAPP were dramatically less neurotoxic to Aβ producing neurons ex vivo
(Figure 13B), suggesting further benefit afforded by combining these therapeutic
approaches. However, it is worth noting that this latter result needs to be interpreted with
the caveat that standard active Aβ vaccination of AD mouse models (unless modified
with the addition of pertussis toxin) (Furlan et al., 2003) does not produce appreciable
brain infiltrates of auto-aggressive T-cells as was observed in the active Aβ AN-1792
vaccine in AD patients (Nicoll et al., 2003; Town et al., 2005).
CD40-CD154 interaction is essential for initiating the adaptive immune response,
as demonstrated by immune deficits observed in patients with mutations in the CD40 or
CD40L genes. These patients develop type 1 hyper IgM immunodeficiency syndrome
(HIGM1) that is characterized by recurrent bacterial and opportunistic infections
(Durandy 2001; Fuleihan 2001; Levy et al., 1997a). Patients with homozygous mutations
in the CD40 gene have a severe immunodeficiency termed HIGM3. Its clinical
phenotype overlaps with that of HIGM1 and is characterized by defective generation of
secondary antibodies and severe opportunistic infections, (Ferrari et al., 2001; Kutukculer
et al., 2003) particularly Cryptosporidium enteritis and Pneumocystis carinii pneumonia
(Levy et al., 1997b). Thus, complete systemic blockade of CD40-CD40L would likely
have deleterious immunosuppressive side effects. For this reason, pharmacotherapy
would need to be titrated such that the CD40-CD154 pathway was partially inhibited.
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Interestingly, as we have shown in our proof-of-concept paradigm in transgenic mice,
even a 50% blockade of CD40 is enough to increase the efficacy of the Abeta vaccine on
reduction of cerebral amyloidosis.
Our observations suggest that partial blockade of CD40 signaling, either by
genetic or by pharmacologic means, increases the effectiveness of Aβ1-42 vaccination by
further reducing cerebral amyloidosis and simultaneously promoting anti-inflammatory
cellular immune processes in the brain and in the periphery. If the benefit afforded by
CD40 pathway blockade to Aβ1-42 vaccinated AD mouse models can translate to the
clinical syndrome, then pharmacotherapy aimed at reducing CD40 signaling in
conjunction with Aβ vaccination may represent an approach that is both safer and more
effective in humans. Future studies will be required to isolate CD40-CD40L downstream
signaling involved in reduced efficacy of Aβ vaccination, as this may uncover additional
targets for pharmacologic intervention.
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CHAPTER FOUR
TRANSCUTANEOUS AΒ PEPTIDE IMMUNIZATION OF TRANSGENIC
ALZHEIMER’S MICE RESULTS IN REDUCED CEREBRAL AΒ DEPOSITS IN
THE ABSENCE OF T-CELL INFILTRATION AND MICROHEMORRHAGE

4.1 Abstract
Alzheimer’s disease (AD) immunotherapy accomplished by vaccination with βamyloid peptide (Aβ) has proved efficacious in AD mouse models. However, “active”
Aβ vaccination strategies for the treatment of cerebral amyloidosis without concurrent
induction of detrimental side effects are lacking. We have developed a novel
transcutaneous (t.c.) Aβ vaccination approach and have evaluated efficacy and
monitored for deleterious side effects, including meningoencephalitis and
microhemorrhage, in wild-type mice and in a transgenic mouse model of AD. We
demonstrate that t.c. immunization of wild-type mice with aggregated Aβ1-42 plus the
adjuvant cholera toxin (CT) results in high-titer Aβ antibodies (mainly of the
immunoglobulin G1 class) and Aβ1-42-specific splenocyte immune responses. Confocal
microscopy of the t.c. immunization site revealed Langerhans cells in areas of the skin
containing the Aβ1-42 immunogen, suggesting that these unique innate immune cells
participate in Aβ1-42 antigen processing. To evaluate the efficacy of t.c. immunization in
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reducing cerebral amyloidosis, transgenic PSAPP (APPsw, PSEN1dE9) mice were
immunized with aggregated Aβ1-42 peptide plus CT. Similar to wild-type mice, PSAPP
mice showed high Aβ antibody titers. Most importantly, t.c. immunization with Aβ1-42
plus CT resulted in significant decreases in cerebral Aβ1-40, 42 levels coincident with
increased circulating levels of Aβ1-40, 42, suggesting brain-to-blood efflux of Aβ.
Reduction in cerebral amyloidosis was not associated with deleterious side-effects of
brain T-cell infiltration or cerebral microhemorrhage. Together, these data suggest that
t.c. immunization constitutes a novel, effective and potentially safe treatment strategy for
AD.

4.2 Introduction
Alzheimer’s disease (AD) is the most common dementing illness and is
pathologically characterized by the presence of intracellular neurofibrillary “tangles” and
extracellular senile plaques primarily composed of 40-42 amino acid Aβ peptides (Selkoe
2001). In a seminal report, Schenk and colleagues showed that intraperitoneal
vaccination of the PDAPP transgenic mouse model of AD with Aβ1-42 plus Freund’s
adjuvant resulted in dramatic reduction of cerebral amyloidosis (Schenk et al. 1999).
This therapeutic approach is clearly highly efficacious; however, the safety of this
strategy has become an important concern. In a recent clinical trial, patients were
administered a synthetic Aβ peptide (AN-1792) plus adjuvant and approximately 6% of
these patients developed aseptic meningoencephalitis, most likely mediated by braininfiltrating activated T-cells (Hock et al. 2003; Bayer et al. 2005). This serious side-
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effect led to suspension of the clinical trial. Furthermore, passive transfer of Aβ
antibodies to transgenic AD mice results in cerebral microhemorrhage, a potentially
adverse side-effect (Wilcock et al. 2004; Racke et al. 2005). Uncovering of these adverse
events has re-directed Aβ vaccination strategies towards the goal of developing an
approach that is both safe and effective.
Studies examining the brains of Aβ vaccinated patients developing
meningoencephalitis implicate Aβ reactive T-cell subsets as major components of this
deleterious response to active Aβ vaccination (Nicoll et al. 2003; Ferrer et al. 2004). To
subvert possible meningoencephalitis resulting from Aβ vaccination, various strategies
have been attempted. Interestingly, recent works suggest that Aβ-derived peptides
delivered intranasally to mucosal epithelial tissues (with adjuvant) results in effective
clearance of Aβ plaques and improvement of cognitive function in animal models of AD.
Moreover, T-cell reactivity appeared to be considerably reduced compared with other
active immunization strategies (Maier et al. 2005; Maier et al. 2006). In other studies,
differential T-cell responses were observed dependent upon the epitope/fragment of Aβ
peptide utilized for vaccination. Specifically, portions of the Aβ peptide seemed to
stimulate different T-cell responses, resulting in either pro-inflammatory T-helper cell
type 1 (Th1) responses, or anti-inflammatory T-helper cell type 2 (Th2) responses. Such
findings imply that Aβ vaccination is not only efficacious, but may also prove to be safe
and therefore a feasible strategy for AD therapy depending upon a number of factors
including route of delivery, adjuvant choice, and Aβ epitope administered.
The skin is a well-established effective route for vaccination, including delivery
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of peptide-based vaccines (Beignon et al. 2005; Itoh; Celis 2005; Dell et al. 2006).
Strong humoral and cellular immune responses have been elicited after transcutaneous
(t.c.) vaccination (Giudice; Campbell 2006), largely owing to the diverse populations of
resident antigen presenting cells (APCs) and other immune cells in the various dermal
layers. Subsets of dermal-resident Langerhans cell (LC) precursors, known as migratory
CD14+ LC precursors, are important immune regulators that demonstrate “professional”
APC capability including reducing T-cell stimulatory function by producing antiinflammatory cytokines (Larregina et al. 2001). Also, skin-resident keratinocytes release
the anti-inflammatory cytokine interleukin (IL)-10 in response to certain stimuli.
Keratinocyte-derived IL-10 serves to buffer harmful pro-inflammatory immune activation
and therby preserves skin barrier integrity (Niizeki; Streilein 1997).
Taken together, these lines of evidence led us to hypothesize that targeting Aβ
immunotherapy to skin tissue may provide an immunotherapeutic approach that is both
efficacious and safe. To evaluate this hypothesis, we tested a t.c. Aβ immunization
strategy using both wild-type and the transgenic PSAPP (APPsw, PSEN1dE9) mouse
model of AD (Jankowsky et al. 2001). We found that t.c. immunization of nontransgenic C57BL/6 mice with aggregated Aβ1-42 peptide plus the adjuvant cholera toxin
(CT) resulted in high Aβ antibody titers [mainly immunoglobulin (Ig) G1], and Aβ1-42specific splenocyte immune responses after re-challenge with the peptide. Confocal
microscopy of the t.c. immunization site revealed CD207 and CD11c double-positive
Langerhans cells in areas of the skin containing the Aβ1-42 immunogen, suggesting that
these unique innate immune cells participate in Aβ1-42 antigen processing. Further,
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transgenic PSAPP mice t.c. immunized with aggregated Aβ1-42 peptide plus CT
manifested effective immune responses against Aβ in concert with reduced cerebral Aβ
pathology, demonstrating the effectiveness of this approach. These mice showed high
Aβ antibody titers and increased circulating Aβ levels, suggesting brain-to-blood efflux
of Aβ. Importantly, brain T-cell infiltration and cerebral microhemorrhage were not
observed after t.c. immunization, indicating that this immunization strategy is potentially
safe.

4.3 Materials and methods

4.3.1 Reagents.
Lyophilized cholera toxin (CT), CT antibody, concanavalin (Con A) and mouse
CD3 antibody were obtained from Sigma (St Louis, MO). Aβ1-42 peptide was purchased
from U.S. peptides (Rancho Cucamonga, CA). As previously described (Schenk et al.
1999), Aβ1-42 peptide was added to 0.9% saline (4 mg/mL), vortexed, and incubated for
24 h at 37º C. This solution was aliquoted, frozen and stored at −80º C. Immediately
prior to use, Aβ aliquots were thawed and then mixed with CT (reconstituted with
distilled water to 0.5 mg/mL). Antibody 4G8 directed against Aβ (amino acids 17-26)
was purchased from Chemicon/Millipore (Billerica, MA). Enzyme-linked
immunoabsorbance assay (ELISA) kits for detection of IFN-γ, IL-2, and IL-4 were
obtained from R&D Systems (Minneapolis, MN). Aβ1-40 and Aβ1-42 ELISA kits were
purchased from IBL-American (Minneapolis, MN). Murine IgG and HRP-conjugated
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goat anti-mouse IgG were obtained from Pierce Biotechnology, Inc. (Rockford, IL).
Biotinylated anti-mouse IgG1, IgG2a and IgG2b were purchased from Zymed®
Laboratories (South San Francisco, CA). Alexa-Fluor™-conjugated secondary antibodies
(including Alexa-Fluor™488, 594, and 647) were purchased from Invitrogen (Carlsbad, CA).
Lactate dehydrogenase (LDH) kit was obtained from Promega (Madison, WI).

4.3.2 Animals
Wild-type C57BL/6 and PSAPP (APPsw, PSEN1dE9) mice were obtained from
Jackson Laboratory (Bar Harbor, ME). Animals were housed and maintained in the
College of Medicine Animal Facility at the University of South Florida, and all
experiments were in compliance with protocols approved by the University of South
Florida Institutional Animal Care and Use Committee. Brain sections from mice induced
with experimental autoimmune encephalomyelitis were provided by Dr. Terrence Town
and used as a positive control for CD3 staining. Brain sections for positive
microhemorrhage staining from mice intraperitoneally passively given Aβ antibodies
were provided by Dr. Dave Morgan (Wilcock et al. 2006).

4.3.3 Transcutaneous (t.c.) immunization of mice
To test whether t.c. delivery of Aβ peptide could stimulate immune responses, we
first t.c. immunized wild-type C57BL/6 mice. These mice (n = 10, 5 male/5 female)
were t.c. immunized with human Aβ1-42 peptide (200 µg/mouse) and CT (10 µg/mouse)
or CT alone (10 µg/mouse) in 100 µL of 0.9% saline on a weekly basis for the first
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month. Thereafter, these mice were continually t.c. immunized with Aβ1-42 (100
µg/mouse) and CT (5 µg/mL) or CT alone (5 µg/mouse) in 100 µL of 0.9% saline biweekly for the following 12 weeks. Transcutaneous immunization was performed
according to a method described by Skelding and colleagues (Skelding et al. 2006) with
minor changes. To ensure mice immobility for the duration of administration for each
immunization, mice were anaesthetized. A small lower back section (1-2 cm2) was
shaved with an extra precaution not to damage the skin. The skin was then swabbed with
acetone to remove surface oils and enhance penetration, allowed to air dry, and then rehydrated by swabbing with 0.9% saline. The shaved edge was coated with a thin
petroleum jelly layer to prevent unnecessary leakage of the immunization solution.
Lastly, 100 µL of Aβ1-42 in combination with CT or CT alone in 0.9% saline was placed
on the shaved region and allowed to be absorbed for 2 h. At the end, the skin was
washed with 0.9% saline and dried, so as to remove any remaining immunization
solution. Mice were cleaned thereafter and returned to their cages. Blood was withdrawn
on weeks 0 (immediately prior to the first immunization), 4, 8 and 16 (immediately prior
to the sacrifice of these mice). We then t.c. immunized PSAPP mice (n = 9, 4 male/5
female) at 4 months of age using the same procedure described above. No mortality was
observed over the course of the t.c. immunization and none of the animals exhibited
symptoms causing their removal from the study.

4.3.4 Splenocyte cultures.
Cell suspensions of splenocytes from individual mice were prepared as
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previously described (Town et al. 2002) and passed in 0.5 mL aliquots into 24-well plates
at 3 × 106/mL. These cells were treated for 48 h with ConA (5 µg/mL), anti-CD3 (1
µg/mL) or Aβ1-42 (20 µg/mL). Supernatants were then collected and assayed by cytokine
ELISA kits in strict accordance with the manufacturer's instruction (R&D Systems). The
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA) was performed to measure
total cellular protein from each of the cell groups under consideration just prior to
quantification of cytokine release by ELISA, and cytokine secretion is expressed in
pg/mg total cellular protein (mean ± SD). To verify whether stimulation of splenocytes
produced any between-groups differences on cell death that might account for altered
cytokine profiles, LDH release assay was carried out as described (Tan et al. 2000) and
LDH was not detected in any of the wells studied.

4.3.5 Immunofluorescence staining.
Non-transgenic C57BL/6 mice were transcutaneouslly treated with Aβ/CT, CT
alone, or PBS for 18 h, as described above. The dorsal skin was removed by careful
razor slicing around pre-labeled regions (1.5 cm in diameter) where the vaccine was
applied. Skin or brain samples were routinely prepared for immunofluorescence staining.
The staining was curried out using the following primary antibodies: anti-mouse CD207
(Langerin; 1:250; eBioscience San Diego, CA), anti-mouse CD11c (1:50; Pierce
Biotechnology, Rockford, IL), and/or anti-human Aβ antibody (clone 4G8; 1:500;
Chemicon/Millipore, Billerica, MA) or rat anti-mouse CD3 antibodies (1:200;
eBioscience) overnight at 4°C, followed by appropriate secondary antibodies conjugated
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with AlexaFluor488, -594, and/or -647 (1:500; Invitrogen) for 45 min. Sections were then
washed 3 times in PBS, and mounted with fluorescence mounting media containing
DAPI (Vector Laboratories, Inc., CA) to counter-stain cell nuclei, and then viewed under
an Olympus BX-51 microscope or visualized in independent channels using a Zeiss
LSM510 META confocal microscope equipped with a 2-photon laser that was used for
exciting DAPI.

4.3.6 Aβ antibody ELISA.
Aβ antibodies in mouse plasma and brain homogenates were measured according
to previously described methods (Maier et al. 2005). Briefly, human Aβ1-40 peptide was
coated at 2 µg/mL in 50 mM carbonate buffer, pH 9.6 (coating buffer) in 96-well
immunoassay plates overnight at 4º C. The plates were washed with 0.05% Tween 20 in
PBS (washing buffer) five times and blocked with blocking buffer (PBS with 1% BSA
and 5% horse serum) for 2 h at room temperature. Murine IgG was serially diluted in
coating buffer (1,000 - 0 ng/mL) to generate a standard curve. Mouse plasma and brain
homogenate samples were diluted in blocking buffer at concentrations ranging from
1:400 to 1:102,400, added to the plates, and incubated for 2 h at room temperature. After
5 washes with washing buffer, a detection antibody (HRP-conjugated goat anti-mouse
IgG, 1 mg/mL) was diluted (1:4,000), added to the plates and incubated for 1 h at 37º C.
Following 8 washes, tetramethylbenzidine (TMB) substrate was added to the plates and
incubated for 15 min at room temperature. Fifty µL of stop solution (2 N N2SO4) was
added to each well to terminate the reaction. The optical density of each well was
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immediately determined by a microplate reader at 450 nm. Aβ antibodies were
represented as ng per mL of plasma (mean ± SD).
ELISAs for Aβ antibody isotypes were carried out as previously described (Town
et al. 2001; Lemere et al. 2002). Ninety-six well plates were coated with Aβ1-40 peptide
(2 µg/mL) in coating buffer and incubated for 2 h at 37° C. Following three washes in
washing buffer, wells were blocked with blocking buffer for 2 h at room temperature.
Mouse plasma was serially diluted in blocking buffer, added to each well, and incubated
for 1 h at 37º C. After five washes, the plates were incubated in secondary antibodies
(biotinylated anti-mouse IgG1, IgG2a or IgG2b) diluted at 1:1,000 in blocking buffer for
1 h, followed by 30 min in streptevidin-HRP (1:200 in blocking buffer) at room
temperature. TMB substrate was added to the plates and incubated for 15 min at room
temperature. Fifty µL of stop solution was added to each well to terminate the reaction.
The optical density of each well was immediately determined by a microplate reader at
450 nm. The ratios of IgG1 to IgG2a or IgG1 to IgG2b were calculated for each time
point from each mouse individually using optical density values and then average ratio
for each group (mean ± SD).

4.3.7 Aβ ELISA.
Mouse brains were isolated under sterile conditions on ice and placed in ice-cold
lysis buffer as previously described (Rezai-Zadeh et al. 2005). Brains were then
sonicated on ice for approximately 3 min, allowed to stand for 15 min at 4°C, and
centrifuged at 15,000 rpm for 15 min. This fraction represented the detergent-soluble
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fraction. Aβ1-40, 42 species were further subjected to acid extraction of brain homogenates
in 5 M guanidine buffer (Johnson-Wood et al. 1997), followed by a 1:10 dilution in lysis
buffer. Soluble Aβ1-40, 42 were directly detected in plasma and brain homogenates
prepared with lysis buffer described above at a 1:4 or 1:10 dilution, respectively. Aβ1-40,
42 was

quantified in these samples using the Aβ1-40, 42 ELISA kits (IBL-America,

Minneapolis, Minnesota) in accordance with the manufacturer’s instructions, except that
standards included 0.5 M guanidine buffer in some cases. Aβ1-40, 42 were represented as
pg per mL of plasma and pg per mg of total protein (mean ± SD).

4.3.8 Immunohistochemistry and image analysis.
As previously described (Tan et al. 2002), five coronal sections from each brain
(5 µm thickness) were cut with a 150 µm interval. Sections were routinely deparaffinized
and hydrated in a graded series of ethanol before preblocking for 30 min at ambient
temperature with serum-free protein block (Dako Cytomation, Carpinteria, CA). Aβ
immunohistochemical staining was performed using anti-human amyloid-β antibody
(clone 4G8; 1:100) in conjunction with the VectaStain Elite ABC kit (Vector
Laboratories, Burlingame, CA) coupled with diaminobenzidine substrate. 4G8-positive
Aβ deposits were examined under bright field using an Olympus (Tokyo, Japan) BX-51
microscope. For congo red histochemistry, sections were routinely deparaffinized and
rinsed in 70% (v/v) ethanol before staining with fresh-filtered 1% (w/v) congo red diluted
in 70% ethanol for 5 min. These sections were rinsed three times for 5 min each in 70%
ethanol, hydrated for 5 min in 0.9% saline, and mounted in Vectashield fluorescence
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mounting media (Vector Laboratories). Congo red-positive β-amyloid plaques were
visualized using an Olympus BX-51 microscope. Quantitative image analysis was
performed for both immunohistochemistry and Congo red-stained tissue sections with an
Oncor V150 image analysis system. The software uses hue, saturation, and intensity
(HSI) to segment objects in the image field. Operationally, thresholds for object
segmentation are established by using a series of standard slides that have extremes of
intensity for the stain being measured. Thresholds in HSI space are established that
accurately identify objects on all standard slides, and these segmentation thresholds
remain constant throughout the analysis session. We do not adjust thresholds for each
section to avoid the introduction of experimenter bias into the estimation. Section-tosection variability in immunostaining is minor, owing to rigid fixation and staining
protocols. In most experiments using the same reaction product (e.g., DAB-peroxidase),
the same thresholds settings can be used for different antibodies. After establishing the
threshold parameters, the image field is digitized with a frame grabber. The computer
software then corrects for heterogeneity in background illumination (blank field
correction) and calculates the measurement parameters for the entire field.
For quantitative image analysis of immunohistochemistry, we combined unbiased
sampling of sections with the videodensitometric procedures we have used extensively in
the past (Wilcock et al., 2004). All procedures were performed by an individual blind to
the experimental condition of each specimen. Sample numbers were randomized before
the start of the tissue processing, and code was broken only after completion of the
analysis. We sampled every fifth section from the mouse brain, starting with a section
between 1 and 5, identified by a random number generator. Frontal cortical
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measurements were performed on laminae II-VI of the most anterior portion of the
cortex. Hippocampal measurements were performed by circumscribing the entire
hippocampus or selected hippocampal subfields. Using the standard nomenclature, "Aβ
load" is defined as percent of area in the measurement field occupied by reaction product.
Similarly, "Congo red staining" (or "amyloid load") refers to the percent of the area that
is stained with Congo red. All values from a single mouse were averaged to represent the
single value for that animal in statistical analyses. Statistical analyses were performed by
using ANOVA followed by Fischer's LSD post hoc means comparison test (Statview
software from SAS). The numbers of animals, not numbers of sections, have been used
for statistical comparisons.

4.3.9 Perl’s Prussian blue reaction for ferric ion-hemosiderin.
Sections were deparaffinized, hydrated through descending grades of ethanol,
washed in distilled water, and incubated for 20 min in a solution containing 20%
hydrochloric acid and 10% potassium ferrocyanide (VWR). These sections were washed
3 X for 5 min with H20 and counterstained with hematoxylin solution (Sigma) for 15
seconds and then mounted (Wilcock et al. 2006).

4.3.10 Statistical analysis.
Means and standard deviations were calculated according to standard practice. In
instances of multiple comparisons of the means, one-way analysis of variance (ANOVA)
was carried out with post-hoc comparison by Bonferroni’s method. In instances of single
mean comparisons, a t-test for independent samples was used to assess significance. P-
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values less than 0.05 were considered to be statistically significant. Data were analysed
using the Statistical Package for the Social Sciences (SPSS), release 13.0 (SPSS Inc.,
Chicago, IL).

4.4 Results

4.4.1 Transcutaneous immunization of mice with Aβ1-42 peptide plus cholera toxin results
in high Aβ antibody titers.
We first sought to determine whether t.c. administration of Aβ1-42 to mice could
result in Aβ antibody production. Twenty non-transgenic C57BL/6 mice at eight weeks
of age were used for this experiment, and ten mice received aggregated Aβ1-42 peptide
with CT (Aβ/CT), while the remaining ten received CT alone. Mice were t.c. immunized
over a 16-week time course; weekly for the first 4 weeks and bi-weekly for the following
12 weeks. To characterize the kinetics of the humoral immune response following
immunization, blood samples were taken at week 0 (baseline, immediately prior to the
first immunization), 4, 8 and 16 (immediately prior to the sacrifice of these mice).
Plasma Aβ antibody titers were measured by ELISA. Aβ antibody isotypes were
determined by an IgG isotyping assay using an isotype-specific secondary antibody
(Town et al. 2001). Aβ antibodies were first detected at week 4 in all immunized mice
and dramatically increased thereafter [(Figure 14A) P <0.001]. Consistent with our
previous studies that utilized an intraperitoneal route of administration of Aβ plus
Fruend’s adjuvant (Town et al. 2002), Aβ antibodies of the IgG1 isotype were produced
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at the highest level, while IgG2a antibodies directed against Aβ were present in
significantly lesser quantity (P <0.001). Aβ IgG2b antibody was least detectable (Figure
14B, C). Transcutaneous immunization was further evaluated by assaying CT antibody
titers in plasma from these mice at weeks 0, 4, 8 and 16 following immunization. A
similar pattern of results was observed, albeit CT antibody titers were higher in plasma
from mice t.c. immunized with either Aβ/CT compared with CT alone (data not shown).
As an additional control group, we injected non-transgenic C57BL/6 mice with PBS
alone (n = 10) in parallel, and we were unable to detect Aβ antibody titers in these
animals, confirming the specificity of our titer assay (data not shown).
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Figure 14
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Figure 14. Generation of immune responses in wild-type C57BL/6 mice t.c. immunized
with aggregated Aβ1-42 peptide plus CT. (A) Aβ antibody titers were measured by
ELISA. Data are presented as mean ± SD (n = 10) of Aβ antibodies (ng/mL plasma).
One-way ANOVA followed by post hoc comparison revealed significant differences in
anti-Aβ titers when comparing week 4 to weeks 8, 12, or 16 (**P < 0.001). IgG isotypes
were determined by an Ig isotyping assay and represented as ratios (mean ± SD; n = 10)
of IgG1 to IgG2a (B) or IgG1 to IgG2b (C). One-way ANOVA followed by post hoc
comparison revealed significant differences between the ratio of IgG1 and IgG2a versus
IgG1 and IgG2b at each week shown (**P < 0.001). (D) Splenocytes were individually
isolated and cultured from wild-type mice t.c. immunized with Aβ1-42/CT, CT alone, or
PBS (control). These cells were stimulated with Con A (5 µg/mL) or Aβ1−42 (20 µg/mL)
for 48 h. Cultured supernatants were collected from these cells for IFN-γ, IL-2 and IL-4
cytokine analyses by ELISA. Data are presented as relative fold mean ± SD (n = 10) of
each cytokine over PBS control. One-way ANOVA followed by post hoc comparison
revealed significant differences between groups for levels of each of three cytokines
[IFN-γ, IL-2 and IL-4 (**P <0.001)] following in vitro Aβ1-42 challenge. As noted, there
was also a significant difference in cytokine levels between IL-4 and either IFN-γ or IL-2
following Aβ1-42 challenge (##P <0.001). (E) To characterize the dermal immune
responses to Aβ/CT t.c. immunization, skin tissues were prepared from non-transgenic
C57BL/6 mice t.c. immunized for 18 h with PBS (control, top panels), CT alone (middle
panels) or with Aβ/CT (bottom panels) as indicated and then analyzed by laser scanning
confocal microscopy with the indicated antibodies (antibody 4G8 was used to reveal Aβ).
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Note the presence of CD207+CD11c+ LCs in Aβ-positive regions in the Aβ/CT t.c.
immunized group.
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Figure 15
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Figure 15. Aβ/CT t.c. immunization resulted in LC recruitment into dermal layers. To
characterize the dermal immune responses to Aβ/CT t.c. immunization, skin tissues were
prepared from nontransgenic C57BL/6 mice treated with Aβ/CT (Left), CT alone
(Center), or PBS (Right) as indicated for 18 h and then analyzed. Skin frozen sections
were stained with anti-mouse CD207 antibody/FITC-labeled anti-rat IgG2a, rabbit antihuman Aβ antibody/Alexa Fluor-555-labeled anti-rabbit IgG, and DAPI. As noted, blue
staining indicates all nucleated cells, ande green indicates CD207 positive cells
(presumed LC, ×40).
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4.4.2 Aβ-specific immune responses in splenocytes from mice transcutaneously
immunized with Aβ plus cholera toxin.
To further investigate splenocyte responses to Aβ, primary cultures of splenocytes
were established from individual mice (non-transgenic C57BL/6) t.c. immunized with
Aβ/CT, CT alone, or PBS only (control) and immune responses were compared. We
quantified key cytokines produced by activated T-cells [interferon-γ (IFN-γ), interleukin
(IL)-2, IL-4] in splenocyte supernatants by ELISA as an indicator of immune
responsiveness. Non-specific mitogenic stimulation of cultured splenocytes with
concanavalin A (Con A) resulted in over two-fold increases in IFN-γ, IL-2, and IL-4
production in cells from mice immunized with Aβ/CT or CT versus PBS-immunized
controls (Figure 14D). No statistically significant difference was noted between Aβ/CT
and CT alone groups for each cytokine (P >0.05). Similar results were observed in
cultured splenocytes stimulated with anti-CD3 (data not shown). On the other hand,
specific recall stimulation with Aβ1-42 peptide of primary cultured splenocytes from
Aβ/CT-t.c. immunized mice resulted in significantly increased production of IFN-γ, IL-2
and IL-4 compared to splenocytes cultured from mice immunized with CT alone (P
<0.001, Figure 14D). Importantly, regarding the anti-inflammatory cytokine IL-4, an 8fold increase in its secretion by splenocytes from Aβ/CT-immunized mice following Aβ142

recall stimulation was observed (P < 0.001) (Figure 14D). Taken together with the

predominantly IgG1 Aβ-specific humoral response in Aβ/CT-t.c. immunized wild-type
mice, this IL-4 result suggests an anti-inflammatory Th2-type immune response.

164

4.4.3 Transcutaneous immunization with Aβ plus CT promotes recruitment of dermal
Langerhans cells.
Given that LCs often play a key role in skin immune responses, we asked whether
LCs might be recruited to the site of t.c. Aβ/CT immunization. Skin tissues and frozen
sections were prepared from non-transgenic C57BL/6 mice 18 h after t.c. vaccination
with Aβ/CT or CT alone, and they were co-stained with antibodies against mouse CD207
antibody (Langerin, a pan-LC marker), mouse CD11c (a marker of an LC subset
(Douillard et al. 2005) and/or rabbit anti-human Aβ. Aβ/CT t.c. immunization resulted in
LC recruitment into dermal layers compared with CT alone or PBS-immunized controls
(Figure 14E and Figure 15), where dermal LCs were much less frequently observed.
Furthermore, these LCs tended to be found in regions of the skin that stained positive for
Aβ peptide by 4G8 Aβ antibody (Figure 14E). These data show the migratory action of
LCs in response to Aβ/CT t.c. stimulation and suggest that this effect is important in
mediating the initial immune response to Aβ/CT t.c. immunization.

4.4.4 Transcutaneous immunization of PSAPP mice with Aβ plus CT results in Aβspecific immune response and increased circulating Aβ.
Having shown high Aβ antibody titers and cultured splenocyte immune responses
to Aβ in Aβ/CT t.c. immunized non-transgenic C57BL/6 mice, we then asked whether
this immunization strategy would reduce cerebral amyloidosis in a mouse model of AD.
Eighteen double-transgenic (APPswe/PSEN1dE9) PSAPP mice, which overproduce
human Aβ and develop significant amyloid deposits by 8 months of age (Jankowsky et
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al. 2001), were immunized at four months of age in this study.

Half of them (n = 9)

received aggregated Aβ1-42 peptide with CT, while the remaining half received CT alone.
The 16-week procedure that we employed was identical to that used above for nontransgenic C57BL/6 mice. Blood samples were taken at weeks 0, 4, 8 and 16 following
immunization. Plasma Aβ antibody titers from these mice were measured by ELISA.
Significant increases in Aβ antibody titers were observed in PSAPP mice t.c. immunized
with Aβ/CT (P < 0.001) (Figure 16A). Similar to non-transgenic C57BL/6 mice, Aβ
antibodies were first detected at week four in plasma from Aβ/CT-immunized PSAPP
mice, and dramatically increased thereafter. By contrast, these Aβ antibodies were not
detected in plasma from CT-vaccinated control mice (Figure 16A). Two weeks after the
final immunization, primary splenocytes were isolated and cultured from individual mice.
Recall stimulation of splenocytes from Aβ/CT-t.c. immunized PSAPP mice with Aβ1-42
peptide resulted in significantly increased production of IFN-γ and IL-2, and particularly
IL-4 (data not shown), similar to results from Aβ/CT-t.c. immunized non-transgenic
C57BL/6 mice.
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Figure 16
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Figure 16. Increased systemic Aβ after Aβ1-42/CT t.c. immunization of PSAPP mice.
For Aβ analysis, blood samples were individually collected from Aβ/CT or CT alone t.c.immunized PSAPP mice at the time points indicated. (A) Plasma Aβ antibody titers were
measured by ELISA. Data are presented as mean ± SD (n = 9) of Aβ antibodies (pg/mL
plasma). ANOVA followed by post hoc comparison revealed significant differences
between Aβ/CT and CT t.c.-immunized PSAPP mice for plasma Aβ antibody levels at
each time point as indicated (**P <0.001). Moreover, this analysis revealed significant
differences between time points within the Aβ/CT t.c. immunized group as indicated (##P
<0.001). (B and C) Plasma Aβ1-40, 42 peptides were measured separately by Aβ ELISA.
Data are presented as mean ± SD (n = 9) of Aβ1-40 or Aβ1-42 (pg/mL plasma). One-way
ANOVA followed by post hoc comparison revealed significant differences between
Aβ/CT and CT alone t.c.-immunized PSAPP mice for plasma Aβ1−40, 42 levels at each
time point as indicated (*P <0.05; **P <0.001). Arrows below the panels show each t.c.
immunization with respect to time of blood sample collection.
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It has been hypothesized that passively-administered Aβ antibodies create a
“peripheral sink”; in essence, shifting the equilibrium of Aβ levels from the brain to the
blood (DeMattos et al. 2001; Matsuoka et al. 2003). To determine whether this
phenomenon was occurring in the Aβ/CT-t.c. immunization paradigm, we quantified Aβ
levels in the blood by ELISA. In support of this hypothesis, we found significantly
increased circulating Aβ1-40, 42 in PSAPP mice t.c. immunized with Aβ/CT as early as 4
weeks after immunization (Figure 16B and C). Importantly, plasma Aβ1−40, 42 levels
increased rapidly to the highest values of 781 ± 118 pg/mL and 129 ± 46 pg/mL,
respectively, by week 8 (two weeks after the third booster t.c. immunization). Thereafter,
plasma Aβ levels remained relatively constant through to the time of sacrifice following
16 weeks of immunization.

4.4.5 PSAPP mice transcutaneously immunized with Aβ plus cholera toxin show reduced
cerebral amyloidosis in the absence of T-cell infiltrates or cerebral microhemorrhage.
Having shown significantly increased circulating Aβ levels in PSAPP mice t.c.
immunized with Aβ/CT, we sought to evaluate Aβ/β-amyloid pathology in these mice.
Using a sandwich ELISA-based method, detergent-soluble Aβ1-40, 42 levels were reduced
by approximately 53 and 48%, respectively (P <0.001) (Figure 17A). Insoluble Aβ1-40, 42
(prepared by acid extraction of detergent-insoluble material in 5 M guanidine and
subsequent ELISA) levels were reduced by 50 and 54%, respectively, in Aβ/CT t.c.immunized PSAPP mice (P <0.001) (Figure 17B). We further analyzed β-amyloid
plaques in brains of mice that received t.c. immunization with Aβ/CT or CT alone by
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4G8 immnunohistochemistry and congo red histochemistry (Figure 17D and F,
respectively). At 10 months of age, Aβ/CT-t.c. immunized PSAPP mice showed 42-58%
(Figure 17E) and 61-65% (Figure 17G) reductions in 4G8 immunoreactive and congo
red-positive Aβ deposits, respectively, across hippocampal and cortical brain regions
examined. Together, these results demonstrate that t.c. immunization with Aβ/CT is
effective in reducing cerebral amyloidosis in PSAPP mice.
As shown above, we found that peripheral levels of human Aβ1-40, 42 were
increased in mice t.c. immunized with Aβ/CT. To determine this systemic increase in
human Aβ1-40, 42 was associated with a reduction in cerebral Aβ levels, we performed
correlation analysis and noted an inverse correlation between plasma and brain soluble
Aβ (Figure 17C and Figure 18), suggesting that circulating Aβ antibodies play an
important role in clearance of Aβ from brain to blood via the “peripheral sink” hypothesis
(DeMattos et al. 2001; Matsuoka et al. 2003). This effect is likely not solely responsible
for reduced cerebral amyloidosis, as, interestingly, we detect Aβ antibodies in brain
homogenates from Aβ/CT-t.c. immunized PSAPP mice [18.87 ± 6.25 (mean ng/mg total
protein ± SD)], while Aβ antibodies were undetectable in PSAPP mice t.c. immunized
with CT-alone (data not shown). Given the presence of these Aβ antibodies in the brain,
it is possible that additional Aβ clearance mechanisms (i.e., mediated by the Fc receptor
on phagocytic microglia) are operating.
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Figure 17
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Figure 17. Reduction of cerebral Aβ/β-amyloid pathology in PSAPP mice t.c.
immunized with Aβ1-42/CT. Detergent-soluble Aβ1-40, 42 peptides (A) and insoluble Aβ140, 42

prepared from 5 M guanidine extraction (B) in brain homogenates were measured

separately by ELISA. Data are presented as mean ± SD (n = 9) of Aβ1-40 or Aβ1-42
(pg/mg protein), and reductions for each group are indicated. (A and B), A t test revealed
a significant between-group difference for either soluble or insoluble Aβ1-40, 42 (P <
0.001). (C) A significant inverse correlation (P < 0.001) between plasma and brain
soluble Aβ levels was revealed. Plasma Aβ levels are presented as percentage mean ±
SD (n = 9) of soluble circulating Aβ at 16 weeks following t.c. immunization of PSAPP
mice with Aβ/CT over CT control mice. (D) Mouse brain coronal paraffin sections were
stained with monoclonal anti-human Aβ antibody 4G8. Left, Aβ1-42/CT t.c. immunized
PSAPP mice; right, CT t.c. immunized PSAPP mice. The top panels are from the
cingulate cortex (CC), the middle panels are from the hippocampus (H), and the bottom
panels are from the entorhinal cortex (EC). (E) Percentages (plaque “burden”, area
plaque/total area) of Aβ antibody-immunoreactive Aβ plaques (mean ± SD; n = 9) were
calculated by quantitative image analysis, and reductions for each mouse brain area
analyzed are indicated. (F) Mouse brain sections from the indicated regions were stained
with congo red. Left, Aβ1-42/CT t.c. immunized PSAPP mice; right, CT t.c. immunized
PSAPP mice. (G) Percentages of congo red-stained plaques (mean ± SD; n = 9) were
quantified by image analysis, and reductions for each brain region are indicated. (E and
G) a t test for independent samples revealed significant differences (P < 0.001) betweengroups for each brain region examined.
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Figure 18
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Figure 18. Simultaneous analysis of plasma and brain soluble Aβ levels on a mouse-bymouse basis. Data are presented as percentage of circulating or brain soluble Aβ at 16
weeks after Aβ/CT t.c. immunization of individual PSAPP mice (n = 9) relative to
average Aβ levels of control mice t.c. immunized with CT alone. Each color bar
represents plasma Aβ levels and brain-soluble Aβ levels from each individual mouse as
indicated.
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In a recent clinical trial, patients were administered a synthetic Aβ peptide (AN1792) plus adjuvant and approximately 6% of these patients developed aseptic
meningoencephalitis, most likely mediated by brain-infiltrating activated T-cells (Hock et
al. 2003; Bayer et al. 2005). This serious complication led to suspension of the clinical
trial. We sought to investigate whether Aβ/CT t.c. immunization might induce T-cell
infiltration into the brain. We immunostained brain sections from mice immunized with
Aβ/CT, CT alone, or, as a positive control, non-transgenic C57BL/6 mice subcutaneously
injected with myelin oligodendrocyte protein emulsified in complete Freund’s adjuvant
(brains were isolated 20 days after immunization, when copious amounts of T-cells have
infiltrated the brain). As shown in Figure 19A-C, we did not detect CD3-positive T-cells
in brains from mice t.c. immunized with CT or Aβ/CT; however, this was not due to a
technical issue as T-cells were detected in the positive control tissue (Figure 19A).
Further, we also immunostained brain sections from the above mice with CD4 or CD8
antibodies (which stain different subsets of T-cells) and did not detect T-cell infiltration
in brains of mice t.c. immunized with CT or Aβ/CT, while such cells were detected in our
positive control tissue (data not shown).
It has been reported that mice receiving passive transfer of Aβ antibodies manifest
cerebral microhemorrhage (Wilcock et al. 2004; Racke et al. 2005). To investigate this
potentially adverse side-effect of Aβ/CT t.c. immunization, we carried out
microhemorrhage analysis via Perl’s Prussian blue stain (which can detect even minute
amounts of deposited iron derived from blood (Wilcock et al. 2004; Racke et al. 2005).
We did not detect positive staining using this method in either t.c. immunized group, but
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did observe staining in our positive control tissue [in this case, from mice
intraperitoneally passively given Aβ antibodies (Wilcock et al. 2006)] (Figure 19D-F).
As an additional indicator of possible blood-brain-barrier breakdown, we analyzed
apolipoprotein B (present in blood but not normally in brain) levels in these brain tissues
by Western blot and it was undetectable in the t.c. immunized groups (Figure 20). It is
noteworthy that both the Prussian blue stain and apolipoprotein B analyses were negative
in t.c. immunized PSAPP mice, suggesting that detection of Aβ antibodies in the brains
of these mice (as mentioned above) was not due to poor perfusion efficiency or detectable
breakdown of the blood-brain-barrier, but rather was likely due to “physiological” entry
of Aβ antibodies into the brain parenchyma.
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Figure 19
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Figure 19. Absence of T-cell infiltration or brain microhemorrhage in Aβ/CT t.c.
immunized mice. To characterize the safety of the vaccine, brain sections were stained
for CD3 as an indicator of T-cell infiltration (top panels). Staining for hemosiderin was
also performed to identify microhemorrhage (bottom panels) in mice immunized with
Aβ/CT (B and E), or CT alone (C and F). These stained sections were compared to
positive controls. For CD3 staining, the positive control consisted of CD3-positive brain
sections from EAE mice (A). For microhemorrhage, experimental sections were
compared to sections from mouse brains suffering microhemorrhage (D). Each panel is
representative of staining repeated in triplicate for each brain section for either CD3 or
hemosiderin. The brain region shown for each panel is the neocortex. Magnification for
CD3 staining is 10 X while it is 20 X for microhemorrhage.
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Figure 20
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Figure 20. Apolipoprotein B protein was undetectable in brain tissue homogenates
derived from both Aβ/CT and CT t.c.-immunized mice. Brain homogenates were
prepared from PSAPP mice t.c.-immunized with Aβ/CT or CT, and an aliquot
corresponding to 100 µg of total protein was electrophoretically separated by using 4%
SDS-polyacrylamide gels. In addition, a series of mouse plasma dilutions (100, 50, and
25 µg per lane) was loaded as positive controls. Western blot analysis by apolipoprotein
B antibody (ab20737, Abcam, Inc, Cambridge, MA) shows apolipoprotein B100 in
plasma but not in brain homogenates as indicated.
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4.5 Discussion
To translate animal Aβ immunization approaches into successful clinical AD
therapies, such strategies should not only be efficacious, but also be safe, including
avoiding meningoencephalitic reactions to Aβ immunization previously observed in
humans (Janus 2003; Monsonego et al. 2003). Experimental and postmortem evidence
suggests that such aseptic meningoencephalitis observed in AD patients after Aβ
vaccination resulted from CNS invasion by Aβ reactive T-cells (Monsonego et al. 2003;
Maier et al. 2006). The requirement of Aβ-reactive T-cells for cerebral amyloid plaque
clearance mediated by “active” Aβ vaccination strategies still remains unclear
(Monsonego et al. 2003; Orgogozo et al. 2003; Ferrer et al. 2004). A previous study
utilizing intranasal delivery of short Aβ-derived peptides lacking T-cell reactive epitopes
with a specific immune-modulating adjuvant (mutant Escherichia coli heat-labile
enterotoxin; LT R192G), demonstrated the possibility of potentiating an effective
humoral anti-Aβ response while minimizing Aβ reactive T-cells (Maier et al. 2006),
suggesting that Aβ-reactive T-cells are not necessary for an effective Aβ antibody
response. If this proves to be true in humans, such an approach may represent reasonable
therapeutic potential; however, it should be noted that anosmia/hyposmia may limit the
usefulness of intranasal Aβ immunization. Further evidence that Aβ-reactive T-cells are
likely not required for Aβ immunotherapy efficacy comes from “passive” immunization
studies, which have shown that humoral responses alone may be sufficient to effectively
reduce cerebral amyloid burden, and thereby mitigate neurodegeneration (Dickstein et al.
2006; Ma et al. 2006).
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Here, we investigated the potential of t.c. Aβ immunization for the treatment of
AD-like cerebral amyloidosis in transgenic mice. Transcutaneous immunization is an
attractive route of delivery, as it is convenient, relatively painless, and minimally
invasive. This strategy is also appealing because the epidermal and dermal immune
systems provide a unique environment for immune stimulation due to LC antigen
presentation (Rozis et al. 2005; Renn et al. 2006; Schiller et al. 2006; Strid et al. 2006).
Indeed, following Aβ/CT t.c. immunization, we observed cells double-positive for
CD207 and CD11c in dermal regions that stained positive for Aβ, showing that these LCs
migrate to the t.c. immunization site and likely participate in antigen processing. The
skin immune environment has likely evolved over millennia, owing to constant
bombardment of the skin with various antigenic stimuli, resulting in a delicate balance
between immunogenic and tolerogenic responses. It is noteworthy that
transcutaneous/epicutaneous immunization has been successful in mitigating
neurodegenerative disease in both induced and spontaneous forms of experimental
autoimmune encephalomyelitis (EAE), mouse models of the demyelinating disease
multiple sclerosis (Bynoe et al. 2003; Bynoe et al. 2005).
To determine the ability of Aβ t.c. immunization to effectively produce Aβ
antibodies, we began our investigation in non-transgenic C57BL/6 mice, where we
measured the kinetics of Aβ-specific antibody titers. Remarkably, the Aβ antibody
response was observed as early as week four in all immunized mice and dramatically
increased thereafter, remaining elevated through 16 weeks post-initial vaccination.
Antibody isotype characterization demonstrated a predominantly IgG1
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(IgG1>IgG2a>IgG2b) response in line with our previous report utilizing an
intraperitoneal route of Aβ vaccination plus Freund’s adjuvant (Town et al. 2002).
Production of IgG1 and IgG2b are typically due to anti-inflammatory Th2 cytokine
signaling, whereas IgG2a typically results from pro-inflammatory Th1 signaling (Abbas
et al. 1996). The Th2 cytokine profile is likely favorable for inducing antibody
production and thus Aβ clearance without the overt pro-inflammatory (i.e., possibly
contributing to auto-immune responses) Th1-type activation that typifies cellular immune
responses (Romagnani 2000; Schwarz et al. 2001; Town et al. 2002). Accordingly, to
circumvent meningoencephalitic reactions, many studies investigating vaccination
methods for reducing cerebral amyloidosis in AD have attempted to bias Th cell
responses towards Th2 profiles utilizing various strategies (Kim et al. 2005; Dasilva et al.
2006; Ghochikyan et al. 2006). The effectiveness and potential safety of these strategies
seems promising, but further investigation is needed to confirm whether the link between
Th cell responses and meningoencephalitis in AD patients is causitive.
Notwithstanding the need for these critical studies, Aβ immunization appears to
modulate immune responses based on three major criteria: 1) tissue route of delivery, 2)
antigen epitope utilized for immunization, and 3) properties of the co-administered
adjuvant. Whether Th2 polarization in this study occurred due to route of delivery, CT
adjuvant choice, or the genetic background of the C57BL/6 strain (Rosas et al. 2005;
Fukushima et al. 2006) remains to be fully determined in future studies. It has been
reported that CT promotes an anti-inflammatory Th2 immune response (Eriksson et al.
2003), and our data demonstrating IgG1 subtype antibodies produced in the greatest
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proportion (compared to IgG2a or IgG2b antibodies) supports this notion. Of note, CT
antibody titers were observed (data not shown), indicating an immunogenic response to
this adjuvant. To confirm specific systemic versus local immune cell activation, we
analyzed primary cultures of isolated splenocytes from t.c. immunized non-transgenic
C57BL/6 mice and found that Aβ/CT t.c. immunization conferred Aβ-specific T-cell
response as measured by secretion of cytokines IFN-γ, IL-2 and IL-4 upon aggregated
Aβ1-42 peptide recall challenge. Importantly, there was a marked increase in IL-4
secretion compared to IFN-γ or IL-2, further suggesting Th2 immune responses after
Aβ/CT t.c. immunization. This is in agreement with our previous study, where we found
Th2-type cytokine responses both in vivo and ex vivo after intraperitoneal Aβ vaccination
with Freund’s adjuvant (Town et al. 2002). Further, the Th2-type response that we
observed following Aβ/CT t.c. immunization is important as anti-inflammatory Th2-type
immune responses are likely preferred to pro-inflammatory Th1-responses in the Aβ
vaccination paradigm, given that pro-inflammatory Th1 cells likely contributed to the
aseptic meningoencephalitis in the human clinical trial of AN-1792 (Nicoll et al. 2003;
Town et al. 2005). When taken together, these findings show that Aβ/CT t.c.
immunization of non-transgenic C57BL/6 mice produces both Aβ-specific local LC
immune response and systemic immune response characterized by high Aβ antibody
titers that are sustained throughout the immunization protocol.
To determine the potential therapeutic efficacy of Aβ t.c. immunization, 6 monthold double-transgenic (APPsw, PSEN1dE9) PSAPP mice [which develop robust amyloid
pathology at 8 months of age (Jankowsky et al. 2001)], were immunized against Aβ/CT
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or CT alone for 16 weeks. Results showed consistently high and sustained Aβ antibody
titers throughout the 16 week immunization period only in the Aβ/CT immunized group.
Interestingly, the magnitude of Aβ antibody response in Aβ/CT t.c. immunized was only
about half of that in wild-type mice (compare Figure 14A with Figure 15A), supporting
the notion that transgenic mouse models of AD are hypo-responsive to Aβ vaccination,
probably owing to overexpression of the human APP transgene throughout their lives
(Monsonego et al. 2001).

This humoral response correlated with high plasma levels of

Aβ1-40, 42 peptides which peaked around eight weeks and remained relatively constant
through to 16 weeks. Immunohistological and histochemical analyses of Aβ
immunoreactive plaques and congophilic plaques, respectively, in cortical and
hippocampal brain sections showed reductions by approximately 50% compared to CT
t.c. immunized PSAPP mice, and a negative correlation existed between brain Aβ and
blood Aβ levels following Aβ/CT t.c. immunization. Taken together, these results show
that Aβ/CT t.c. immunization is effective at mitigating cerebral amyloidosis and suggest
activation of Aβ brain-to-blood clearance. This “peripheral sink” mechanism has been
reported by others following passive transfer of Aβ antibodies to AD transgenic mice
(DeMattos et al. 2001; Matsuoka et al. 2003).
In order for AD immunotherapy approaches to be useful, they must not only be
efficacious, but such approaches must also be safe and well-tolerated. Importantly, while
we did observe peripheral Aβ-specific T-cell responses consistent with an antiinflammatory Th2 response (characterized in vivo by IgG1 Aβ antibody production and
ex vivo by IL-4 secretion after Aβ recall stimulation of splenocytes) after Aβ/CT t.c.
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immunization, no signs of aseptic meningoencephalitis and/or cell-mediated immunity
were observed in brains as evidenced by lack of CD3 positive T-cell infiltrates.
However, we did observe evidence of humoral immunity in brain as demonstrated by Aβ
antibody titers in brain homogenates, similar to data from previous reports using other
modes of Aβ immunotherapy (Bard et al. 2000; Bacskai et al. 2001), suggesting transport
of Aβ antibodies across the blood-brain-barrier. This observation was not due to poor
PBS perfusion at the time of sacrifice, as Perl’s stain (which normally detects even trace
amounts of iron which could be present due poor perfusion) results were consistently
negative. Finally, other investigators have reported that passive transfer of Aβ antibodies
to transgenic AD mice results in cerebral microhemorrhage (Wilcock et al. 2004; Racke
et al. 2005). Importantly, Perl’s stain did not show this potentially adverse side-effect in
mice t.c. immunized with Aβ/CT. Thus, when taken together, t.c. immunization holds
potential as a novel, effective, and safe potential treatment strategy for AD.
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CHAPTER FIVE
DISCUSSION

Alzheimer’s disease is the most common progressive neurodegenerative disorder.
Based on genetic, biochemical, and post-mortem evidence, Aβ peptides are key
etiological contributors to AD pathogenesis (Selkoe, 2001). In addition to parenchymal
Aβ deposits, deposition of Aβ in the cerebral vasculature (known as CAA) is another
pathological feature of AD, and occurs with 83% frequency in AD patients (Ellis et al.,
1996; Selkoe, 2001; Jellinger, 2002; Green et al., 2005). It is well know that there is a
chronic activation of inflammatory pathways in AD brain, including the production of
proinflammatory cytokines and acute-phase reactants in and around Aβ plaques. In
addition, a number of other molecules important in the proinflammatory acute-phase
response are also found at high levels in AD brain, including the activated glial product
S100 beta, the protease α-1-antichymotripsin and α-2-macroglobulin, the prostaglandin –
generating enzymes cyclooxygenases 1 and 2, and components of the classical protein
complement cascade such as C1q and C3 (Akiyama et al., 2000; McGeer and McGeer,
2001). Thus, the neuroinflammatory response can be regarded as a central feature of AD
brain.
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5.1 Microglia and central nervous system
Microglia are innate immune cells of myeloid origin that take up residence in the
central nervous system (CNS) during embryogenesis. While classically regarded as
macrophage-like cells, it is becoming increasingly clear that reactive microglia play more
diverse roles in the CNS. Microglial “activation” is often used to refer to a single
phenotype; however, a continuum of microglial activation exists, with phagocytic
response (innate activation) at one end and antigen presenting cell function (adaptive
activation) at the other. Where activated microglia fall in this spectrum seems to be
highly dependent on the type of stimulation provided.
Here, we suggest a model wherein microglial cells exist in at least two
functionally discernable states once “activated”, namely a phagocytic phenotype (innate
activation) or an antigen presenting phenotype (adaptive activation), as governed by their
stimulatory environment. When challenged with certain PAMPs (particularly CpGDNA), murine microglia seem to activate a “mixed” response characterized by enhanced
phagocytosis and pro-inflammatory cytokine production as well as adaptive activation of
T cells. In the EAE model, murine microglia seem to largely support adaptive activation
of encephalitogenic T cells in the presence of the CD40-CD40 ligand interaction. In the
context of Aβ challenge, CD40 ligation is able to shift activated microglia from innate to
adaptive activation. Further, it seems that the cytokine milieu that microglia are exposed
to biases these cells to innate activation (i.e., anti-inflammatory Th2-associated cytokines
such as IL-4, IL-10, TGF-β1) or an adaptive form of activation (i.e., pro-inflammatory
Th1-associated cytokines such as IFN-γ, IL-6, and TNF-α; summarized in Fig. 21).
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Figure 21
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Figure 21. Model for innate versus adaptive microglial activation responses. In the
context of β-amyloid challenge, microglia activate a phagocytic response. If costimulated with CD40 ligand, a shift from innate activation to adaptive antigen-presenting
cell response ensues. Additionally, certain anti-inflammatory Th2-type cytokines shift
this balance back towards innate phagocytic response, while some pro-inflammatory
Th1-associated cytokines tip the balance further towards adaptive activation of microglia.
See the text and Table for references. Abbreviations used: APC, antigen presenting cell;
CD40L, CD40 ligand; Th1, CD4+ T helper cell type I response; Th2, Th type II
response; TGF, transforming growth factor; IL, interleukin; IFN, interferon, TNF, tumor
necrosis factor.
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Not all forms of microglial activation are deleterious, as activated microglia may serve a
protective role as was shown in Aβ1-42-immunized mouse models of AD.

It seems that

enhanced microglial phagocytosis of β-amyloid plaques is at least partly responsible for
the therapeutic benefit in these animals, so perhaps stimulation of innate microglial
activation contributes to these reported benefits. In conclusion for microglial activation,
if we can learn how to better harness microglia in order to produce specific forms of
microglial activation, this could be key to turn a pathogenic cell into a therapeutic
modality.

5.2 Immunotherapy for Alzheimer disease
In a seminal report, Schenk and colleagues showed that peripheral immunization
of the PDAPP mouse model of AD with Aβ1-42 peptide resulted in high antibody titers, a
small fraction of which (0.1%, (Bard et al., 2000) crossed the blood-brain-barrier and
entered the brain parenchyma. Most importantly, these authors found that Aβ1-42
vaccination markedly diminished β-amyloid plaque burden (Schenk et al., 1999). These
authors also found evidence of cells in the brains of the Aβ1-42 immunization animals that
contained Aβ. Many of these cells stained for the activated microglia marker MHC II
and phenotypically resembled activated microglia, suggesting that these cells were able to
phagocytose Aβ deposits. In a follow-up report, Bard and colleagues supported this
hypothesis by showing ex vivo that certain antibodies against Aβ peptides could trigger
microglial phagocytosis and subsequent clearance of Aβ through the Fc receptor (Bard et
al., 2000) (Bard et al., 2003). Clearance of brain β-amyloid deposits was beneficial, as
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Aβ1-42-vaccinated mice had markedly reduced cognitive impairment as assayed by
behavioral testing in AD mice (Janus et al., 2000) (Morgan et al., 2000). Thus, in mouse
models of AD, innate (phagocytic) microglial activation mediated by the Fc receptor in
the presence of antibody-opsonized Aβ appears beneficial rather than deleterious.
Based on the above-mentioned data, a human clinical trial was begun to
peripherally administer a synthetic Aβ1–42 peptide (AN-1792) with an adjuvant to AD
patients. Unfortunately, the trial was halted when a small percentage of patients
developed aseptic T cell meningoencephalitis. This response most likely occurred
because of an immune reaction to Aβ mediated by infiltrating T cells (Pfeifer et al.,
2002). In the post-mortem brain of one patient who died as a consequence of this sideeffect of treatment, there was significant clearance of Aβ plaques in parts of the
neocortex and, in other areas where plaques remained, Aβ-immunoreactivity was
associated with microglia (Nicoll et al., 2003). It is not yet clear whether this fulminate
infiltration of T cells in AD patients who developed aseptic T cell meningoencephalitis
was due to adaptive activation of microglia, but this is a distinct possibility given that
microglia did seem to recognize antibody-opsonized Aβ (Nicoll et al., 2003) (Monsonego
and Weiner, 2003). These results indicate the potentially damaging and overwhelming
effects of a full-blown T cell autoimmune response, which does not normally occur in
AD, and which may have been mediated by adaptively activated microglia. Thus, to
translate animal Aβ immunization approaches into successful clinical AD therapies, such
strategies should not only be efficacious, but also be safe, including avoiding
meningoencephalitic reactions to Aβ immunization previously observed in humans
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(Janus, 2003; Monsonego et al., 2003b).

5.2.1. Immunotherapy: transcutaneous vaccination
Transcutaneous (t.c.) vaccination is an attractive route of delivery, as it is
convenient, relatively painless, and minimally invasive. The skin is a well-established
effective route for vaccination, including delivery of peptide-based vaccines (Masliah et
al., 1991; Tan et al., 2002a; Beignon et al., 2005). Strong humoral and cellular immune
responses have been elicited after transcutaneous (t.c.) vaccination (Giudice and
Campbell, 2006). Taken together, these lines of evidence led us to hypothesize that
targeting Aβ immunotherapy to skin tissue may provide an immunotherapeutic approach
that is both efficacious and safe. Here, we first found that t.c. immunization of nontransgenic C57BL/6 mice with aggregated Aβ1-42 peptide plus the adjuvant cholera toxin
(CT) resulted in high Aβ antibody titers [mainly immunoglobulin (Ig) G1], and Aβ1-42specific splenocyte immune responses after re-challenge with the peptide. Similar
response was observed in transgenic PSAPP mice and resulted in effective immune
responses against Aβ in concert with reduced cerebral Aβ pathology, demonstrating the
effectiveness of this approach. These mice showed high Aβ antibody titers and increased
circulating Aβ levels, suggesting brain-to-blood efflux of Aβ. Importantly, brain T-cell
infiltration and cerebral microhemorrhage were not observed after t.c. immunization,
indicating that this immunization strategy is potentially safe. Aβ immunization appears to
modulate immune responses based on three major criteria: 1) tissue route of delivery, 2)
antigen epitope utilized for immunization, and 3) properties of the co-administered
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adjuvant. Whether Th2 polarization in our study occurred due to route of delivery, CT
adjuvant choice, or the genetic background of the C57BL/6 strain (Rosas et al., 2005;
Fukushima et al., 2006) remains to be fully determined in future studies. It has been
reported that CT promotes an anti-inflammatory Th2 immune response (Eriksson et al.,
2003), and our data demonstrating IgG1 subtype antibodies produced in the greatest
proportion (compared to IgG2a or IgG2b antibodies) supports this notion. Further we
showed that splenocytes isolated from t.c. immunized mice and found Aβ-specific T-cell
responses as measured by secretion of cytokines IFN-γ, IL-2 and IL-4 upon aggregated
Aβ1-42 peptide recall challenge. Importantly, there was a marked increase in IL-4
secretion compared to IFN-γ or IL-2, further suggesting Th2 immune responses after
Aβ/CT t.c. immunization. This is in agreement with our previous study, where we found
Th2-type cytokine responses both in vivo and ex vivo after intraperitoneal Aβ vaccination
with Freund’s adjuvant (Town et al., 2002). Further, the Th2-type response that we
observed following Aβ/CT t.c. immunization is important as anti-inflammatory Th2-type
immune responses are likely preferred to pro-inflammatory Th1-responses in the Aβ
vaccination paradigm, given that pro-inflammatory Th1 cells likely contributed to the
aseptic meningoencephalitis in the human clinical trial of AN-1792 (Nicoll et al., 2003;
Town et al., 2005). Finally, other investigators have reported that passive transfer of Aβ
antibodies to transgenic AD mice results in cerebral microhemorrhage (Arendash et al.,
2001; Racke et al., 2005). Importantly, Perl’s stain did not show this potentially adverse
side-effect in mice t.c. immunized with Aβ/CT. Thus, when taken together, t.c.
immunization holds potential as a novel, effective, and safe prospective treatment
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strategy for AD.
We have previously shown the CD40-CD40L interaction enhances proinflammatory microglial activation triggered by cerebral Aβ deposits (Tan et al., 1999a).
This form of microglial activation is deleterious, as both genetic ablation of CD40L and
CD40L neutralizing antibody reduce brain levels of several neurotoxic inflammatory
cytokines and mitigate cerebral amyloidosis in AD mouse models (Tan et al., 2002a).
Blocking the CD40-CD40L interaction mitigates Aβ-induced inflammatory responses
and enhances Aβ clearance (Tan et al., 2002b; Townsend et al., 2005). Here, we utilized
genetic and pharmacologic approaches to test whether CD40-CD40L blockade could
enhance the efficacy of Aβ1-42 immunization, while limiting potentially damaging
inflammatory responses. We show that genetic or pharmacologic interruption of CD40CD40L interaction enhanced Aβ1-42 immunization efficacy to reduce cerebral amyloidosis
in the PSAPP and Tg2576 mouse models of AD. Potentially deleterious proinflammatory immune responses, cerebral amyloid angiopathy (CAA) and cerebral
microhemorrhage were reduced or absent in these combined approaches. Pharmacologic
blockade of CD40L decreased T-cell neurotoxicity to Aβ-producing neurons. Further
reduction of cerebral amyloidosis in Aβ-immunized PSAPP mice completely deficient
for CD40 occurred in the absence of Aβ immunoglobulin G (IgG) antibodies or efflux of
Aβ from brain to blood, but was rather correlated with anti-inflammatory cytokine
profiles and reduced plasma soluble CD40L. Recently soluble CD40L was reported to be
significantly increased in AD patients vs. healthy elderly controls, further supporting a
role for this receptor/ligand dyad in the pathogenesis of AD (Desideri et al., 2006). These
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results suggest CD40-CD40L blockade promotes anti-inflammatory cellular immune
responses, likely resulting in promotion of microglial phagocytic activity and Aβ
clearance while precluding generation of neurotoxic Aβ-reactive T-cells. If the benefit
afforded by CD40 pathway blockade to Aβ1-42 vaccinated AD mouse models can
translate to the clinical syndrome, then pharmacotherapy aimed at reducing CD40
signaling in conjunction with Aβ vaccination may represent an approach that is both safer
and more effective in humans. Future studies will be required to isolate CD40-CD40L
downstream signaling involved in reduced efficacy of Aβ vaccination, as this may
uncover additional targets for pharmacologic intervention.

5.2.2. Immunotherapy: human umbilical cord blood cells
Considering that inflammation plays a crucial role in propagation of Alzheimer’s
disease, a second or parallel therapy would be desired. This alternative therapy approach
would mainly immunomodulate peripheral immunity such that desired anti-inflammatory
Th2 responses would predominate, in other words an increased Th2/Th1 ration should be
observed. A possible strategy would involve a partial blockade of CD40-40L. However,
it is rather challenging to partially block CD40-40L interaction with the use of CD40
agonists or CD40L antagonists since it could lead to immunodeficiencies and hyper IgM
syndrome. Human cord blood cells (HUCBC) have unique immunomodulatory potential.
HUCBC have been shown to oppose the pro-inflammatory Th1 response, as
demonstrated in an animal model of stroke where HUCBC infusion promoted a strong
anti-inflammatory Th2 response (Vendrame et al., 2004). Importantly, this effect was
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associated with reduced infarct volume and rescue of behavioral deficit (Vendrame et al.,
2004). HUCBC infusion has also shown therapeutic benefit in other neuroinflammatory
conditions including multiple sclerosis, amyotrophic lateral sclerosis, age-related
neuromacular degeneration, and Parkinson’s disease (El-Badri et al., 2006; GarbuzovaDavis et al., 2006; Henning et al., 2006). In AD preclinical models, administration of
these cells to the PSAPP mouse model of AD was associated with extension of lifespan,
although high doses were administered in this paradigm (Ghorpade et al., 2001). Here,
we showed a marked reduction of Aβ levels/β-amyloid plaques and associated
astrocytosis following multiple low dose infusions of HUCBC. HUCBC infusions also
reduced cerebral vascular Aβ deposits in the Tg2576 AD mouse model. Interestingly,
these effects were associated with suppression of the CD40-CD40L interaction as
evidenced by decreased circulating and brain soluble CD40L (sCD40L) and elevated
systemic IgM levels, attenuated CD40L-induced inflammatory responses, and reduced
surface expression of CD40 on microglia. Importantly, deficiency of CD40 abolishes the
effect of HUCBC on elevated plasma Aβ levels. Moreover, microglia isolated from
HUCBC-infused PSAPP mice demonstrated increased phagocytosis of Aβ. Further, sera
from HUCBC-infused PSAPP mice significantly increased microglial phagocytosis of
Aβ1-42 peptide while inhibiting IFN-γ-induced microglial CD40 expression. Increased
microglial phagocytic activity in this scenario was inhibited by addition of recombinant
CD40L protein. Thus, the data suggests that HUCBC infusion confers mitigation of ADlike pathology by disrupting CD40L activity. When taken together, our results provide
the basis for a novel immunomodulatory strategy for AD using HUCBC.
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In conclusion, there is no current treatment for Alzheimer’s disease.
Immunotherapy is emerging as a potential therapy not just for AD but other diseases as
well. Previous vaccines were very effective yet came with undesired side effects for a
small population of patients. Since then, the accent have been given to safety as much as
to efficacy of any treatment. Alternative routes, adjuvants, and antigens could be used to
bypass this problem. Here, we showed that transcutaneous immunization of a whole Aβ
peptide with a cholera toxin adjuvant could be the answer. This vaccine could further be
enhanced with inhibitors of yet to be identified specific CD40-40L signaling molecules
involved in inflammation. Lastly, human cord blood cells could be used in parallel with
the vaccine as they provide the host with required tools for needed immunomodulation.
In addition, these cells do not represent any ethical concerns and they are readily
available. Based on these finding and current trends in research it is highly likely that
future AD treatments will incorporate both the vaccine- and the cell-based therapies.
Future studies are needed to further examine the safety of these approaches since both
have shown very effective.
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